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Alzheimer’s disease (AD) is pathologically characterized by the deposition of amyloid beta 
(Aβ) and neurofibrillary tangles (NFT) consisting of hyperphosphorylated tau protein. Since 
familial mutations in proteins involved in the Aβ generating cascade inevitably lead to AD, 
the deposition of Aβ is widely believed to be the underlying pathological mechanism of AD. 
In contrast, mutations in tau lead to frontotemporal dementia. The amyloid hypothesis states 
that the accumulation of Aβ42 is the underlying cause of AD driving neuron and synapse 
impairment and loss, eventually leading to behavioral deficits. For many years, the focus of 
the Aβ hypothesis has been the extracellular deposition of Aβ plaques; however numerous 
mouse models have been generated based on the familial AD mutations successfully 
modeling the deposition of Aβ plaques, but with little or no behavioral deficits and only 
seldom showing a loss of neurons. Furthermore, Aβ plaque deposition does not correlate well 
with cognitive decline in AD patients and can be found in non-demented controls as well as in 
AD patients. Recently, a modification of the amyloid hypothesis has been introduced 
suggesting that intraneuronal accumulation of Aβ rather than extracellular Aβ plaque 
deposition may be an early pathological hallmark of AD initiating pathological events. 
However, the presence of intraneuronal Aβ in the human AD brain is currently under debate. 
The present thesis investigates the presence of intraneuronal Aβ in human AD brain tissue and 
studies the role of intraneuronal Aβ versus plaques in transgenic mouse models of AD 
focusing on neuron loss, fiber pathology, and functional deficits concerning immediate early 
gene (IEG) regulation. Concerning pathological alterations, the present thesis corroborates the 
intraneuronal Aβ hypothesis, supporting the view of intraneuronal Aβ as an early pathological 
initiator and showing strong implications for intraneuronal Aβ in the generation of large 
plaque-independent axonal fiber pathology and neuronal loss. In contrast, plaques are found 
likely to cause functional disturbances such as deficits in the induction of IEGs upon neuronal 
activity, but seem not to be involved in the loss of neurons. Optimization of the 
immunohistochemical staining method for the detection of intraneuronal Aβ peptides 
provided a strong and robust staining of intraneuronal N-terminal Aβ peptides as well as 
fibrillar oligomeric Aβ and Aβ fibrils in neurons of the hippocampal formation of AD brain 
tissue. Finally, a highly significant correlation was identified between the accumulation of 
intraneuronal N-terminal Aβ peptides and the well-recognized AD risk factor of having one 
ApoE4 allele, emphasizing an important role of intraneuronal Aβ in AD pathology. 
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1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a severely disabling neurodegenerative disorder characterized by 
progressive cognitive decline and accounts for 50-70% of all cases of dementia, thereby 
representing the main cause of dementia among the elderly population. Alzheimer’s 
association reports that AD was the fifth-leading cause of death for those aged 65 and older in 
2006 in US, only surpassed by heart disease, breast cancer, prostate cancer, and stroke 
(Alzheimer's Association Report 2009). However, AD was the only one of these indications 
actually showing an increasing rate of deaths from 2000 to 2006 of as much as 47%, which 
emphasizes a continuing lack of effective treatments of AD. Patients often live about 10 years 
after appearance of the first symptoms and end up completely dependent on care givers. Thus 
WHO predicted the direct costs of AD in US alone to be about US$ 500 billion in year 2000 
making AD a major socioeconomic problem that will expand in near future (Vas et al. 2002). 
1.1.1 Clinical features 
The final diagnosis of AD is based on neuropathological hallmarks and can therefore only be 
given for certain after autopsy. In the clinic, the diagnosis is described as senile dementia of 
the Alzheimer type (SDAT) until confirmed by neuropathology. Unlike dementia, AD does 
not only affect memory function, but also other cognitive functions such as language, 
planning ability, attention, and orientation in time and space. Many patients start to forget 
recent events and appointments and progress to forgetting year and location. As the disease 
progresses, patients may have difficulties finding words and suffer from impairments in 
abstract thinking and judgment such as related to the concept of money. Problems start to 
arise with familiar tasks as buttoning a shirt or placing things at their right location. Mood 
changes can also appear with the patient showing anger for no apparent reason and with 
changes in personality showing paranoia, jealousy, and confusion. Eventually, patients often 
end up without initiative and completely passive without any language having reached the so 
called “bed-state” (Alzheimer´s Association Brochure 2005). To give the clinical diagnosis of 
SDAT, an individual is assessed by for example the Mini-Mental State Examination (MMSE), 
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which is a practical method for grading the cognitive state of patients (Folstein et al. 1975). 
Still, the symptoms vary with each patient often complicating the assignment of a diagnosis, 
but appearance of any of the early symptoms may be a sign of AD. Clinicians assign the term 
“mild cognitive impairment” (MCI) to patients where problems with memory, language, or 
other cognitive functions are severe enough to be noticed by others and show up on cognitive 
tests, but are not severe enough to interfere with daily life (Alzheimer's Association Report 
2009). It is estimated that as many as 10-20% of people age 65 and older have MCI 
(Alzheimer's Association Report 2009; Levey et al. 2006), but not all of these develop AD. 
The definition of MCI is broad and encompasses several subtypes. Amnestic MCI is 
characterized by memory deficits. Multiple-domain MCI is characterized by impairments in 
several cognitive functions such as language, executive functions, and visuospatial skills, but 
may also include memory deficits. A third subtype of MCI involves patients with impairment 
in a single cognitive domain that does not involve memory. Multiple-domain MCI without 
memory impairment can progress to dementia with Lewy bodies as can MCI affecting a 
single non-memory domain, which in addition can progress to frontotemporal dementia. Only 
MCI patients with memory impairment are likely to progress into AD. Although they may 
also suffer from depression, patients with 
amnestic MCI are very likely to develop 
AD with an incidence of 10-15% per year 
compared to 1-2% in healthy controls 
(Levey et al. 2006). All three types of MCI 
can also show complete remission; 
however, in a longitudinal study from the 
Mayo clinic, 80% of 76 patients with 
amnestic MCI had converted to AD after 6 
years, translating into the annual incidence 
of 15% (Fig. 1) (Levey et al. 2006; 
Petersen et al. 2001; Petersen et al. 1999). 
Fig. 1 Progression of amnesic mild cognitive 
impairment to AD. After 6 years, one study showed a 
rate of 80% conversion to Alzheimer’s disease for 
individuals with amnesic mild cognitive impairment 





Already in 1906, two major neuropathological lesions of AD were identified by the German 
psychiatrist Alois Alzheimer in his investigations of the most famous AD patient, Auguste D, 
a woman in her early 50s that suffered from progressive senile dementia (Hardy 2006). At 
that time, life expectancy was low compared to today, and what Alois Alzheimer thought to 
have identified as a rare dementia occurring in the “presenile” period of life, was only much 
later recognized to be the most common cause of dementia with an incidence rising 
exponentially with age. Using the limited microscopic technology of the time, Alois 
Alzheimer identified extracellular senile plaques and intracellular neurofibrillary tangles 
(NFTs) as the two major neuropathological lesions of AD, which are still thought to underlie 
AD pathogenesis and to date defines the final diagnosis of AD that can only be given after 
neuropathological examination following autopsy (Selkoe 2001).  
Much later, the extracellular plaques were found to 
consist of amyloid beta (Aβ) peptides, and two types 
of plaques were identified (Dickson 1997; Masters et 
al. 1985; Selkoe 1989). Neuritic plaques, or cored 
plaques (Fig. 2A), are microscopic foci of 
extracellular filamentous Aβ deposits surrounded by 
dystrophic neurites, which are swollen axons and 
dendrites that accumulate amongst others enlarged lysosomes and numerous mitochondria. 
The neuritic plaques are surrounded by microglia and Optimization for intraneuronal Aβ1-x 
staining in reactive astrocytes and are found in large numbers throughout limbic and 
association cortices. In contrast, diffuse amorphous plaques are not surrounded by dystrophic 
fibers or glial changes (Fig. 2B). They are thought to consist of less aggregated Aβ and might 
represent a stage of precursor lesions for neuritic plaques. Another form of Aβ deposition 
often observed in AD brains is cerebral amyloid angiopathy (CAA), where Aβ is found to 
accumulate inside the walls of blood vessels (Fig. 2C) (Alafuzoff et al. 2008; Selkoe 1989).  
Fig. 2 Aβ pathologies visualised by Aβ
immunohistochemistry. A) Cored or 
neuritic plaque. B) Diffuse amorphous 
plaque. C) cerebral amyloid angiopathy 
(CAA) (Alafuzoff et al. 2008). 
The NFTs are large non-membrane bound bundles of fibers occupying much of the 
perinuclear cytoplasm and consist of paired helical filaments (PHFs) wound into larger 
helices (Fig. 3). During the 1980´s, the PHFs were found to be composed of microtubule-
associated protein tau (MAPT) commonly referred to as “tau”, which is a protein normally 
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associated with microtubules supporting their assembly (Selkoe 
1989). The tau protein in PHFs is hyperphosphorylated, which is 
thought to be an initiating factor promoting the tau protein to 
dissociate from the microtubules and aggregate into PHFs 
forming the NFTs. Many kinases have been found capable of 
phosphorylating tau at various sites, amongst others the glycogen 
synthase kinase 3 (GSK3), mitogen-activated protein kinase 
(MAPK), cyclic AMP-dependent protein kinase (PKA), and, 
more recently, cyclin-dependent kinase 5 (cdk5). Nevertheless, 
the identities of the true physiological and pathological kinases in vivo remain unknown 
(Hanger et al. 2009). Many in vitro studies show neurotoxicity of hyperphosphorylated tau 
protein, however, the in vivo consequences of the hyperphosphorylation are still a matter of 
debate. One study of European ground squirrels in torpor during hibernation described the 
formation of highly phosphorylated tau in large amounts especially in the entorhinal cortex, 
hippocampus, and isocortical areas. The PHF-like phosphorylation of tau did not lead to fibril 
formation and was fully reversible after arousal, indicating that hyperphosphorylation itself is 
not the irreversible step in a fatal cascade (Arendt et al. 2003). Still, tau pathology has been 
found to correlate better with cognitive decline than Aβ plaques and the extend of tau 
pathology in AD brains is therefore used to stage the severity of the disease into six stages, 
Braak I-VI (Braak et al. 2006; Braak and Braak 1991). 
Fig. 3 Confocal image of 
neurofibrilary tangle (NFT). 
Aggregated hyperphosphory-
lated tau protein stained by 
immunohistochemistry (red) 
accumulates in the cytoplasma 
and surrounds the nucleus (N) 
(Luna-Munoz et al. 2005). 
Another pathological determinant of AD is brain atrophy and loss of neurons, which occurs 
predominantly in the cortex, hippocampal formation, and nucleus Basalis of Meynert. The 
loss of cholinergic neurons of the nucleus basalis of Meynert provided the first evidence of 
neuron loss, where as much as 90% neuron loss can be observed (Davies and Maloney 1976; 
Whitehouse et al. 1982). In comparison, neuron losses of approximately 50% have been 
established in the superior temporal cortex as well as in the enthorinal cortex proximate to the 
hippocampal formation (Gomez-Isla et al. 1997; Gomez-Isla et al. 1996). Concerning the 
hippocampal formation, there are some disagreements concerning the specific loss of neurons 
in subregions, but one study reported neuron losses of 23% in the subiculum and granule cell 
layer of the dentate gyrus (DG) (Simic et al. 1997), and another reported as much as 68% in 
the CA1, 47% in the subiculum and 25% in the hilus also named the CA4 region of the 
hippocampal formation (West et al. 1994). Accordingly, only the CA2-3 region of the 
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hippocampal formation seems to be 
somewhat resistant to neuronal loss in AD. 
The brain atrophy is evident by macroscopic 
examination and is characterized by 
enlargement of the ventricles and loss of 
volume especially in the hippocampal region 
concerned with memory processing and in 
cortical regions concerned with amongst 
others language skills, correlating well with 
the deficits in cognitive functions observed in 
AD patients (Fig. 4). Thus a total volume 
loss of about 30% has been found in the 
hippocampal formation using in vitro 
microscopy (Huesgen et al. 1993; Simic et al. 1997), which is in line with in-vivo magnetic 
resonance imaging (MRI) studies showing hippocampal and entorhinal cortical atrophy of 40-
50% (Erkinjuntti et al. 1993; Kesslak et al. 1991). Recently, significant atrophy of the 
olfactory bulb has been reported that probably accounts for the decrease in olfactory function 
also observed in AD patients (Thomann et al. 2009).  
Fig. 4 Brain atrophy in AD. Coronal brain sections of 
normal control subject (left) and a patient with 
Alzheimer’s disease (right) showing enlargement of 
ventricles and evident tissue loss especially in the
hippocampal region concerned with memory and in the 
cortex amongst others dealing with language function 
(www.ahaf.org/alzdis/about/BrainAlzheimer.htm). 
Also synapses are lost in AD and is believed to be an early pathological alteration in the brain, 
especially in the frontal cortex where a loss of 30-40% of the synapses in layer III and V of 
AD biopsy tissue has been reported (Scheff et al. 1990; Tiraboschi et al. 2000). As synaptic 
plasticity is a key player in cognitive function, the loss of synapses could very well result in 
cognitive impairments. Accordingly, the loss of synapses seems to strongly correlate with the 
cognitive decline in AD patients (DeKosky and Scheff 1990; Dickson et al. 1995; Terry et al. 
1991). 
In addition, abnormalities and impairments in axonal transport have been reported in a variety 
of neurodegenerative diseases (Yagishita 1978) and are suggested to be an important 
pathological alteration underlying AD (Roy et al. 2005; Stokin and Goldstein 2006; Zhu et al. 
2005). The axonal pathology in AD is evident by swollen dystrophic fibers in which various 
proteins accumulate including APP (Cras et al. 1991), synaptic proteins like alpha-synuclein 
(Wirths et al. 2000), glycogen (Mann et al. 1987), or abnormal filaments (Praprotnik et al. 
1996) (Fig. 5). With the implementation of new imaging techniques it has recently been 
Introduction  11
 
shown in in-vivo studies that impairment of axonal transport 
mechanisms and decreased axonal transport rates early in the 
disease process might have a significant impact on the 
pathogenesis of AD (Cross et al. 2008; Minoshima and Cross 
2008; Smith et al. 2007; Teipel et al. 2007). 
Fig. 5 APP-positive dystrophic 
neurites surrounding neuritic 
plaque (Cras et al. 1991). 
 
 
1.1.3 Risk factors 
The major risk factor of AD is aging, which is evident 
by the exponential increase in AD incidence with age. 
Thus, a study performed by the American National 
Institute on Aging estimated a fairly low incidence rate 
of 0.08% per year in the 60-65 year age group that was 
found to double each 4.4 years resulting in 6.48% new 
AD cases each year in the 85+ age group (Fig. 6A) 
(Kawas et al. 2000). In prevalence, this means that 
1.4% of the population aged 60-65 suffers from AD, 
whereas this applies to 23.6% of people aged 85 or 
more (Fig. 6B). The world health organization (WHO) 
estimates that there are currently 18 million people 
worldwide suffering from AD and expects this number 
to have doubled by 2025 (Vas et al. 2002). Since aging 
is the major risk factor of AD, much of this dramatic 
increase in the number of AD patients is expected to be 
caused by an ongoing demographic change with an 
increasing proportion of elderly people owing to 
higher living standards, medical improvements, and 
better care that altogether prolongs life expectancy.  
Fig. 6 Aging is a major risk factor of AD.
AD incidence rate increases exponentially 
with age (A) (Kawas et al. 2000) causing a 
dramatic increase in AD prevalence in 
older age (B) (Vas et al. 2002). 
Alzheimer’s association reports a higher prevalence of AD in women compared to men in the 
US, but also concludes that this is caused by the longer life span of women, and not by 
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women having a higher risk of developing AD. This is in line with reports of no differences in 
AD risk factor between men and woman as well as the observed incidence rate in men and 
woman rising equally exponentially with age (Fig. 6A) (Kawas et al. 2000; Sandberg et al. 
2001).  
Whereas the majority of all cases of AD occur sporadically, 2-5% are caused by familial 
inherited mutations most often resulting in an early onset of the disease before the age of 65 
years that can be as early as around 30 years of age (Bentahir et al. 2006; Kumar-Singh et al. 
2006). So far, all mutations resulting in familial AD (FAD) have been identified in only three 
genes encoding the beta amyloid precursor protein (APP), presenilin 1 (PS1) or presenilin 2 
(PS2), which are all proteins involved in the cascade leading to Aβ deposition (Janssen et al. 
2003). Most of these mutations have been shown to elevate the levels of the Aβ isoform 
ending at amino acid 42 (Aβ42), which is considered to be highly neurotoxic and tends to 
aggregate into amyloid fibrils more rapidly that then isoform ending at amino acid 40 (Aβ40) 
(Iwatsubo 1998). Mutations in the MAPT gene encoding the tau protein have also been 
identified; however, these cause frontotemporal dementia and not AD (Kumar-Singh and Van 
Broeckhoven 2007).  
Whereas FAD can be caused by a single mutation, sporadic AD is generally believed to be a 
multifactorial disease and is therefore not expected to be caused by a single genetic mutation 
or variation. So far, the strongest genetic variation linked to AD is that of apolipoprotein E 
(ApoE) of which three different alleles can be found in the general population: 2, 3, and 4. 
The ApoE3 is the most common allelic form and is found in 77-78% of the general 
population. The ApoE2 is rather rare and is found in only 7-8% of the population. The ApoE4 
constitutes the remaining 14-16%, however, in people with AD, the ApoE4 genotype is found 
in about 40% of the patients being much more common than in the general population. Thus 
the ApoE4 genotype is believed to be a major risk factor of AD, and individuals with one 
ApoE4 allele are considered 3-4 times as likely to develop AD as those without ApoE4 (Bu 
2009; Corder et al. 1993; Schmechel et al. 1993; Strittmatter et al. 1993). Why ApoE4 
predisposes to AD is yet unclear, however, ApoE4 has been shown to directly influence APP 
processing to Aβ. More indirectly, apolipoproteins are the major carriers of cholesterol in the 
blood and delivers cholesterol to cells that incorporate it into cell membranes, where 
cholesterol is considered important for the function of lipid rafts that are considered to 
regulate the cleavage of APP to Aβ (Riddell et al. 2001; Vetrivel et al. 2004).  
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1.2 APP processing 
The major breakthrough in AD biochemistry happened in the mid 1980’s when Aβ was 
isolated and characterized as the core peptide of amyloid plaques (Glenner and Wong 1984; 
Masters et al. 1985), which was shortly followed by the identification of the gene encoding 
the peptide’s parent protein, the APP (Kang et al. 1987; Tanzi et al. 1987). The APP gene was 
mapped to the Down’s syndrome region of chromosome 21, which was especially intriguing 
since Down’s syndrome is a chromosomal disorder where the patients have three copies of 
chromosome 21 and invariably develops AD at an early age (Kang et al. 1987; Wisniewski et 
al. 1978). The APP protein turned out be a type 1 transmembrane glycoprotein (Tanzi et al. 
1987) that is widely expressed in many cell types of the brain including neurons, glial cells, 
astrocytes, and endothelial cells as well as in many peripheral tissues (Beer et al. 1995; 
Schmechel et al. 1988). Anchored in the membrane, full-length APP undergoes post-
translational proteolytic processing through at least two distinct pathways, differing in the 
proteases involved and the resulting production of protein fragments (Fig. 7A). In the non-
amyloidogenic pathway, cleavage of APP by α-secretase results in release of the large soluble 
ectodomain fragment α (sAPPα) from the membrane. The resulting membrane-associated 83-
amino-acid long C-terminal fragment (C83) remains associated with the membrane and is in 
turn processed by the γ-secretase generating the so-called P3 peptide and the APP intracellular 
domain (AICD, also referred to as CTFγ). In this pathway, cleavage within the Aβ sequence 
Fig. 7 Proteolytic processing of APP. A) In 
the nonamyloidogenic pathway (left) cleavage 
of APP by the α-secretase results in the release 
of the large soluble ectodomain fragment α 
(sAPPα). The membrane-associated 83-amino-
acid long C-terminal fragment (C83) is further 
processed by the γ-secretase within the 
transmembrane domain (TM) liberating the P3 
peptide and the APP intracellular domain 
(AICD/CTFγ). Alternatively, APP can undergo 
the amyloidogenic pathway (right) in which 
APP is initially cleaved by the β-secretase 
releasing the soluble ectodomain fragment β
(sAPPβ).    Subsequent processing of the C-
terminal derivative (C99) by the γ-secretase 
generates the Aβ peptide and the C-terminal 
AICD fragment (inspired by (Senechal et al. 
2006)) B) The generation of Aβ is believed to 
take place in the membranes of intracellular 
compartments, most likely the endosomes, 
accumulating Aβ inside the vesicle structures 
(adapted from (Small and Gandy 2006)).
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by the α-secretase prevents the formation of Aβ peptides. Alternatively, APP can be cleaved 
in the amyloidogenic pathway in which APP is initially cleaved by the β-secretase resulting in 
the formation of an N-terminal ectodomain fragment β (sAPPβ) that is released from the 
membrane and a membrane-bound 99-amino-acid long C-terminal derivative (C99). 
Subsequent processing of C99 by the γ-secretase within the transmembrane domain releases 
the Aβ peptide and the C-terminal AICD fragment from the membrane (Senechal et al. 2006).  
The nature of the secretases as well as the intracellular localization of the cleavage process 
has been of great interest and many questions are not yet finally answered. Three enzymes 
have been identified having α-secretase activity, 
ADAM9, ADAM10, and ADAM17, all 
belonging to the ADAM family (a disintegrin- 
and metalloproteinase-family enzyme) of  
integral membrane proteins (Allinson et al. 
2003). They are thought to cleave the APP at 
the cell surface membrane releasing sAPPα into 
the extracellular space (Laferla et al. 2007). 
Several groups have identified the β-secretase to 
be the β-site APP-cleaving enzyme 1 (BACE 1), 
which is, like APP, a type 1 integral membrane 
protein (Hussain et al. 1999; Sinha et al. 1999; 
Vassar et al. 1999). Like most transmembrane 
proteins, APP and BACE1 are sorted via the 
secretory and endocytic pathways where the 
trans-Golgi network (TGN) and the endocomes 
function as coordinators of the complex 
movement of transmembrane proteins within the 
cell (Fig. 8A) (Small and Gandy 2006). The 
sorting through the different compartments is 
highly regulated and clathrin has been identified 
to mediate the movement from the TGN to 
endosomes and between the endosomes and the 
Fig. 8 Sorting of APP and BACE1. A) Both are 
sorted via the secretory and endocytic pathways 
where the trans-Golgi network (TGN) and the 
endocomes function as coordinating compartments. 
B) The retromer complex transports type-I 
transmembrane proteins from the endosome to the 
TGN. VPS35 is the core of the retromer and binds 
directly to the protein cargo (red bar). VPS26, 
VPS29, and sortin nexins (SNX) 1 or 2 assemble 
onto VPS35 to generate the complete functional 
retromer complex. The retromer sorts APP and
BACE1, either by direct binding to the retromer or 
by indirect binding through the adaptor protein 
sorLA (light blue) (Small and Gandy 2006). 
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cell surface (Wahle et al. 2005). A novel coat complex, the retromer, has been found to be 
involved primarily in retrograde transport from the endosome to the TGN where an adaptor 
protein, sorLA, is thought to bind the retromer complex to cargo proteins such as APP and 
BACE1 and could provide interaction between the two proteins (Seaman 2004). Both APP 
and BACE1 can be found, at least transiently, in almost all membranous compartments of 
these pathways as well as on the cell surface, but biochemical studies suggest maximal 
BACE1 activity in an acidic environment, making the lysosomes a likely compartment for the 
initial cleavage. However, mature BACE1 is found predominantly in the endosomes with 
lower levels on the cell surface and in the TGN and not in lysosomes or in the endoplasmic 
reticulum (Small and Gandy 2006). A fluorescence resonance energy transfer (FRET) study 
analyzed the interaction between APP and BACE1 and confirmed that wild-type APP binds 
BACE1 with greatest efficiency in the endosomes, lesser on the cell surface, and to a 
negligible degree in the TGN and secretory pathway (Kinoshita et al. 2003). The γ-secretase 
has been identified as a multimeric complex of at least 4 enzymes being the PS1 or PS2, 
nicastrin, anterior pharynx defective enzyme 1 (APH-1), and presenilin enhancer 2 (PEN-2) 
(Fig. 9) (Gandy 2005). The multimeric nature of the γ-secretase has made the localization of 
its cleavage even more complicated than that of β-secretase. The best clue is that γ-secretase 
cleavage takes place in presynaptic terminals of neurons where the only existing organelles 
involved in the γ-cleavage are the endosomes (Kamenetz et al. 2003). Thus both β- and γ-
cleavage is thought to take place in endosomes (Fig. 7B), but it remains unsolved whether γ-
secretase cleavage also takes place in other compartments of the secretory and endocytic 
pathways.  
Fig. 9 The structure of γ-secretase. γ-secretase is a 
complex of 4 enzymes: presenilin (PS1 or PS2), 
nicastrin, anterior pharynx defective enzyme (APH-1), 
and presenilin enhancer 2 (PEN-2). The complex is a 
zymogen being inactive until the presenilin is cleaved at 
the black bar causing the complex to self associate and 
form the active enzyme (Gandy 2005). 
1.2.1 APP physiological functions 
The APP gene sequence shows extensive conservation throughout evolution suggesting an 
important physiological function of the APP protein (Coulson et al. 2000), which is 
alternatively spliced resulting in three major isoforms differing in length, functional domains, 
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and expression pattern in the brain (Sola et al. 1993; Tanaka et al. 1989). The APP695 
consists of 695 amino acids and is the most abundant form in the brain expressed 
predominantly in neurons, whereas the APP751 and APP770 isoforms have one additional 
domain and are present mostly in glial cells and other non-neuronal tissues. Within neurons, 
the highest expression levels of APP are found in the hippocampal formation and cerebellum, 
where APP undergoes fast anterograde axonal transport, is expressed at neuronal synapses, 
and is found throughout vesicular structures of the cell bodies, axons, and dendrites (Koo et 
al. 1990; Sola et al. 1993). The physiological role of APP is not as extensively investigated as 
its pathological role and is thus not very well understood, however, some information are 
supplied from KO or knock-down studies of APP expression as well as mutations of the 
different domains. APP KO or deficient mice are in fact viable but show weight loss, reduced 
forelimb grip strength and decreased locomotor activity, suggesting impairment in muscular 
or motoneuronal function (Muller et al. 1994; Zheng et al. 1995). On the biochemical level, 
the APP protein has been found to contain many domains capable of interacting with a variety 
of proteins as well as metal ions. For example, the extracellular part of APP was shown to 
interact with ApoE and Notch receptors involved in development, during which APP 
expression actually increases in correlation with intense neurite outgrowth and synaptogenesis 
(Moya et al. 1994; Senechal et al. 2006). Thus APP is thought to play an important role in 
synaptic development, cell migration, early postnatal survival, and neurogenesis, and possibly 
has a role in maintenance and repair (Senechal et al. 2006). In the periphery, APP is highly 
expressed in Sertoli cells, follicle cells, secretory cells, podocytes, and macrophages found in 
the spleen, liver, kidney, testis, ovary, pancreas, and salivary glands (Beer et al. 1995). 
Common to these cells is their high membrane turnover and their functional characteristics 
mediating endocytosis and exocytosis supporting a peripheral role of APP in tissue 
maintenance and repair. 
1.2.2 Aβ toxicity 
Aβ is a 4 kDa peptide that shows a high tendency to polymerize and aggregate. Thus Aβ can 
self-associate to form oligomers ranging from dimers and trimers to larger oligomers of more 
than 100 kDa, although it mostly forms low-n oligomers (dimers to octamers). The oligomers 
are described as soluble as they are soluble in aqueous buffer and remain in solution following 
high speed centrifugation. Monomers are thought to be in equilibrium with the oligomers, but 
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when a certain threshold amount of monomers is reached, they initiate a nucleation-dependent 
polymerization process in which monomeric Aβ forms nuclei that are polymerized into Aβ-
derived diffusible ligands (ADDLs), which assemble into larger protofibrils. The ADDLs and 
protofibrils are plastic structures that can again dissociate to monomers, but the protofibrils 
can also aggregate further into full-length fibers (Fig. 10). Aβ fibers are insoluble and 
represent the major constituents of plaques, whereas the solubility of ADDLs and protofibrils 
following high speed centrifugation has not yet been addressed (Roychaudhuri et al. 2008; 
Walsh et al. 1997; Walsh and Selkoe 2007).  
Aβ peptides have been shown to have toxic properties in cell cultures (Kihara et al. 1997; Loo 
et al. 1993; Yankner et al. 1990), but so far, the mechanism whereby Aβ induces cell death 
has not been clarified and there is an ongoing debate concerning which type of Aβ peptides 
represents the most toxic species. Most people agree that Aβ42 peptides are more neurotoxic 
than Aβ40, probably owing to their increased tendency to aggregate (Small and McLean 
1999). However, variations also exist at the N-terminal region where a considerable part of 
the Aβ found in AD brains is N-terminally truncated beginning for example with 
phenylalanine at position 4, or with a pyroglutamate modification at position 3 (AβN3pE) 
(Masters et al. 1985; Saido et al. 1995). The N-terminal truncated Aβ peptides generally show 
Fig. 10 Aβ fibrillogenesis. Monomers are in equilibrium with oligomers that can be of low-n (2-12) or further 
associate to larger oligomers. Monomers initiate a nucleation-dependent polymerization process in which 
nuclei are the basis for generation of Aβ-derived diffusible ligands (ADDLs) that further assemble into
protofibrils. Protofibrils give rise to full-length fibers by simple end-to-end annealing, lateral association of 
protofibrils followed by addition of monomers or oligomers to ends, and lateral association followed by end-to-
end annealing (adapted from (Walsh et al. 1997)). 
Introduction  18
 
enhanced tendency to aggregate in vitro (Pike et al. 1995), and especially AβN3pE shows 
increased cellular toxicity compared to full-length Aβ (Russo et al. 2002) and has been shown 
to mediate neuron death in a mouse model expressing specifically AβN3pE (Wirths et al. 
2009). AβN3pE also shows high stability (Kuo et al. 1998) and aggregation propensity (He and 
Barrow 1999), and is thought to have seeding properties inducing the aggregation of other Aβ 
peptides (Schilling et al. 2006). Thus prevention of the aggregation of Aβ peptides by 
inhibition of AβN3pE generation is considered a potential target in AD (Schilling et al. 2008). 
Not only the Aβ species, but also the confirmation of Aβ peptides is currently under 
discussion. Early studies demonstrated that aggregation of Aβ is essential for its toxicity 
(Yankner 1996), however, it has recently been suggested that soluble oligomeric Aβ is more 
toxic than the aggregated fibers (Walsh et al. 2000), and one study even isolated a specific 
oligomeric Aβ species, the Aβ56*, claiming that this is solely responsible for the memory 
impairment caused by Aβ in a mouse model of AD (Lesne et al. 2006). Thus there seems to 
be a lack of agreement within the field as to which primary species of Aβ is actually 
mediating its toxic effects. Supporting the hypothesis of the toxic oligomers to be the most 
toxic is the lack of correlation between the accumulation of aggregated Aβ in plaques and the 
deterioration in memory and cognitive functions of AD patients (Aizenstein et al. 2008; 
Dickson et al. 1995; Terry et al. 1991), whereas soluble Aβ species have recently been 
reported to correlate much better with the cognitive decline in AD (McLean et al. 1999; 
Naslund et al. 2000).   
Only very little is known about the physiological role of Aβ, but the peptide has been reported 
to play a role in the regulation of neuronal excitation (Kamenetz et al. 2003), and a very 
recent finding identifies Aβ as an antimicrobial peptide of the innate immune system (Moir et 
al. 2009). Others have found a link between APP processing and the metabolism of 
cholesterol and sphingomyelin, both part of cellular membranes. According to these studies, 
Aβ42 should reduce the level of sphingomyelin by activating the sphingomyelin degrading 
enzyme, whereas Aβ40 reduces cholesterol de novo synthesis by inhibiting its synthesizing 
enzyme. This regulation strictly depends on γ-secretase, and cholesterol and sphingomyelin 
should directly affect the γ-secretase activity providing a feedback mechanism where 
cholesterol induces the activity of the γ-secretase (Grimm et al. 2005). Corroborating these 
results, hypercholesterolemia has been suggested as an early risk factor in the development of 
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AD, and cholesterol-lowering drugs are being evaluated as a potential treatment for AD 
(Cutler et al. 2004; Simons et al. 2002; Sparks et al. 2005). 
1.3 Mouse models of Alzheimer’s disease 
The knowledge of identified FAD mutations can be used to generate model systems for 
studying the pathology and course of AD. The most widely used model organism is the 
mouse. The choice is a compromise between having a mammalian organism being in many 
ways similar to humans and practical considerations such as handling, generation time, and 
the extensive knowledge of the mouse genome obtained in 2002 by complete sequencing. 
Owing to the complicated techniques of introducing mutations, the mouse is in fact the only 
mammal in which targeted mutation is yet possible (Pluck and Klasen 2009). However, 
drosophila is also quite often applied because of its very easy handling, extremely fast 
generation time, low costs, and the ability to conduct fast screenings of drug candidates (Sang 
and Jackson 2005). 
1.3.1 Generation of mouse models 
Presently, two technically different approaches can be applied to generate a mouse model. 
Pronuclear injection of a vector containing a relevant DNA sequence into fertilized oocytes 
generates transgenic mice by introducing a foreign target gene, however, with random 
integration into the genome. Targeted mutagenesis using homologous recombination in 
embryonic stem (ES) cells can be used to specifically modify a target gene and is thus used to 
produce genetically modified mice where a gene is knocked in (KI) to obtain a gain of 
function or knocked out (KO) to obtain inactivation of gene expression. 
Pronuclear injection is the most widely used technique to generate transgenic animals as it is a 
straightforward method to consistently integrate a transgene at a single site in the 
chromosome (Ittner and Gotz 2007). Female mice are superovulated, mated to fertile males 
and sacrificed the following day to recover fertilized oocytes from the oviducts. The DNA of 
interest is injected into the male pronucleus of the oocytes using a micro injection pipette, and 
surviving oocytes are reimplanted into the oviducts of a pseudopregnant foster female (Fig. 
11). During this procedure, the microinjected DNA randomly integrates into the chromosomal 
DNA at nicks, usually at a single site, however, often containing multiple head-to-tail copies 
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of the transgene. To target specific 
tissues and cell types, e.g. neurons of the 
brain, expression vectors are applied 
containing promotors specific for the 
target tissue. To express APP in neurons 
of the brain and spinal cord, the prion or 
Thy1 promotor are often used of which 
the latter has shown to give a high APP 
mRNA level throughout the brain, being 
most notably in the hippocampal 
formation and cerebral cortex (Ittner and 
Gotz 2007). If the foreign DNA has 
integrated at the one-cell stage of 
development, it should be transmitted to 
50% of the offspring, which is checked 
by polymerase chain reaction (PCR) for 
the presence of the desired DNA 
sequence. The advantage of the 
pronuclear injection is that the molecular 
biology work is quite simple and development time to first offspring is rather low (~22 
weeks), however, as the transgenic integration is random it can disrupt an existing gene 
possibly causing phenotypic changes or lethality. Also, the transgene usually integrates with a 
non-predictable copy number, and expression patterns and levels are usually highly variable 
in different transgenic founders. Therefore, several mouse lines have to be screened for the 
optimal transgenic phenotype until one is chosen for further breeding and characterization. 
Extensive housing capacity must therefore be available for the breeding procedure and it takes 
approximately a year from making the DNA construct for pronuclear injection to the 
establishment of a new transgenic mouse strain with some phenotypic characterization (Ittner 
and Gotz 2007; Strachan and Read 1999). 
Fig. 11 Generation of transgenic mice by pronuclear 
microinjection. A micro injection pipette is used to inject 
the DNA into the male pronucleus of the oocyte. The 
introduced DNA clones integrate into the chromosomal 
DNA at nicks, forming transgenes, usually containing 
multiple head-to-tail copies. The oocytes are reimplanted 
into the oviducts of pseudopregnant foster females. 
Newborn mice resulting from development of the 
implanted embyos are checked by PCR for the presence of 
the desired DNA sequence (Strachan and Read 1999).  
Specific genetic modifications in a mouse genome can be obtained by isolating and culturing 
ES cells from the inner cell mass of blastocytes. While in culture, the ES cells can be 
genetically modified by homologous recombination. The modified ES cells are injected back 
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into isolated host blastocysts and 
reimplanted into a pseudopregnant foster 
mother. The developing embryo is a 
chimera which contains two populations 
of cells derived either from ES cells of 
the host blastocyst or from the implanted 
ES cells (Fig. 12). If the two strains of 
cells are derived from mice with 
different coat colors, chimeric offspring 
can be easily identified on their mixed 
fur coat color. Backcrossing of the 
chimeras can then generate mice that are 
heterozygous for the genetic 
modification, and subsequent cross-
breeding of heterozygous mutants can 
generate homozygous animals (Pluck 
and Klasen 2009; Strachan and Read 
1999). The specific DNA changes 
performed on the cultured ES cells are 
introduced using vectors designed to 
target the locus of interest through 
sequence homology between the 
introduced DNA and the target gene. Two types of vectors are used. Insertion vectors target 
the locus of interest by a single homologous sequence causing insertion of the entire 
introduced DNA including the vector sequence. By inserting foreign DNA into the target 
gene, this is the most reliable way of causing a KO mutation. Replacement vectors target the 
locus of interest by containing the DNA of interest flanked by two homologous sequences that 
then recombinate with the chromosomal DNA resulting in replacement of some of the 
sequence in the chromosomal gene. The result can inactivate the gene of interest if the 
introduced sequence contains a premature termination codon or lacks a critical coding 
sequence, but can also be used to change the coding sequence producing a change of function 
for the encoded protein thus producing a KI mutation (Strachan and Read 1999). The main 
Fig. 12 Specific modification of target gene by 
homologous recombination in ES cells. Embryonic stem 
(ES) cells from the inner cell mass of blastocytes are 
cultured, genetically modified, injected into isolated 
blastocyte of another mouse strain with different fur color, 
and then implanted into pseudopregnant foster mother. 
Development of introduced blastrocyst results in a chimera 
containing two populations of cells evident by the presence 
of differently colored coat patches. Backcrossing produces 
mice that are heterozygous for the genetic modification 
(Strachan and Read 1999).  
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disadvantage of the ES cell method is that gene cloning and construction of the targeting 
vector is quite time consuming and technically advanced. However, a huge advantage is that 
specific genetic modifications can be obtained and that these can be verified in the tissue 
culture, before insertion of the genetically modified cells are implanted into the foster mother. 
This renders the genetic manipulation highly effective and minimizes the time spend on 
breeding and phenotypic screening as the insertion can be performed in a single mouse line.  
1.3.2 FAD mutations in mouse models of AD 
Even though FAD only makes up 2-5% of AD cases, the many identified FAD mutations 
have the major advantage of being able to modulate the pathology of the disease in model 
organisms. Many mouse models of AD have been generated utilizing FAD mutations of APP 
and PS1 or PS2 causing the mice to develop an age-dependent Aβ deposition. FAD mutations 
in APP are generally named after the population in which they were first identified thus 
leading to amongst others the Swedish, Flemish, Dutch, Italian, Arctic, Iowa, French, 
German, Florida, London, Indiana, and Australian mutations of which the Swedish and 
London mutations are probably the most extensively studied (Fig. 13) (Janssen et al. 2003). 
The mutations segregate around the secretase cleavage sites affecting the activity of the 
restriction enzymes. Only one mutation has been identified at the β-cleavage site, the Swedish 
double mutation, which generally increases the production of Aβ (Scheuner et al. 1996). 
Mutations near the γ-secretase 
cleavage site generally increase 
the production of the more 
amyloidogenic Aβ42 (Scheuner 
et al. 1996), although the 
French mutation results in a 
reduction of Aβ40 without 
affecting Aβ42 production, 
suggesting that it is the 
increase in the ratio of Aβ42 to 
Aβ40 that is important rather 
than the absolute amount of 
Aβ42 (Ancolio et al. 1999). 
Fig. 13 Pathogenic mutations in APP. The mutations are given 
according to the APP amino acid sequence producing the Aβ peptide, 
related to β-, α-, and γ-cleavage sites as well transmembrane domain 
(TM). For each mutation is given name, amino acid mutation, and 
number in APP sequence (Janssen et al. 2003). 
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Intra-Aβ mutations near the α-secretase cleavage site as the Dutch and Flemish mutations are 
generally associated with CAA amyloid deposition in blood vessels in addition to amyloid 
plaque formation, however, the effect of these mutations on the levels of Aβ40 and Aβ42 are 
less clarified with evidence of reduced Aβ42 or generally reduced Aβ levels in cell culture 
studies (Janssen et al. 2003). More than 150 mutations have been identified in PS1 and PS2, 
which are part of the γ-secretase complex. PS1 mutations are the major cause of FAD 
accounting for 18-55% of all families. The PS1/PS2 mutations are scattered throughout the 
presenilin protein and generally result in an increased ratio of Aβ42/Aβ40 causing early and 
aggressive forms of AD (Bentahir et al. 2006; Kumar-Singh et al. 2006). 
The mouse models generated by introduction of, often several, FAD mutations are numerous. 
Much important information has come from the analysis of these mouse models; however, the 
differences in background, transgenic expression pattern, and combination of mutations 
render the comparison between the models almost impossible and irrelevant. Still, many show 
pathological features also observed in AD patients. For example, extracellular deposition of 
Aβ in plaques and vasculature as well as the accumulation of different forms of Aβ having N-
terminal modifications and being of different aggregation states correlates with findings in 
AD patients (Duyckaerts et al. 2008). Disturbances of neuronal structure in the form of 
dystrophic neurites surrounding plaques, decreased fiber and synapse density, and synaptic 
dysfunctions also correlate to observations in AD patients (Aucoin et al. 2005; Bellucci et al. 
2006; Bronfman et al. 2000; Hu et al. 2003; Luth et al. 2003; Wong et al. 1999), as does the 
observation of inflammatory changes (Baron et al. 2007; Eikelenboom et al. 2006). Neuron 
loss, however, assessed by stereological quantification is a feature only observed in very few 
mouse models, which complicates the study of the mechanism behind the massive neuron loss 
observed in AD patients and weakens the hypothesis of the Aβ deposition driving the AD 
pathogenesis (Casas et al. 2004; Schmitz et al. 2004). Also, none of the mouse models 
containing FAD mutations develop tau pathology in the form of NFT, making the link 
between Aβ and tau pathology a still unsolved mystery.  
1.3.3 The APP/PS1KI mouse model 
The bigenic APP/PS1KI mouse model is a result of the breeding of two different lines, a 
PS1KI mouse line and a transgenic APP Swedish London (APPSL) mouse line. The PS1KI 
mouse line was derived using a two-step mutagenesis strategy, based on the construction of a 
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targeting vector that bears base changes in the coding region at codons M233T and L235P and 
surrounding introns of the murine Ps1 gene. Homozygous mice were established and referred 
to as PS1KI. PS1KI mice on a mixed 129SV-C57BL/6 genetic background were bred with 
APPSL transgenic mice generated by pronuclear injection overexpressing human APP751 
carrying the London (V717I) and Swedish (K670N, M671L) mutations under the control of 
the Thy1 promoter on a mixed C57BL/6-CBA genetic background. When present, the APP 
transgene was heterozygote, and the resulting APP/PS1KI animals statistically have the same 
genetic background: 50% C57BL/6, 25% CBA, and 25% 129SV (Casas et al. 2004).  
The bigenic APP/PS1KI mice accumulates almost exclusively Aβ42, but with different N-
terminal modifications. The model is one of the currently most interesting as the mice develop 
an extensive neuron loss of about 30% in the CA1 region of the hippocampal formation 
already at 6 months, which is even more obvious in 10-month-old mice (Fig. 14A) (Breyhan 
et al. 2009; Casas et al. 2004). The bigenic mice are smaller and have a thoracolumbar 
kyphosis observed as a characteristic bend in the spinal cord compared to PS1KI control mice 
and they show a severe motor pathology evident by a hind limb clasping phenotype when 
dispensed by the tail. Significant impairments in the balance beam, string suspension, and 
vertical grip hanging tasks become obvious at the age of 6 months (Wirths and Bayer 2008). 
The APP/PS1KI mice also show inflammatory changes (Wirths et al. 2008a) and many 
dystrophic neurites marking axonal degeneration throughout the brain and spinal cord (Fig. 
14B) (Wirths et al. 2007; Wirths et al. 2006). The observed extensive pathology apparently 
results in behavioral deficits, which can be detected in working memory assessed by Y- and 
T-maze at the age of 6 months (Fig. 14C) (Wirths et al. 2008b). 
Fig. 14 Data from APP/PS1KI mice. A) Micrographs of hippocampal cresyl violet stained sections from 10-
month-old PS1KI, APPSL, and APPSLPS1KI mice. Massive cell loss is observed in the CA1 of bigenic 
APPSLPS1KI mice only (arrows) (Casas et al. 2004). B) Large axonal spheroids stained with antibody against 
NF200 labeling neurofilaments in neurons of 10-month-old APP/PS1KI mice (Wirths et al. 2007). C) Analysis of 
alternation behavior in T-maze revealed significant impairment in working memory at the age of 6 and 12 months 
in the APP/PS1KI mice compared to PS1KI controls (Wirths et al. 2008b). 
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1.4 The amyloid hypothesis 
For many years, scientists have been split concerning the etiology of AD depending on their 
belief in Aβ or tau as the driving pathological mechanism of AD. The amyloid hypothesis 
states that the accumulation of Aβ, preferable Aβ42, is the underlying cause of AD driving 
neuron and synapse impairment and loss, eventually leading to behavioral deficits (Hardy 
2006; Hardy and Allsop 1991). The major argument for the amyloid hypothesis is the genetics 
of FAD in which mutations have been identified only in genes linked to the Aβ generating 
cascade, whereas mutations in tau lead to frontotemporal dementia (Kumar-Singh and Van 
Broeckhoven 2007). Thus at present, the amyloid hypothesis is widely believed to be the 
primary pathological mechanism of AD, whereas the tau pathology is believed to be 
downstream of Aβ pathology since FAD also show NFTs, but frontotemporal dementia 
caused by tau mutations shows no Aβ pathology. Another argument for the Aβ hypothesis is 
the discovery of the familial British and Danish dementias. These dementias are caused by 
two different mutations in the BRI2 gene generating two similar proteins of 34 amino acids 
varying in their C-terminal part (Vidal et al. 1999; Vidal et al. 2000). These two proteins 
aggregate and form amyloid plaques similar to Aβ plaques in AD and the proteins are thus 
named amyloid Bri (ABri) and amyloid Dan (ADan) according to their presence in British 
and Danish dementia. Interestingly, the processing of the BRI2 gene reminds a lot of that of 
APP as it can also be cleaved by ADAM10 and has been shown to undergo regulated 
intramembrane proteolysis (Martin et al. 2008), and the British and Danish dementias also 
develop tau pathology, which further suggest that tau pathology is downstream of the amyloid 
pathology (Holton et al. 2001).  
Plaques have been shown to cause toxic effects such as disturbances in the fiber network with 
development of dystrophic swellings in surrounding fibers and loss of dendritic spines, as 
well as decreased synaptic bouton density, preferably of cholinergic cortical fibers (Blanchard 
et al. 2003; Delatour et al. 2004; Hu et al. 2003; Tsai et al. 2004; Wirths et al. 2007). Still, 
much remains to be resolved about their actual toxicity as the accumulation of extracellular 
Aβ plaques does not seem to correlate with the cognitive decline observed in AD patients and 
can be found in non-demented control subjects (Aizenstein et al. 2008). Furthermore, loss of 
neurons is rarely observed in the various mouse models generated accumulating abundant Aβ 
plaque pathology (Duyckaerts et al. 2008; Games et al. 2006). 
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1.4.1 The intraneuronal amyloid hypothesis 
A possible modification of the 
amyloid hypothesis is that the driving 
pathological factor is not Aβ 
accumulation in extracellular plaques, 
but rather Aβ accumulation inside 
neurons. Intraneuronal accumulation 
of Aβ has received considerable 
attention in the past recent years and 
is believed to precede extracellular 
plaque deposition (Gouras et al. 2005; 
Gyure et al. 2001; Laferla et al. 2007; 
Wirths et al. 2004). Thus the 
intraneuronal Aβ hypothesis of AD is 
a modification of the original amyloid 
hypothesis and suggests that risk 
factors such as aging, ApoE4 
polymorphism, trisomy 21 (Down 
Syndrome), or FAD mutations 
initially cause Aβ accumulation inside neurons, leading to functional deficits and loss of 
neurons and synapses ending up in cognitive decline (Fig. 15) (Gouras et al. 2005; Laferla et 
al. 2007; Wirths et al. 2004). In this model, plaques are considered a result of Aβ leakage or 
release from the intraneuronal pool, or to originate from the lysis of neurons accumulating 
intraneuronal Aβ. The plaques are believed to cause disturbances of the neuronal network, but 
they are not considered the primary cause of AD pathogenesis (D'Andrea et al. 2001; Gouras 
et al. 2005; Wang et al. 2002). 
Fig. 15 The intraneuronal Aβ hypothesis of AD. Due to risk 
factors as ageing, Trisomy 21 and FAD mutations, 
intraneuronal Aβ42 levels increase and leads to synaptic and 
neuronal dysfunction followed by neurodegeneration. In 
parallel, increased release and deposition of Aβ42 leads to 
extracellular plaque formation, from which Aβ can possibly 
again be internalized and contribute to the intraneuronal pool of 
Aβ peptides. (Wirths et al. 2004). 
The accumulation of intraneuronal Aβ peptides in AD brains has been sporadically reported 
since the late 1980´s (Grundke-Iqbal et al. 1989), however, initial problems with the inability 
of the antibodies to distinguish full length APP from Aβ founded a skepticism towards the 
presence of intraneuronal Aβ that has been exceedingly difficult to eliminate (Gouras et al. 
2005; Laferla et al. 2007). Despite the initial technical complications, several studies using 
Aβ40/42 end-specific antibodies have since reported the presence of intraneuronal Aβ in AD 
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brains (D'Andrea et al. 2002a; D'Andrea et al. 2002b; D'Andrea et al. 2001; Fernandez-
Vizarra et al. 2004; Gouras et al. 2000; Mochizuki et al. 2000; Nagele et al. 2002; Wegiel et 
al. 2007), as well as in Down Syndrome patients who are known to develop AD in early age 
(Gyure et al. 2001; Mori et al. 2002). One study even isolated human hippocampal granular 
neurons from the CA1 of AD patients by laser capture microdissection and identified an 
increased intraneuronal ratio of Aβ42/Aβ40 in AD patients compared to controls (Aoki et al. 
2008). However, people still remain skeptical towards the presence of intraneuronal Aβ in 
human AD brains, probably because most of the studies show pictures of variable quality and 
often reports of findings in only one or a very low number of AD cases. Also, some 
antibodies, especially monoclonal, directed toward an internal part of Aβ seem to cross-react 
with lipofuscin, which is a protein that accumulates abundantly in neurons with age showing a 
very distinct cap-like granular staining nearby the nucleus (Bancher et al. 1989). The reports 
of intraneuronal Aβ have thus been inconsistent with pictures showing very different patterns 
of intraneuronal Aβ accumulation of which some have actually been lipofuscin, and the 
accumulation of intraneuronal Aβ remains under discussion (Duyckaerts et al. 2008).  
In AD mouse models, intraneuronal Aβ was first reported in familial PS1 transgenic mice that 
also showed neurodegeneration without the formation of plaque pathology (Chui et al. 1999), 
and has since been convincingly reported in several mouse models including APPSDLPS1M146L 
(Wirths et al. 2001), Tg2576 (Takahashi et al. 2002), 3xTg-AD (Oddo et al. 2003), 5xFAD 
(Oakley et al. 2006), APPArc (Knobloch et al. 2007; Lord et al. 2006), APPT714I (Van Broeck 
et al. 2008), as well as in APP/PS1KI mice (Casas et al. 2004). In the mouse models, 
intraneuronal Aβ has amongst others been reported to disrupt fast axonal transport in isolated 
axoplasms (Pigino et al. 2009) and impair multivesicular body sorting by inhibiting the 
ubiquitin-proteasome system (Almeida et al. 2006). In addition, it induces synaptic 
dysfunction leading to reduced postsynaptic density 95 protein (PSD-95) levels and 
consequently reduces the levels of the glutamate receptor subunit, GluR1, in synapses 
(Almeida et al. 2005). Strikingly, of the very few mouse models based on FAD mutations 
which have been documented to show robust neuron loss, two are accumulating intraneuronal 
Aβ: the APPSLPS1M146L and the APP/PS1KI models (Casas et al. 2004; Schmitz et al. 2004). 
The 5xFAD mice, which also accumulate intraneuronal A peptides, have been described to 
have a lower density of neurons in the cortex and subiculum based on a qualitative evaluation 
of a cresyl violet staining, however, this needs to be confirmed by unbiased stereological 
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quantifications (Oakley et al. 2006). This renders the mouse models accumulating 
intraneuronal Aβ especially interesting for studying the neuron loss in AD, which most likely 
symbolizes the irreversible step in the pathological cascade of AD where clinical deficits 
become apparent (Price et al. 2001).  
1.5 Transmitter deficits in Alzheimer’s disease 
The first transmitter specific deficits to be identified in AD were of the cholinergic system 
utilizing acetylcholine (ACh) as a neurotransmitter that were reported already in the 1970s 
leading to the cholinergic hypothesis of AD (Davies and Maloney 1976). Parallel to 
Parkinson´s disease, which is primarily a neurodegenerative disease of the dopaminergic 
neurons of the substantia nigra, AD was hypothesized to be a neurodegenerative disease of the 
cholinergic system, owing mainly to degeneration of cholinergic neurons of the nucleus 
basalis of Meynert, which is the largest cholinergic nucleus of the human basal forebrain 
projecting to the cortex (Coyle et al. 1983). The cholinergic system of the brain comprises two 
projecting neuron complexes: the basal forebrain and the pons complex, as well as motor 
nuclei projecting to the periphery and interneurons located mainly in the striatum. In the 
present thesis, the cholinergic projecting nuclei will be designated according to the Ch1-6 
nomenclature, which is based on common connectivity patterns that are virtually identical in 
human and rodents (Lucas-Meunier et al. 2003; Mesulam et al. 1983). From the basal 
forebrain complex, cholinergic neurons from the medial septum (Ch1) and the vertical limb of 
the diagonal band (Ch2) project to the hippocampal formation, whereas those of the basal 
nucleus of Meynert (Ch4) mainly 
project to the cortex (Fig. 16). The Ch3 
is a minor nucleus of the horizontal 
part of the diagonal band and its 
cholinergic neurons project to the 
olfactory bulb. The cholinergic 
neurons of Ch5-6 belong to another 
projecting complex located in the pons 
projecting mainly to the thalamus. 
Initially, a reduction in the activity of 
Fig. 16 Overview of Ch1-6 nomenclature and projections.
The figure is based on a sagital section of the rat brain. 
Hatched area: the diagonal band (Lucas-Meunier et al. 2003). 
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both the ACh synthesizing enzyme, choline acetyltransferase (ChAT), and the ACh degrading 
enzyme, acetylcholine esterase (AChE), was reported being most severe in the cortex (Davies 
1979; Davies and Maloney 1976). Subsequently, a loss of cholinergic forebrain neurons of the 
nucleus basalis of Meynert was discovered as the first evidence of neuron loss in AD (Arendt 
et al. 1988; Mufson et al. 1989; Whitehouse et al. 1981). These cholinergic forebrain neurons 
projecting to the cortex participate in the mediation of attention, and their degeneration is thus 
thought to cause part of the cognitive decline observed in AD (Sarter et al. 2005).  
Based on the cholinergic hypothesis, AD patients have long been treated with AChE 
inhibitors to decrease the breakdown of ACh and thereby prolong its action in the synaptic 
cleft. However, the clinical impact of the AChE inhibitors has turned out to be quite 
disappointing with only minor beneficial effects and it was soon recognized that AD is a 
complex disease affecting multiple transmitter systems, although perhaps with the cholinergic 
basal forebrain neurons being especially vulnerable. According to the nerve growth factor 
(NGF) hypothesis, this vulnerability is thought to be caused by decreased NGF stimulation of 
the cholinergic basal forebrain neurons as their survival is highly dependent on NGF being 
retrogradely transported from the hippocampal formation or cortex (Counts and Mufson 
2005). Thus in vivo, cholinergic Ch4 neurons of the nucleus basalis degenerated following 
experimental neocortical infarction in monkeys (Burgos et al. 1995) or excitotoxic neocortical 
lesions in rats (Charles et al. 1996), but were rescued by exogenous NGF treatment. In 
parallel, infusion of NGF can prevent death of cholinergic Ch1/2 neurons following 
septohippocampal axotomy (Hefti 1986; Tuszynski and Gage 1995; Williams et al. 1986) or 
hippocampal lesions (Burke et al. 1994). Finally, transgenic mice that express anti-NGF 
antibodies in adulthood display an age-dependent specific loss of cholinergic basal forebrain 
neurons (Capsoni et al. 2000; Ruberti et al. 2000). In AD patients, the NGF system has been 
found to be dysregulated early in the disease progress and in end-stage AD patients, 
cholinergic basal forebrain neurons have reduced protein levels of NGF and its high and low 
affinity receptors, TrkA and p75, whereas both stable, increased, as well as decreased levels 
of NGF have been reported in the cortical and hippocampal projection regions of end-stage 
AD (Mufson et al. 1995; Scott et al. 1995). Thus impairment in retrograde transport of NGF is 
thought to be responsible for the lack of trophic support of Ch4 neurons, rendering the 
cholinergic neurons more vulnerable, or directly mediate their degeneration (Lad et al. 2003). 
NGF treatment is therefore another potential treatment for AD directly targeting the 
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degeneration of the cholinergic basal forebrain neurons, however, there is a need for highly 
specific delivery to avoid aberrant sprouting of neuronal fibers. So far, one successful phase I 
clinical trial has been conducted in which mild AD subjects received grafts of autologous 
fibroblasts genetically modified to secrete human NGF (Tuszynski et al. 2005). The cells were 
implanted directly in the nucleus basalis of Meynert bypassing putative defects in the 
retrograde transport of NGF and avoiding systemic exposure. The patients showed minor 
improvements in cognitive decline and cortical glucose uptake; still, more studies are needed 
to confirm a positive effect of NGF treatment in AD patients. Apart from administration, a 
major challenge of NGF treatment will be early intervention, as NGF must be given prior to 
degeneration of the cholinergic neurons to have any effect on their survival (Montero and 
Hefti 1988). 
To date, only 5 drugs have been approved by the food and drug administration (FDA) in the 
US for treatment of AD. These are tacrine (Cognex), rivastigmine (Exelon), galantamine 
(Razadyne), donepezil (Aricept), and memantine (Namenda), of which the first four are all 
AChE inhibitors. It has been evaluated that at least rivastigmine, galantamine, and donepezil 
have similar efficacy showing only minor benefits of treatment on cognitive function, 
activities of daily living, and behavior and there is currently a debate concerning whether the 
AChE inhibitors have any effect at all (Birks 2006).  
Also receptors of the cholinergic system are being discussed as potential targets for future 
treatments of AD. Two types of cholinergic receptors exist, the nicotinic ACh receptors 
(nAChRs) which are ligand-gated ion channels, and the muscarinic receptors that are 7-
transmembrane receptors coupled to G proteins. The muscarinic receptors, especially the M1 
receptor, have received much attention in the past showing stimulation of α-secretase 
cleavage by Protein Kinase C (PKC) activation (Nitsch et al. 1992), but presently, the 
nAChRs are at the center of most attention (D'Andrea and Nagele 2006). The nAChRs are 
composed of 5 transmembrane subunits of which there are 2 major types, α and β. At least 9 
α-type subunits (α2 through α10) and 3 β-type subunits (β2 through β4) are expressed 
throughout the CNS, where two of the most abundant neuronal nAChRs are the heteromeric 
high affinity α4β2 and the homomeric low affinity α7 receptors (Alkondon and Albuquerque 
2004). All the nAChRs are stimulated by ACh and nicotine with varying affinities and are 
cation selective, being permeable to small monovalent and divalent cations, where the α7 
nAChR has a high relative permeability of Ca2+ to Na+ of ≥ 10 as compared to ~ 2.0 for the 
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heteromeric neuronal receptors (Dani and Bertrand 2007). The nAChRs mediate fast synaptic 
signal transmission and are involved in learning, memory, and attention (Hasselmo 2006; 
Sarter et al. 2005). In AD post-mortem studies, reductions in both α4 and α7 subunits have 
been reported in the cortex and hippocampal formation (Guan et al. 2000; Teaktong et al. 
2004). Although, increased immunohistochemical staining of α7 reactive neuropil was 
observed in some areas of the hippocampus (Teaktong et al. 2004) and cholinergic neurons of 
the nucleus basalis of Meynert express an increased level of  α7 nAChRs, probably as a 
compensatory mechanism in reaction to their dysfunction and degeneration (Counts et al. 
2007). In contrast, little depletion or dysregulation of muscarinic cholinergic receptors has 
been found in patients with AD (Nordberg et al. 1992). 
The nAChR showing most implication in AD is the α7 nAChR, of which a direct interaction 
with Aβ42 has been repeatedly reported, and genetic variation in the α7 nAChR gene has 
recently been shown to influence AD susceptibility (Carson et al. 2008). In human AD brain 
tissue, α7 nAChRs show co-localisation with Aβ42, and also co-immunoprecipitate with 
Aβ42 in AD hippocampal neurons, as does α7nAChRs purified from culture and incubated 
with synthetic Aβ42 (Wang et al. 2000). In membranes, the same study found that Aβ42 
displaces α-bungarotoxin (α-BTX) binding specific for α7nAChRs (Wang et al. 2000). In 
contrast, another study in cultured cells found that Aβ does not bind to α7nAChRs, but binds 
to lipids within the plasma membrane that could, potentially, influence the function of a 
variety of receptors and channels on the cell surface (Small et al. 2007). However, Aβ42 
specifically blocks the response evoked by ACh or nicotine of α7 nAChRs in cell culture and 
hippocampal neurons (Liu et al. 2001; Pettit et al. 2001; Spencer et al. 2006), and α7 nAChR 
activation protected against Aβ-induced neurotoxicity (Kihara et al. 1997). Interestingly, the 
α7 nAChR has been suggested to mediate endocytosis of Aβ42, facilitating intraneuronal 
accumulation of Aβ (Nagele et al. 2002).  
In addition to direct cholinergic behavioral deficits, the α7 nAChRs can cause behavioral 
symptoms by interaction with other transmitter systems. For instance, α7 nAChRs are located 
presynaptically at excitatory synapses and enhance both glutamatergic and cholinergic 
synaptic transmission by increasing presynaptic intracellular Ca2+ levels (McGehee et al. 
1995). This suggests that fluctuations in α7 receptor levels may lead to functional deficits in 
the glutamatergic excitatory system thus influencing processes of learning, memory, and 
synaptic plasticity, or even influence excitotoxicity. In fact, the AChE inhibitor, galantamine, 
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is thought to also block glutamate toxicity through α7 mediated phosphatidylinositol 3-kinase 
(PI3K) activation (Kihara et al. 2004). 
The involvement of the cholinergic system in the pathogenesis of AD is supported by the 
observation that nicotine reduces Aβ levels in APPswe mice (Hellstrom-Lindahl et al. 2004a), 
which correlated with the finding that smoking had a lowering effect on Aβ and an increasing 
effect on radioactive-ligand binding of nicotinic receptors in the brains of AD patients and 
control subjects (Hellstrom-Lindahl et al. 2004b). These studies indicate that selective 
nicotinic agonists may be beneficial in AD by lowering Aβ levels and even increasing nAChR 
levels. Accordingly, some pharmaceutical companies are presently developing α7 agonists for 
AD patients; however, many believe that the best strategy to treat neurotransmitter deficits in 
AD will be to use a combination of drugs toward multiple targets within neurotransmission 
(Geerts and Grossberg 2006; Grossberg et al. 2006; Gsell et al. 2004).  
1.6 Introduction to experiments 
The loss of neurons in AD represents a fatal irreversible step in the cascade of AD 
development; however, thus far, the mechanism of the neuron loss remains unclear. As 
specified, very few mouse models generated by use of FAD mutations have so far shown any 
loss of neurons, and especially, the specific loss of the cholinergic neurons of the nucleus 
basalis of Meynert lacks to be modeled. The intraneuronal Aβ hypothesis is a fairly new 
modulation of the amyloid hypothesis, stating that intraneuronal Aβ rather than plaque 
pathology is the primary toxic mechanism of AD pathogenesis. The present thesis focuses on 
the impact of intraneuronal Aβ on neuron function and degeneration, mainly utilizing the 
APP/PS1KI model, which is one of the presently most interesting mouse models of AD 
showing cognitive deficits, extensive neuron degeneration in the CA1, and abundant 
accumulation of intraneuronal Aβ in many regions prior to development of plaque pathology 
in early age (Casas et al. 2004; Wirths et al. 2008b; Wirths et al. 2007). The following studies 
were undertaken to investigate the impact of Aβ, especially intraneuronal, on neuron function 
and degeneration, and their backgrounds are further explained below: 
1. The neuron number in selected parts of the cholinergic system of the APP/PS1KI 
mouse model was quantified and correlated to the accumulation of intraneuronal Aβ.  
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2. The impact of intraneuronal Aβ versus plaques on neuronal survival was studied in the 
APP/PS1KI mouse model by neuron quantification in an area with plaques only 
compared to an area with plaques as well as intraneuronal Aβ. 
3. Intraneuronal Aβ staining was optimized in four AD mouse models as well as human 
AD tissue, and subsequently used to semi-quantify the intensity of intraneuronal Aβ 
staining in human sporadic AD brains that was correlated to patient data. 
4. The toxic effect of Aβ on axonal pathology was studied in APP/PS1KI mice.  
5. Collaboration was established with Neurosearch A/S in Denmark to evaluate the 
impact of the potential interaction between Aβ and the α7 nAChR in AD.  
6. Through collaboration with Neurosearch as well as the group of Mark West in Århus, 
Denmark, the potential dysfunction of the Arc system was investigated in the 
APP/PS1ΔE9 mouse model of AD following novelty stimulation. 
1.6.1 Neuron loss in the cholinergic system of APP/PS1KI mice 
Because the APP/PS1KI mice develop an extensive neuron loss in the CA1 region of the 
hippocampal formation, the present study investigated Aβ accumulation and its influence on 
neuronal survival in the cholinergic system of this bigenic mouse model. The objective of the 
study was to establish whether the APP/PS1KI mouse model represents a valid model for the 
cholinergic neuron loss observed in AD. The expression of the APP transgene and 
accumulation of intraneuronal Aβ was initially investigated by qualitative fluorescent 
immunohistochemistry using antibodies towards ChAT to indentify neurons of the cholinergic 
system. The pattern of APP transgene expression and corresponding intraneuronal Aβ 
accumulation was applied as a model system to study the effect of intra- and extracellular Aβ 
accumulation on neuron loss in the cholinergic system analyzed by design-based stereology 
quantifying ChAT-positive neurons stained by free-floating immunohistochemistry.  
1.6.2 Effect of intraneuronal Aβ versus plaques on neurodegeneration 
The study of the impact of intraneuronal Aβ on neuronal survival in the cholinergic system 
was extended to a study comparing the impact of intraneuronal Aβ versus plaques on neuron 
loss. For this purpose, the APP/PS1KI mice presented an optimal model system as they have 
regions of the brain not accumulating intraneuronal Aβ, but with abundant deposition of 
Introduction  34
 
plaques as well as regions accumulating intraneuronal Aβ together with the deposition of 
plaques. The thalamus was chosen as a region accumulating plaques only, whereas the frontal 
cortex was used to study the impact of the combined accumulation of plaques and 
intraneuronal Aβ. Initially, the Aβ deposition was thoroughly investigated in the two chosen 
regions and neuron quantifications were subsequently performed using design-based 
stereology comparing the APP/PS1KI mice to PS1KI control mice showing no Aβ pathology. 
1.6.3 Intraneuronal Aβ staining in AD patients and transgenic AD mouse 
models 
Many scientists remain skeptical toward the presence of intraneuronal Aβ in human AD 
brains. Thus the present study had the objective of optimizing and confirming the staining of 
intraneuronal Aβ in human AD tissue using a highly specific N-terminal Aβ antibody, 
whereas other studies have mainly targeted the C-terminus of Aβ. Compared to mouse tissue, 
human tissue offers challenges such as post-mortem delay and less consistent tissue fixation, 
which might cause problems with the immunohistochemical staining techniques. Also, the 
staining protocols so far applied to study intracellular Aβ accumulation in human tissue have 
been inconsistent with varying use of heat and formic acid (FA) for antigen retrieval. 
Microwave heat treatment has been reported to enhance the staining of intraneuronal Aβ as 
compared to no or enzymatic pretreatment (D'Andrea et al. 2002b). FA is widely used to 
increase the staining of plaque pathology in AD, yet, the effect of FA on intraneuronal Aβ 
staining has been reported to be low and similar to the effect of heat (D'Andrea et al. 2003) or 
even to counteract the enhancing effect of heat pretreatment on intraneuronal Aβ 
immunohistochemical detection (Ohyagi et al. 2007).  
The study was divided in two parts. First, the staining protocol for intraneuronal Aβ was 
optimized in relation to heat and FA in four different mouse models being positive controls 
known to accumulate intraneuronal Aβ. Secondly, the optimization was extended to human 
brain tissue from AD patients.  
Optimization for staining of intraneuronal Aβ in mouse models of AD 
The effect of FA versus microwave heating on the staining of plaques and intracellular Aβ 
was quantified in the APP/PS1KI mouse model utilizing the regional discrepancy of Aβ 
deposition in relation to plaques and intraneuronal Aβ accumulating in the thalamus and CA1, 
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respectively. The quantification of Aβ staining was performed using ImageJ, where a fixed 
intensity threshold was applied to micrographs defining the 3,3-diaminobenzidine (DAB) 
staining, and the percentile area covered by Aβ staining was calculated. The results of the 
quantification were confirmed in a qualitative optimization in three other mouse models using 
two different Aβ antibodies, where four conditions were compared; no pretreatment, FA 
pretreatment, heat pretreatment, and combined FA and heat pretreatment, applying time 
intervals optimized in the quantitative study in the APP/PS1KI mice.  
Staining of intraneuronal Aβ in brain tissue of AD patients 
The four optimized conditions from the studies in the mouse models were applied to human 
brain tissue of sporadic, familial Swedish and familial Arctic AD cases as well as non-
demented controls. The best protocol was used to screen 10 controls and 20 sporadic AD 
cases for the intensity of intraneuronal Aβ staining, which was correlated to patient data 
including gender, Braak stage, plaque load, and ApoE genotype.  
1.6.4 Effect of Aβ on axonopathy in transgenic AD mouse models 
Abnormalities and impairments in axonal transport are suggested to strongly contribute to the 
pathological alterations underlying AD (Roy et al. 2005; Stokin and Goldstein 2006; Zhu et 
al. 2005). Indications for axonopathy resulting in disturbances in axonal transport have also 
been described in various APP-based transgenic AD mouse models (Salehi et al. 2006; Stokin 
et al. 2005; Wirths et al. 2007; Wirths et al. 2006). Surprisingly, it has recently been shown 
that an increase in the A42/A40 ratio, as well as an increased deposition of A peptides, 
resulted in a suppression of APP-induced axonal deficits in both transgenic mouse and 
drosophila models, leading to the suggestion that APP-induced axonal defects are not caused 
by Aβ peptides (Stokin et al. 2008). To evaluate the effect of Aβ accumulation on axonopathy 
in our APP/PS1KI model, the present study quantified large plaque-independent axonal 
spheroids in the brain of APP single transgenic mice overexpressing APP751 with the 
Swedish and London mutations under control of the Thy-1 promotor, as well as in APP 
transgenic mice co-expressing the mutant PS1KI gene on endogenous levels in either a hemi- 
(APP/PS1KIhe) or homozygous (APP/PS1KIho) manner. Using this strategy, APP expression 
levels did not differ between the different mouse lines, however, increased PS1KI gene 
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dosage caused a dramatic increase in Aβ peptide levels, allowing the study of the impact of 
Aβ independently of APP expression. 
APP can be applied as a marker of axonopathy since it is transported into fibers and 
accumulates in dystrophic swellings and APP is thus often used in the detection of axonal 
pathology for example in the analysis of traumatic brain injury (Pierce et al. 1996) and has 
previously been used to detect axonal degeneration in APP/PS1KIho mice (Wirths et al. 2007). 
However, a problem of using APP as a marker of axonal degeneration in APP-transgenic 
mouse models is its very broad staining pattern. This includes cell bodies, axonal swellings 
and dystrophic neurites in the vicinity of amyloid plaques, thereby complicating the analysis 
of distinct pathological alterations like axonal pathology especially in plaque-rich brain areas. 
One solution is to use an antibody which detects APP phosphorylated at T668 (anti-pT668) 
that has proved not to stain cell bodies, but only stains dystrophic neurites that can be plaque-
associated or plaque-independent. NF-200 is a 200 kDa neurofilament and is another possible 
marker of axonopathy. Neurofilaments are the most abundant fibrillar components of the axon 
and serve as major elements of the cytoskeleton supporting the axonal structure and NF-200 
has the advantage of mostly staining the large axonal swellings independent of plaques. Thus 
antibodies toward phosphorylated APP and NF-200 were applied as markers in the 
quantification of axonopathy in the APP, APP/PS1KIhe, and APP/PS1KIho mice. 
Equal APP expression levels in the three mouse lines were confirmed qualitatively and 
quantitatively by APP immunohistochemical staining and western-blots. The accumulation of 
Aβ was likewise evaluated by western-blots and Aβ immunohistochemical staining, which 
was quantified by micrographs and Image-J software analysis.  
To study possible mechanism of the axonopathy observed in the APP/PS1KI mice, the level 
of ubiquitin and ubiquitinated proteins was qualitatively investigated in the different mouse 
lines using immunohistochemistry and western-blotting. Furthermore, yellow fluorescent 
protein (YFP) transgenic mice expression YFP in 2-3% of neurons were crossed with 
APP/PS1KIhe mice to obtain visualization of fibers in fluorescent analyses and the presence of 
intracellular Aβ in dystrophic fibers was directly analyzed using confocal microscopy. 
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1.6.5 Interaction between α7 nAChR and Aβ 
The cholinergic system modulates cognitive functions such as attention and memory, and 
smoking was found to have a lowering effect on Aβ and an increasing effect on radioactive-
ligand binding of nicotinic receptors in the brains of AD patients and control subjects, 
indicating that selective nicotinic agonists may be beneficial in AD (Hellstrom-Lindahl et al. 
2004b). This was supported by a study in APPswe mice, where 10 days of treatment with 
nicotine reduced insoluble Aβ40 and Aβ42 levels with 80% in brain tissue (Hellstrom-Lindahl 
et al. 2004a). Which of the nAChRs that mediates the beneficial effects of nicotine is 
unknown, but many studies have reported a direct interaction between the α7 nAChR and 
Aβ42, implicating the α7 nAChR in AD. If Aβ in fact interacts with the α7 nAChR it could 
mediate part of its toxic effect by inducing desensitization of the α7 nAChR. The present 
study thus set out to investigate if specific activation of the α7 nAChR could mediate a 
lowering effect on the generation of Aβ, and whether endogenous accumulation of Aβ had an 
effect on the binding capacity of the α7 nAChR in vivo.  
The study was performed as cooperation with the group of Mark West at the department of 
Neurobiology, Anatomical Institute, Aarhus University, Denmark. Three groups of 9-month-
old APP/PS1ΔE9 mice were treated twice daily for 10 days with subcutaneous injections of 
saline, 10 mg/kg of the α7 nAChR agonist SSR180711 (1,4-Diazabicyclo[3.2.2]nonane-4-
carboxylic acid, 4-bromophenyl ester, synthesized at Neurosearch A/S, DK), or 10 mg/kg 
nicotine ((−)-1-Methyl-2-(3-pyridyl)pyrrolidine (+)-bitartrate salt, Sigma-Aldrich, St Louis, 
USA) as a positive control replicating the data from the APPswe mice. The mice were 
decapitated and half of the brains were directly frozen on dry ice and stored at -80°C, whereas 
the other halves were immersion fixated in 4% formaldehyde for 5 days until they were 
embedded in paraffin. Aβ levels were quantified in micrographs of Aβ immunohistochemistry 
on 2 µm paraffin sections using Image-J software. A radioactively labeled α-BTX binding 
assay was set up at Neurosearch A/S in Denmark and applied to brain sections from 9-month-
old APP/PS1ΔE9 and C57Bl6 control mice to evaluate the effect of in vivo Aβ accumulation 
on α7 nAChR binding levels in the brain.  
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1.6.6 Functional integrity of immediate early gene responses following novelty 
stimulation 
Immediate-early genes (IEGs) are the first genes to be expressed following synaptic activity, 
they do not require de novo synthesis for expression, and are considered to play a key role in 
activity-dependent synaptic modification and memory consolidation (Guzowski 2002; 
Steward and Worley 2002). The activity-regulated cytoskeletal-associated protein (Arc) and 
the regulatory transcription factor, c-fos, are IEG products produced by the corresponding 
IEGs, Arc, and c-fos. An especially interesting feature of the Arc protein is that newly 
synthesized Arc mRNA is rapidly delivered into the active synaptic sites based on a targeting 
signal in the mRNA sequence and is translated locally in the synapse (Wallace et al. 1998). 
Taking part in the targeting of Arc mRNA, N-Methyl-D-Aspartat (NMDA) receptor activation 
has been shown to be sufficient and necessary to trigger the translocation of Arc mRNA into 
dendrites, and upon translation, the Arc protein forms an integral part of the synaptic 
junctional complex that also involves the NMDA receptor, which strongly support a role of 
Arc in synaptic plasticity underlying the consolidation of long-term memory (Steward and 
Worley 2001). Accordingly, infusion of Arc antisense oligonucleotides directly into the 
hippocampus in vivo not only blocked the expression of the corresponding protein, but also 
disrupted the maintenance of LTP and impaired memory in a spatial maze task (Guzowski et 
al. 2000). In vivo, IEGs take part in encoding observations from the surrounding environment. 
Thus a five-minute exposure to a novel environment has been shown to dramatically increase 
the expression of IEGs such as Arc and c-fos in neurons of the CA1, CA3, and upper DG of 
the hippocampal formation as well as in the parietal cortex, and medial prefrontal cortex 
(Chawla et al. 2005; Guzowski et al. 1999; Klebaur et al. 2002; Vazdarjanova and Guzowski 
2004; Vazdarjanova et al. 2002). The population of neurons thereby upregulating Arc 
expression in the CA1 has even been shown to be specific for a certain environment, and the 
induction of IEG expression is therefore thought to be linked to neural encoding processes of 
the surrounding environment (Guzowski et al. 1999). An inability to upregulate expression of 
IEGs could thus lead to deficits in cognitive functions and disable the encoding of memories, 
which could underline part of the functional deficits observed in AD patients showing 
disturbances in cognitive functions such as memory deficits and orientation in time and space 
(Reisberg 2006). The present study therefore investigated the ability of APP/PS1ΔE9 mice to 
upregulate the expression of the two IEGs, Arc and c-fos, upon experiencing a novel 
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environment. The study was performed as cooperation with the group of Mark West at the 
department of Neurobiology, Anatomical Institute, Aarhus University, Denmark, where 4 
groups of 9-month-old APP/PS1ΔE9 or C57BL6 wild-type control mice were either 
decapitated directly from their home-cage or stimulated for 5 min in a novelty paradigm after 
which they were returned to their home cage for 30 min before decapitation. The levels of Arc 
and c-fos mRNA were analyzed at Neurosearch A/S in Denmark by semi-quantitative in situ 
hybridization and compared to the expression levels of the house keeping gene synaptophysin. 
Because exposure to a novel environment is a light stressor and has been shown to induce the 
hypothalamic-pituitary-adrenal (HPA) axis, trunk blood was collected for plasma 
corticosterone quantification and used to verify the effect of the novelty paradigm (Briski 
1996; Chandramohan et al. 2007). 
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2 Methods and Materials 
2.1 Transgenic mice 
Several mouse models of AD have been applied in the current thesis and their genetic 
modifications are described in Table 1. The most extensively used mouse model is the 
APP/PS1KI model which has been described in the introduction (Chapter 1.3.3) and was bred 
at the University of Göttingen, Germany. All mice designated PS1KI were homozygous for 
PS1KI mutations, in comparison to the APP/PS1KI mice that were hemizygous for the 
APP751 isoform carrying the Swedish and London mutations (APP751SL transgene). PS1KI 
mice showed no pathology or phenotype and were generally used as littermate controls. In the 
study of axonopathy were applied variations of the APP/PS1KI mouse model. APP mice were 
hemizygous for the APP751SL transgene, whereas APP/PS1KIhe and APP/PS1KIho mice 
additionally carried one or two alleles with the PS1KI mutations, respectively. 
YFP/APP/PS1KI mice were generated by crossing of APP/PS1KIhe mice and yellow 
fluorescent protein (YFP) transgenic mice overexpressing YFP in a proportion of neurons in 
the brain under the control of the Thy 1 promoter (Feng et al. 2000) (The Jackson Laboratory, 
US). APP/PS1KI mice were a generous gift of Dr. Laurent Pradier, Sanofi-Aventis, France. 
Only female mice were applied for stereological quantifications, whereas males were also 
applied for qualitative immunohistochemical analyses.  
APP/PS1ΔE9 transgenic mice were hemizygous for the APP and PS1 mutations (Borchelt et 
al. 1996). Only female mice were applied and non-transgenic wild-type female littermates 
were used as controls. The mice were bred at the Anatomical Institute, Aarhus University, 
Denmark, where in vivo experiments were also carried out.  
APP/PS1 transgenic mice (Blanchard et al. 2003; Wirths et al. 2002) were hemizygous for 
both transgenes and three 8-month-old mice were used in the qualitative optimization for 
intraneuronal Aβ. APP/PS1 mice were a generous gift of Dr. Laurent Pradier, Sanofi-Aventis, 
France. The 5xFAD mice (Oakley et al. 2006) (The Jackson Laboratory, US) were likewise 
hemizygous for the APP and PS1 transgenes and three 6-month-old mice were used in the 
qualitative optimization study. 
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All animals were handled according to German guidelines for animal care and the European 
Communities Council Directive European Communities Council Directive of 24 November 
1986 (86/609/EEC). 
Mouse model Gene Protein Mutations Promotor 
APP APP751 
Swedish (K670N, M671L) and 
London (V717I ) 
murine Thy-1 
APP/PS1KI 
PSEN1 PS1 M233T and L235P endogenouse PS1 
APP APP APP751 




Swedish (K670N, M671L) and 
London (V717I ) 
murine Thy1 
APP/PS1 
PSEN1 PS1 M146L HMG-CoA reductase 
APP APP695 
Swedish (K670N, M671L), 




PSEN1 PS1 M146L, L286V murine Thy-1 
APP APP695 Swedish (K670N, M671L) murine prion protein 
APP/PS1ΔE9 
PSEN1 PS1 ΔE9 murine prion protein 
Table 1 Mutations in mouse models specified according to APP isoform, promoter, and amino acid exchange. 
2.1.1 Genotyping 
Genotyping of APP/PS1ΔE9 mice was performed at the Anatomical Institute, Aarhus 
University, Denmark, and analysis of YFP hemizygosity or homozygosity was carried out by 
quantitative real time polymerase chain reaction (qRT-PCR) explained below. Genotyping of 
APP/PS1KI, APP/PS1, and 5xFAD mice was performed by a technician in our laboratory and 
will be briefly explained. 
Using specially designed DNA-primers and PCR, a specific gene of interest can be amplified 
and its presence verified by agarose gel-electrophoresis. The PCR reaction is composed of 
cycles of brief temperature stages in which different reactions take place. First step is 
denaturation of the DNA strands at high temperature (95°C) followed by a lower temperature 
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(50-70°C) at which the oligonucleotide primers are allowed to anneal to the denaturated DNA 
strands. The temperature is then raised to 70-75°C for optimal function of the DNA 
polymerase which syntheses new DNA strands. The cycle is then repeated 35-40 times.  
For DNA isolation, 500 µL of lysis buffer (100 mM Tris/HCl pH 8.5, 5 mM EDTA, 0.2 % 
sodium dodecyl sulphate (SDS), 200 mM NaCl, 10µL/mL Proteinase K) were added to mouse 
tail clippings obtained from the animal facility and shaken overnight at 55 °C and 400 rounds 
per minute (rpm) in a heating block. Next day, the solutions were centrifuged for 10 min at 
13000 rpm and the supernatants were transferred to a new 1.5 mL tube containing 500 µL of 
isopropanole. Samples were again vortexed and centrifuged for 10 min at 13000 rpm. Pellets 
were then washed by vortexing in 500 µL of 70% ethanol and centrifuged for 10 min at 13000 
rpm. The supernatants were discarded and the pellets dried on a heating block at 37 °C and 
subsequently dissolved  in  70  µl  H2O  (Aqua  ad iniectabilia)  (37°C,  30  –  45  min  or 
overnight at 4°C). 
PCR was then used to exponentially amplify a DNA fragment of the transgene of interest. The 
reaction was performed in a total volume of 10 µL (0,5 µL 10 pM primer forward, 0,5 µL 10 
pM primer reverse, 1 µL 10 x PCR-Puffer, 1 µL 200 µM dNTPs, 5.9 µl H2O, 0.1 µL Taq-
Polymerase, 1 µL diluted DNA containing 25 ng of genomic DNA) and run with the 
following cycling parameters: heating at 94°C for 5 min followed by 35 cycles of 94°C for 60 
sec, 55°C for 60 sec, and 72°C for 1.5 min mediating denaturing, annealing, and extension of 
the DNA. The PCR reaction was finished at 72°C for 5 min and stored at 4°C until further 
processing. Primers targeted the APP transgenes, forward: 5’-
GTAGCAGAGGAGGAAGAAGTG-3’, revers: 5’- CATGACCTGGGACATTCTG -3’ 
generating a product of either a 505 bp (APP/PS1KI and APP/PS1 mice) or 324 bp (5xFAD 
mice).  
The presence of the desired PCR products was verified by agarose gel-electrophoresis that 
separates DNA fragments according to size. A 2.5% agarose gel was prepared in a tris-
acetate-EDTA (TAE) buffer with 1 µg/mL ethidiumbromide that intercalates into the double-
stranded DNA structure and allows visualization of DNA bands by UV-light-
transillumination at a wavelength of 366 nm. The 10 µL PCR products were loaded along 
with a suitable DNA ladder to enable analysis of the size of the separated DNA fragments, 
each were added an equal volume of loading dye and the gel was run at 170 V. PCR product 
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bands were visualized in an UV-chamber (Gel-Doc 2000, Bio-Rad) connected to a computer 
and using QuantityOne software program (Bio-Rad) producing a photo of the gel. 
2.2 Novelty exposure 
APP/PS1ΔE9 and wild-type littermate control mice were divided in 4 groups of 6 animals per 
cage and housed for 1 week before the experiment. The groups were as follows:  
 Group 1: Wild-type non-handled, home-cage controls (n=6) 
 Group 2: Wild-type novelty-exposed (n=6) 
 Group 3: APP/PS1ΔE9 non-handled, home-cage controls (n=6)  
 Group 4: APP/PS1ΔE9 novelty-exposed (n=6)  
The mice to be exposed to novelty were transferred to a box one at a time. The box was 41 x 
21 cm and 18 cm high and was made of see through plastic. Red and blue cardboard paper 
was placed at bottom and sides: blue paper on the longer sides and red at the ends, blue paper 
was placed underneath the box to be able to clean the box between each mouse. The room 
was enlightened by standard bright light and the box was placed in the middle of the room so 
that the mice could look up and find itself in a novel environment. The mice were placed in 
the box for a total of 5 min, and they were sitting still for more than 5 sec, they were moved to 
another area of the box by gently pulling them by the tail. The mice were replaced to the 
home-cage and killed 30 min after novelty-exposure. After each animal, the box was cleaned 
in 70% ethanol and allowed to evaporate for another 5 min. Non-handled home-cage control 
animals were taken directly from their cage and care was taken that non-handled animals were 
not exposed to novelty. All animals were killed by decapitation, trunk blood was collected in 
EDTA-vials (kept on ice), and brains were immediately removed and directly frozen in 
crushed dry-ice. Blood samples were centrifuged at 300 rpm for 10 min and plasma was 
collected and frozen at -20ºC. Plasma corticosterone levels were measured directly without 
prior extraction using a commercial [125I]-radioimmunoassay kit (TKRC1, Siemens Medical 
Solutions Diagnostics). 
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2.3 Tissue collection and preservation 
Tissue is collected and preserved in different ways according to the following analyses. 
Directly frozen tissue is needed for mRNA and protein extractions as well as for ligand 
binding and in situ hybridization. For these purposes, mice were either directly killed by 
decapitation using a sharp scissor or briefly anaesthetized by 1 min exposure to CO2 in a box 
with dry-ice and then killed by spinal dislocation and decapitated. Brain and spinal cord tissue 
was quickly removed at directly frozen on dry ice, and the tissue was kept at -80C until 
further processing.  
For immunohistochemical staining, the tissue must be preserved by fixation in 4% 
paraformaldehyde (PFA). The best is to do a perfusion fixation in which the mouse is 
anesthetized by 10 mL/kg intraperitonal injection of 1% Ketamin (Pharmanovo GmbH, 
Hannover, Germany) and 0.1% Xylazin (Riemser, Gristow, Germany) in aqua ad injectabilia. 
When the mouse is deeply anesthetized transcardial perfusion is carried out through the left 
ventricle with 30 mL ice-cold phosphate buffered saline (PBS) followed by 30 mL 4% PFA 
dissolved in PBS. Brains and spinal cords are carefully removed and brains were divided at 
the midline. Alternatively, the tissue can be directly removed as for direct freezing and then 
immersion fixed by storage in 4% PFA over night, however, this method does not remove the 
blood cells as well as the perfusion fixation, which can increase background staining when 
applying immunohistochemistry. The PFA fixed tissue will be frozen or embedded in 
paraffin. For fixed frozen tissue preparation, the tissue is post fixed in 4% PFA for at least 2 
hrs and then cryo protected in 30% sucrose in PBS overnight. Next day, the tissue is quickly 
frozen on dry ice and stored at -80°C until further processing. The fixed frozen tissue can be 
sectioned on a cryostat and was used for free-floating immunohistochemistry as well as for 
cresyl violet histochemistry. For paraffin embedding, the tissue is post fixed in 4% buffered 
formalin at 4°C for a minimum of 1 day before the tissue was embedded in paraffin by 
dehydration in a series of ethanol of 50%, 60%, 70%, 80%, 90%, and 2x 100% followed by 
Xylol treatment and a final emersion in liquid paraffin for 2 hours before being embedded in 
solid paraffin blocks. The paraffin embedded tissue was used for immunohistochemistry in 
thin slices of 2-4µm that gives the best pictures of pathological structures when using a 
normal transmitted light or fluorescent microscope. The tissue processing is summarized in 
Table 2. 
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Tissue preservation Storage Analyses 
Directly frozen -80°C mRNA/protein extraction, radioactive 
Frozen -80°C 
Free-floating immunohistochemistry and 
cresyl violet histochemistry 
Fixed 
tissue 
Paraffin embedded Room temperature Immunohistochemistry on glass slide 
Table 2 Summary of tissue preservation, storage, and applied analyses. 
2.4 Histological staining 
Histological structures in tissue can be 
revealed by using various dyes specific for 
e.g. cell nucleic proteins or aggregated 
proteins, however, they can also be revealed 
by using highly specific antibodies 
recognizing a target protein of interest. The 
primary antibody is applied to the tissue of 
interest and its FC region can then be 
identified by a secondary antibody generated 
in another species. The secondary antibody 
can be conjugated directly to different enzymes mediating colorimetric reactions or to 
fluorescent molecules, or be conjugated to proteins with specific affinities such as the avidin-
biotin complex (ABC). In the ABC method, the secondary antibodies are biotinylated. Upon 
addition of avidin and a peroxidase enzyme bound to biotin, the peroxidase enzyme will be 
indirectly bound to the secondary antibody. When a colorimetric substrate is added such as 
DAB, the enzyme mediates accumulation of a reddish brown product (Fig. 17). 
Fig. 17 The avidin-biotin complex (ABC) method.
A primary antibody (Ab) is used to recognize a 
target protein, and the substrate diaminobenzidine 
(DAB) is applied to visualize the protein by a 
reddish brown color.
Free-floating immunohistochemistry was applied for antibody staining of rather thick sections 
for stereology or confocal microscope imaging. Immunohistochemistry of paraffin embedded 
tissue was performed directly on glass slides and was used for qualitative antibody staining as 
well as Aβ and dystrophic fiber quantifications. Immersion in cresyl violet solution provided a 
blue staining of nuclei that were used for general quantification of neurons by design-based 
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stereology, whereas immersion in Thioflavin S was used to visualize aggregated proteins. 
Primary antibodies applied for immunohistochemistry are specified in Table 3 and secondary 
antibodies in Table 4. 
Target Name Host Dilution Manufactor 
Aβ1-x Aβ[N] Rabbit 1:200 - 1:1000 IBL, Germany 
Aβ1-x AβN1(D) Rabbit 1:500 
Takaimo Saido, RIKEN 
Institute, Japan 
Aβ17-24 4G8 Mouse 1:1000 - 1:10.000 Covance, USA 
Fibrillar Aβ 
oligomers 
OC Rabbit 1:200 - 1:2000 Gift of C. Glabe and R. Kayed 
Aβ31-40 G2-10 Mouse 1:500 Genetics company, Switzerland 
AβN3pE N3pE Rabbit 1:500 
American Research Products, 
USA 
APP 22C11 Mouse 1:1000 Millipore, Germany 
APP 23850 Rabbit 1:500 Gift of Gerd Multhaup 
Phosphorylated 
APP 
anti-pT668 Rabbit 1:500 
Cell Signalling Technologies, 
Germany 
Neurofilaments NF-200 Rabbit 1:1000 Millipore, Germany 
GFAP GFAP Mouse 1:1000 Synaptic Systems, Germany 
ChAT AB144P Goat 1:300 - 1:1000 
Millipore, Schwalbach, 
Germany 
Ubiquitin Z0458 Rabbit 1:500 DAKO, Denmark 
Table 3 Details of primary antibodies applied for immunohistochemistry. All mouse antibodies were 
monoclonal, whereas all rabbit and goat antibodies were polyclonal.  
 
Antibody Product number Manufactor 
Rabbit anti-mouse immunoglobulins, biotinylated E0465 DAKO, Denmark 
Swine anti-rabbit immunoglobulins, biotinylated E0353 DAKO, Denmark 
Rabbit anti-goat immunoglobulins, biotinylated E0466 DAKO, Denmark 
AlexaFluor568-conjugated immunoglobulins. 
goat anti-rabbit 
A11036 Invitrogen, Germany 
AlexaFluor594-conjugated immunoglobulins,  
donkey anti-goat 
A11058 Invitrogen, Germany 
AlexaFluor488-conjugated immunoglobulins, 
chicken anti-rabbit, rabbit anti-mouse 
A21441, A11059 Invitrogen, Germany 
Table 4 Details of polyclonal secondary antibodies applied for immunohistochemistry. 
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2.4.1 Free-floating immunohistochemistry 
For ChAT stereology, fixed frozen brain tissue was cut on a cryostat in 10 series of 40 µm 
coronal sections with collection of every 10th section throughout the brain. For qualitative 
evaluation of fiber pathology in YFP mice, the brains were cut in 8 series of 50 µm coronal 
sections collecting every 8th section throughout the forebrain. All sections were stored frozen 
at -80°C until further processing. One series from each animal comprising either every 8th or 
10th section was carefully transferred to a net well and stained by free-floating technique with 
a 12-well net system (Costar, Corning, New York, USA) on a horizontal stirring table 
providing constant floating of the sections. Sections were hydrated for 15 min in PBS (0.01M, 
throughout staining techniques) and endogenous peroxidases were blocked in PBS containing 
0.3% H2O2 for 30 min (only for DAB staining). Antigen retrieval was achieved by 10 min 
incubation in 88% FA (only for A staining) followed by thorough washing for 3 x 5 min in 
PBS. Sections were washed 3 x 10 min in PBS containing 0.1% Triton X-100 for membrane 
permeabilization, and unspecific binding was blocked by treatment with 4% skim milk 
powder and 10% fetal calf serum (FCS) in PBS for 1 hour prior to overnight incubation in 
primary antibodies with 10% FCS in PBS (Table 3). Next day, sections were washed 3 x 10 
min in PBS containing 0.1% Triton X-100 followed by 2 hrs incubation with secondary 
antibodies in 10% FCS in PBS. Following secondary fluorescent antibody incubation, 
sections were washed 3 x 10 min in PBS, mounted onto super frost glass slides, and left to dry 
overnight. Following secondary biotinylated antibody incubation, sections were washed 3 x 
10 min in PBS and then incubated 1.5 h in ABC Vectastain kit (1:300 in PBS, Vector 
Laboratories, Burlingame, USA). The staining was finally visualized in a DAB solution 
(Sigma, Taufkirchen, Germany) of 0.5 mg/mL in Tris/HCl pH 7.5 for 5-10 min providing a 
reddish brown color. Sections were washed 3 x 10 min in PBS, mounted onto super frost glass 
slides, and left to dry over night. Next day, sections were rehydrated for 10 min in PBS, after 
which fluorescent staining were counterstained for 1 min in 1 µg/ml 4’6-diamidine-2’-
phenylindole dihydrochloride (DAPI, Sigma, Taufkirchen, Germany) and washed 3 x 5 min 
in PBS containing 0.1% Triton X-100. Embedding was performed in an aqueous fluorescent 
protecting mounting medium (Vectashield Hard Set, Linaris, Wertheim, Germany) and upon 
drying, the edges were sealed with transparent lacquer to prevent evaporation of the mounting 
medium. DAB stainings were counterstained with hematoxylin for 40s followed by 5 min 
under running tap water providing a blue staining of nuclei. The sections were then 
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dehydrated in a series of ethanol (1 min 70%, 5 min 95%, 10 min 100%) and xylol (2 x 5 min) 
and embedded in Roti-Histokitt mounting medium (Carl Roth GmbH, Germany).  
2.4.2 Immunohistochemistry of paraffin embedded sections 
Paraffin embedded fixed tissue blocks were cut on a microtome in 2-4 µm sagital sections and 
carefully transferred to a container with double distilled water of room temperature. The 
sections were collected on super frost glass slides, briefly dipped in a heated water bath 
containing double distilled water of 52-56C, and left to dry on a hot plate of same 
temperature for about 15 min or until the sections had dried. Sections were left overnight at 
37C to dry completely before staining. Glass slides with paraffin embedded sections were 
deparaffinized 2 x 5 min in xylol and rehydrated in a series of ethanol (10 min 100%, 5 min 
95%, 1 min 70%, 1 min H2O). Endogenous peroxidases were blocked for 30 min in 0.3% 
H2O2 in PBS (only for DAB staining), and antigen retrieval was achieved by boiling sections 
10 min in 0.01 M citrate buffer pH 6.0 in a microwave after which the sections were left 15 
min at room temperature to cool down. Membrane permeabilization was carried out by 3 x 5 
min washes in PBS containing 0.1% Triton X-100, followed by antigen retrieval in 88% FA 
for 3 min (only for A staining). Non-specific binding sites were blocked by 1 hour treatment 
with 4% skim milk and 10% FCS in PBS, prior to over night incubation in a humid chamber 
at room temperature with primary antibodies (Table 3) in PBS containing 10% FCS. Next 
day, sections were washed 3 x 5 min in PBS containing 0.1% Triton X-100 and incubated 
with secondary antibodies (DAKO, Glostrup, DK) at 37°C for 1 hour (DAB staining) or 1.5 
hrs (fluorescent staining). Following secondary fluorescent antibody incubation, sections were 
washed 3 x 5 min in PBS, directly counterstained for 1 min in DAPI, washed 2 x 3 min in 
PBS, and embedding in Vectashield aqueous fluorescent protecting mounting medium. 
Following secondary biotinylated antibody incubation, sections were washed 3 x 5 min in 
PBS and incubated 1.5 h in ABC Vectastain kit (1:100) at 37°C. The staining was finally 
visualized in a 0.5 mg/mL DAB solution in Tris/HCl pH 7.5 for 1-5 min providing a reddish 
brown color, followed by 3 x 5 min PBS washes. DAB staining were counterstained with 
hematoxylin for 40s followed by 5 min under running tap water, and sections were dehydrated 
in a series of ethanol (1 min 70%, 5 min 95%, 10 min 100%) and xylol (2 x 5 min) and 
embedded in Roti-Histokitt mounting medium. For double ABC staining, DAB visualization 
was followed by repetition of the protocol from the blocking step in 4% skim milk applying a 
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second primary antibody produced in a species different from the first. The second primary 
antibody was visualized using the ABC method with Vectastain kit, however, with the 
HistoGreen kit (Linaris, Germany) as chromogen providing a blue color.  
To prevent autofluorescence from lipofuscin, 20 min incubation was performed in a saturated 
Sudan Black B solution of 1g dissolved in 200 ml methanol following antigen retrieval in FA 
prior to non-specific blocking in 4% skim milk.  
2.4.3 Thioflavin-S staining 
Thioflavin-S is a fluorescent dye that binds to aggregated β-sheet conformations thus labeling 
aggregated forms of Aβ, but not monomers or dimers (LeVine 1993). The staining was 
performed in paraffin embedded sections with 1% Thioflavin S (Sigma, Taufkirchen, 
Germany) dissolved in distilled water. The sections were deparaffinized and rehydrated as for 
the immunostaining, washed 2 x 1 min in distilled water and immersed for 8 min in the 
Thioflavin S solution. Sections were then washed 2 x 1 min in distilled water and once more 
immersed for 4 min in the Thioflavin S solution. The last incubation was followed by 2 x 1 
min washes in 80% ethanol and 3 x 1 min washes in distilled water before being 
counterstained with DAPI and embedding in Vectashield aqueous fluorescent protecting 
mounting medium. 
2.4.4 Cresyl violet histochemistry 
For neuronal stereology, fixed frozen brains were cut in 10 series of 30 µm coronal sections 
with collection of every 10th section throughout the brain and stored frozen at -80°C until 
further processing. One series comprising every 10th section from each animal was carefully 
mounted in PBS onto super frost glass slides. When dried, sections were washed 2 x 10 min 
in 0.04 M Sodiumacetate/0.1% acetic acid solution (B1), delipidated 20 min in 0.025% Triton 
X-100/75% ethanol, washed 2 x 10 min in B1 and stained for 2 x 8 min in 0.01% cresyl violet 
disolved in B1. The sections were then washed 3 x 1 min in B1, 3 min in 100% ethanol, 10 
min in isopropanol, and 2 x 5 min in xylol before being embedded in Roti-Histokitt mounting 
medium. 
Methods and Materials  50
 
2.5 Microscopy and photography 
Photomicrographs were taken using an Olympus BX51 microscope equipped with an 
Olympus DP-50 digital camera. Final figures were constructed using Image-J (NIH, USA) 
and GIMP 2.6 software and only minor adjustments of contrast and brightness were made, 
which in no case altered the appearance of the original images. 
Confocal microscopy was performed in cooperation with the Max Planck Institute for 
Experimental Medicine, Göttingen. Images were acquired with a Leica SP2 laser scanning 
confocal microscope equipped with an acousto-optical beam splitter (Leica, Germany) using a 
63x/1.4 oil-immersion objective. The 405-nm line of a blue laser diode (DAPI), 488-nm line 
of an argon laser (YFP), and 561-nm line of a DPSS laser (AlexaFluor568) were used at 40%, 
5-10%, and 5-10% power, respectively. Reasonable detector gains were used between 550 
and 650 AU in the Leica LSC software. Pictures were processed in Image-J using a Median 
filter to smoothen the images.  
2.6 Quantification of plaque independent dystrophic neurites 
For each animal, two series of three paraffin embedded sections at least 25 µm afar were 
stained simultaneously using either the NF-200 or anti-pT668 antibodies with DAB as 
chromogen, followed by an ABC staining with the 4G8 antibody using Histogreen as 
chromogen marking Aβ plaques in blue. Quantification of plaque-independent dystrophic 
neurites was performed using the meander scan option of StereoInvestigator 7 
(MicroBrightField) and a BX51 microscope (Olympus) to count dystrophic fibers larger than 
10 µm that were not plaque-associated. The average of the counting from the three sections 
per animal was used for statistical analyzes. Quantifications were performed in two regions; 
pons and spinal cord as these regions had obvious dystrophic fiber pathology together with 
moderate plaque pathology, making it possible to distinguish plaque-associated from plaque-
independent axonal swellings. Quantification was performed in 6 mice of each of the 
genotypes APP, APP/PS1KIhe, and APP/PS1KIho. 
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2.7 Quantification of Aβ staining 
For each animal, 5 paraffin embedded sections at least 25 µm afar were stained 
simultaneously for Aβ immunoreactivity using DAB as chromogen. Micrographs of the Aβ 
staining were systematically captured in the region of interest with an Olympus BX-51 
microscope equipped with an Olympus DP-50 camera. Using the ImageJ software (NIH, 
USA), pictures were binarized to 8-bit black and white pictures, a fixed intensity threshold 
was applied defining the DAB staining, and the percentile area covered by Aβ DAB staining 
was calculated together with the number and size of Aβ grains. 
2.8 Stereology 
Stereological counting procedures were 
developed in order to estimate a massive 
amount of cells in the brain in an unbiased 
systematic random fashion without 
considering size, shape and orientation of the 
cells being counted. Thus quantification of 
neurons can be obtained by the optical 
fractionator stereological method (Fig. 18), 
where the “fractionator” is the systematic 
random sampling of sections, sampling e.g. every 10th with random selection of the first 
section in the area of interest, and the “optical dissector” is a three-dimensional probe 
associated with a set of rules for counting neurons (West 1993; West et al. 1991). In practise, 
an unbiased counting frame divided in grids is superimposed on the section being counted. 
The optical dissector is systematically applied to the grid taking up a defined area (aframe) of 
the grid area (astep).  The optical dissector probe is three dimensional, and when counting 
through the thickness (t) of the section, guard zones of e.g. 2 µm can be left uncounted near 
the surfaces and counting is then performed within a certain dissector height (h) being less or 
equal to t. According to the principle of stereology (Schmitz and Hof 2005; West 2002; West 
et al. 1991), the total number of neurons (N) in an area of interest can be estimated by: 
Fig. 18 The optical dissector method. An optical 
dissector with areal (a) and height (h) is defined by a 





    
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Where ∑Q- is the sum of the neurons 
counted by the optical fractionator in 
the area of interest. The remaining 
stereological parameters are 
explained in Table 5.  
Two overall quantifications were 
performed: One of ChAT-positive 
neurons throughout the brain 
cholinergic system, and another of 
cresyl-violet stained neurons. The optical fractionator method was applied by probes 
constructed to count approximately 300-400 cells in each region for each animal resulting in 
coefficient of errors around 0.05, and the quantification was performed by an observer blinded 
to the genotype of the animals using StereoInvestigator 7 (MicroBrightfield) together with a 
BX51 microscope (Olympus). Only female mice were quantified, and the number of mice in 
each group is given directly in the graphs of the respective results chapters.  
Stereological parameters: 
ssf Fraction of sections sampled 
asf Fraction of area of sections sampled 
tsf Fraction of sections thickness sampled (h/t), µm 
aframe Area of optical dissector counting frame, μm
2 
astep Area associated with movement to next frame, μm
2 
h Height of optical dissector, μm 
t Section thickness, μm 
CE Coefficient of error 
Table 5 Definition of stereological parameters. 
For quantification of ChAT-positive neurons, frozen fixed hemispheres were cut in 10 series 
of 40 µm coronal sections that were systematically collected resulting in 10 series containing 
every 10th section throughout the forebrain to the ventral hippocampus (bregma 2.22 mm  -
3.64 mm) (Paxinos and Franklin 2001). The posterior brains were cut throughout in 40 µm 
with collection of all sections (bregma -3.64 mm  -6.84 mm) (Paxinos and Franklin 2001). 
The following brain regions were 
selected for quantification: The 
caudate putamen (CPu); Ch1/2 
comprising the medial septum and 
the vertical limb of the diagonal 
band; Ch4 comprising the horizontal 
limb of the diagonal band, the ventral 
pallidum, the basal nucleus, and 
substantia innominata; as well as the 
brainstem motor nuclei Mo5 and 7N. 
The identification of a neuron was 
 CPu Ch1/2 Ch4 Mo5 7N 
ssf 10 5 10 1 1 
asf 0.38  1 0.44 0.33  
tsf 1 1 1 1 1 
aframe,  µm
2 34500 28000 10000 10000 5625 
agrid,  µm
2 90000 28000 22500 30000 40000 
h,  µm 18.2 14.8 17.7 16.9 17.3 
t,  µm 18.2 14.8 17.7 16.9 17.3 
Sec.counted 11 8 7 20 27 
CE 0.040 0.09 0.052 0.052 0.046 
Table 6 Sampling scheme for stereological analysis of the 
cholingeric system. CE, t, and tsf are average values. 
Sec.counted is average number of sections counted per animal. 
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performed on the basis of the typical shape of a neuron with at least one visible process. The 
stereological parameters of the counting are given in Table 6. 
Stereological quantification of neurons in the frontal cortex and thalamus was performed in 30 
µm cresyl-violet stained frozen hemisphere sections systematically collected in 10 series 
containing every 10th section 
throughout the brain. Neurons were 
identified based on their typical 
morphology with large nuclei. The 
frontal cortex was quantified from 
Bregma 3.08 to 0.26 (Paxinos and 
Franklin 2001), and the thalamus was 
quantified from Bregma -0.94 to -
2.54 (Paxinos and Franklin 2001). 
Stereological parameters for the 
counting are given in Table 7. 
 Frontal cortex Thalamus 
ssf 10 10 
asf 0.00357 0.0246 
tsf 0.61 0.65 
aframe,  µm
2 625  1600 
agrid,  µm
2 175000  65000 
h,  µm 6 6 
t,  µm 9.8 9.3 
Sec.counted 11 6 
CE 0.045 0.045 
Table 7 Sampling scheme for stereological analysis of 
neurons in the frontal cortex and thalamus. CE, t, and tsf are 
average values, and sec.counted gives the average number of 
sections counted per animal. 
2.9 qRT-PCR 
Assesment of gene dosage was carried out using qRT-PCR in YFP transgenic mice to identify 
homozygous mice for the breeding with APP/PS1KIhe mice. In qRT-PCR, mRNA or DNA is 
purified from a sample of interest, and for analysis of mRNA, reverse transcription is 
performed to generate cDNA. A PCR reaction is initiated and continuously monitored by the 
incorporation of a dye that becomes fluorescent when incorporated into the PCR product as 
the reaction proceeds. The fluorescence of the sample correlates with the concentration of 
amplified product and is continuously plotted as a function of cycle number. As the amount of 
PCR product increases exponentially with time, the fluorescent will start to rise dramatically 
after a certain amount of cycles. The Threshold cycle (CT) is the cycle value at which a 
statistically significant increase in fluorescence is first detected. The CT value is of a 
continuous scale and at this cycle, the concentration of the amplified gene will be the same in 
all samples, assuming the efficiency of the amplification is the same in all tubes. The lower 
the amount of starting DNA, the longer time it will take for the fluorescence to reach 
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threshold level and thus the higher the CT value. Based on measured CT values, the expression 
level of a gene or gene dosage can be quantified.  
DNA isolation was performed from mouse tail biopsies in 500 µL of lysis buffer (100 mM 
Tris/HCl pH 8.5, 5 mM EDTA, 0.2 % SDS, 200 mM NaCl, 10µL/mL Proteinase K) and 
shaken overnight at 55 °C and 400 rpm in a heating block. Next day, the solutions were 
centrifuged for 10 min at 13000 rpm and the supernatants were transferred to a new 1.5 mL 
tube containing 500 µL of isopropanole. Samples were again vortexed and centrifuged for 10 
min at 13000 rpm. Pellets were then washed by vortexing in 500 µL of 70% ethanol and 
centrifuged for 10 min at 13000 rpm. The supernatants were discarded and the pellets dried on 
a heating block at 37 °C and subsequently dissolved  in  70  µl  H2O  (Aqua  ad iniectabilia)  
(37°C,  30  –  45  min  or overnight at 4°C). 
qRT-PCR was performed using a Stratagene MX3000P Real-Time Cycler and 10 ng of DNA 
was used per reaction. For quantification of the PCR product was applied the SYBR-green 
based 2x SensiMix DNA Kit containing ROX as an internal reference dye (peqLab, 
Germany). Measurements of CT values were performed in duplicates, and relative 
quantification was performed using APP as a housekeeping gene normalising the expression 
level of YFP to that of APP and calibrating it to a chosen YFP heterozygous animal using the 




For an animal (q) quantifying the level of YFP gene expression normalized to the expression 
of APP as a reference gene and calibrated to the animal (cb), -ΔΔCT is calculated as follows: 
 
APPTYFPTT CCC ,, 
 )( ,, cbTqTT CCC 
 
An example of the identification of homozygous animals by qRT-PCR is given in Fig. 19. 
YFP and APP amplification efficiencies were analysed and found to be equal. 
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Fig. 19 Identification of homozygous YFP animals by RT q-PCR. The YFP expression is quantified relative 
to APP. All animals were calibrated according to mouse number 5. Mouse 1, 2, 3, 7, 23, and 27 were identified 
as homozygous for YFP, whereas the rest were considered to be heterozygous. 
2.10 Western blot 
Proteins can be separated based on their size by SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) in which protein samples are loaded in equal amounts onto the gel. SDS is an 
anionic detergent that denatures secondary and non–disulfide–linked tertiary structures, and 
applies a negative charge to each protein in proportion to its mass as smaller proteins travel 
faster. Thus when an electric field is applied over the gel, the proteins will be separated based 
on their size. The proteins can then be blotted onto a nitrocellulose membrane where 
antibodies can be applied to recognize specific proteins of interest. Secondary antibodies 
proteins conjugated to horseradish peroxidase (HRP) can be used to visualize the proteins as 
HRP oxidizes amongst others luminol, after which protein bands can be detected by light 
sensitive films. 
Qualitative western blots were made for two proteins: APP and ubiquitin. As ubiquitin is 
attached to many proteins of varying size, the protocol was varied to extract a higher 
proportion of high-molecular weight proteins. Directly frozen brain hemispheres stored at -80 
°C were homogenized using 10 strokes of a glass Teflon homogenizer at 800 rpm in 150 mM 
NaCl, 50 mM Tris, 1% Triton X-100, 5 mM EDTA, pH 7.6 extraction buffer, supplemented 
with complete protease inhibitor cocktail (Roche, Germany). The amount of buffer was 
adjusted to the brain weight in a 10:1 ratio. Lysates were centrifuged at 4°C and 13.000 rpm 
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for 30 min, and the supernantant was collected and stored at – 80°C for quantification of 
soluble proteins. The pellets were dissolved in 0.01 M PBS buffer containing 2% SDS, pH 7.4 
and homogenized on ice using a Branson Ultrasound Homogenizer followed by centrifugation 
at 4°C and 17.000 rpm for 30 min to obtain the SDS-soluble fraction. Protein concentrations 
were measured by the commercially available Roti-Quant universal solution (C. Roth, 
Germany). Of each sample, 20 µg (APP) or 50 µg (ubiquitin) proteins as well as 5 µL color 
plus prestained protein marker (BioLabs, England) were mixed 1:1 with Vario loading buffer 
(Anamed Elektrophorese, Germany) and heated for 4 min at 95°C, after which they were 
loaded onto precast 4-12% vario gels (Anamed Elektrophorese, Germany) and run in Vario 
running buffer for approximately 45 min at 200 V. Proteins were transferred to nitrocellulose 
membranes (Hybond-ECL, Amersham Biosciences, USA) using either semidry blotting for 
30 min at 25 V or wet blotting for 2 hr at 25 V in 48 mM Tris, 39 mM glycine, and 20% 
methanol, pH 9.2 transfer buffer. Membranes were blocked in 10% non-fat dry milk in Tris 
buffered saline buffer (0.01 M Tris, 0.15 M NaCl) containing 0.05% Tween-20 (TBS-T), 
pH=8.0 (TBS-T) for 1 hour. Monoclonal mouse anti-APP (1:5000, 22C11) or rabbit anti-
ubiquitin (1:5000, DAKO, Denmark) primary antibodies were applied overnight in TBS-T 
buffer at 4°C followed by a 2 hrs incubation with goat anti-mouse or swine anti-rabbit HRP-
conjugated secondary antibodies (1:3000, DAKO, Denmark) at room temperature. Blots were 
developed using light sensitive X-ray films and a 0.25 mg/mL luminol solution in 0.1 M 
Tris/HCl, pH 8.6 together with a 1.1 mg/mL para-hydroxycoumarine acid solution in DMSO 
mixed 9:1 just before use and with the addition of 0.03% H2O2. A mouse monoclonal β-Actin 
antibody (1:5000, Chemicon, USA) was used as a reference protein to assure equal loading of 
the samples. 
2.11 Radioactive ligand binding 
The level of receptors expressed in a tissue can be semi-quantified using receptor 
autoradiography that can be conducted in tissue homogenates or in tissue slides in which the 
latter offers the advantage of anatomical resolution and was the method of choice in this thesis 
(Kuhar et al. 1990). The basic principle of receptor autoradiography is the addition of a 
radioactively labelled ligand (radioligand) that binds to the receptor of interest. The amount of 
bound radioactivity in the tissue will then be proportional to the amount of receptors. Non-
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specific binding (NSB) to glass surfaces etc., is determined by displacing the radioligand with 
an excessive amount of non-labeled receptor ligand and is subtracted from the total binding 
resulting in the specific binding. 
Directly frozen half brains were cut in 12 µm serial coronal sections on a cryostat and directly 
mounted onto super frost glass slides. Sections were collected in parallel series with 4 
sections per glass slide throughout the prefrontal cortex (8 series, bregma 1.98 mm) (Paxinos 
and Franklin 2001) and the dorsal hippocampal region (15 series, bregma -1.46 mm  -2.18 
mm) (Paxinos and Franklin 2001). Two slides from each animal were dried at room 
temperature for 30 min, followed by 30 min hydration in 50 mM Tris buffer, pH 7.3 (binding 
buffer). Slides were incubated 2 hrs in binding buffer with 0.5 nM [125I]Tyr54-mono-iodo-α-
bungarotoxin (2,200Ci/mmol, #NEX126H, Perkin Elmer, DK) to asses total binding. For 
analysis of non-specific binding, incubation was performed together with 1 mM (-)-nicotine 
(#N5260, Sigma-Aldrich, DK). After the incubation, slides were dipped in buffer, followed 
by 2 x 30 min wash in ice-cold buffer. Finally, slides were rinsed briefly in ice-cold distilled 
water, dried for 24 hrs, and exposed to a radioactive sensitive Kodak Biomax MS film (GE 
Healthcare) for 24 hrs. Optical densities were measured using Quantity One software 
(BioRad) by bilateral delineation of PFC in at least two sections per animal and of the 
hippocampal formation in at least three sections per animal. Specific α-BTX binding was 
calculated by subtracting non-specfic binding from total binding. 
2.12 In situ hybridization 
The expression level of a particular gene expressed in a tissue can be semi-quantified using in 
situ hybridisation in which a radioactively labeled probe is applied to tissue sections. The 
amount of bound radioactivity in the tissue will then be proportional to the mRNA produced 
by the target gene.  
Twelve-μm parallel coronal brain sections were cut through the PFC, and the dorsal 
hippocampus as explained in the chapter of radioactive ligand binding (2.11). One glass slide 
with four brain sections from each animal was processed in the same experiment for one 
transcript to achieve the highest level of standardization. The slides were incubated for 5 min 
in 4% PFA in 0.2 M PBS, and then washed twice for 1 min in PBS. This was followed by 
acetylation (0.25% acetic anhydride, 0.1 M triethanolamine in 0.9% NaCl, pH 8,0) for 10 min 
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at room temperature. The slides were then delipidated and dehydrated in a series of ethanol 
(70%/5 min; 80%/1 min; 95%/2 min; and 99%/1 min) and finally incubated for 5 min in 
chloroform. Excessive chloroform was washed off the slides in 99% and 96% ethanol, and the 
slides were air-dried. Synthetic oligonucleotide DNA probes complimentary to the rat Arc 
mRNA (targeting bases 789-839; Genbank accession number: NM019361), c-fos (targeting 
bases 133-180; Genbank accession number: X06769), synaptophysin (codon 131-175, TGT 
TGG CAC ACT CCA CGC TCA GCC GAA GCT CCC CGG TGT AGC TGC), and PSD-95 
(codon 383-393, GTT TAT ACT GAG CGA TGA TCG TGA CCG TCT GAC CC) genes 
were applied (DNA Technology, Risskov, Denmark). The probes were labeled at the 3’-end 
with α[35S]-dATP (>3000 Ci/mmol, Amersham Bioscience) using terminal transferase. 
Labeled probe was added at a specific activity of 106 cpm/100 μL to the hybridisation buffer 
containing 45% formamid (v/v), 4X saline sodium citrate (SSC) (1XSSC is 0.15M NaCl, 
0,015M NaCitrate*2H2O, pH 7.2), 1X Denhardts solution (0,02% ficoll, polyvinylpyrrolidone 
and BSA), salmon sperm ssDNA (0.5 mg/ml), 0.25 mg/mL yeast transfer RNA, 10% (w/v) 
dextran sulfate, and 10 mM dithiotreitol. After incubation overnight (37°C), the sections were 
initially transferred to 4 rapid consecutive washes in 1XSSC (room temperature) and then 
washed 4 times 15 min in 1XSSC (55°C) and 2 times 30 min in 1XSSC at room temperature. 
Finally, the sections were air dried and exposed together with [14C]-standards to a Kodak 
Biomax MR film (Amersham Bioescience) for 8-14 days. Optical densities were quantified in 
medial PFC, CA1, CA3, upper DG, and parietal cortex (S1) using Quantity One software 
(BioRad) performed by an observer blinded to the genotype and treatment of the animals. The 
optical densities were converted to nCi/g tissue using the [14C]-standards and the individual 
values for each animal were calculated as the average of three sections measured within the 
areas of interest. A background measurement outside the sections was subtracted from each 
measurement. 
2.13 AD brain tissue 
Familial Swedish and Arctic brain tissue was kindly provided by Lars Lannfelt, Uppsalla 
University, Sweden. Sporadic AD brain tissue was supplied from the Netherlands Brain Bank, 
Amsterdam, The Netherlands. 
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2.14 Statistical analysis 
Data were analyzed using unpaired t-tests, two-way analysis of variance (ANOVA) or one-
way ANOVA followed by post-hoc tests as specified in the figure legends of the results 
chapter (3). Data are presented as mean  s.e.m. Significance levels were given as follows: 
***P < 0.001; **P < 0.01; *P < 0.05. All statistical analyses were conducted using GraphPad 
Prism version 4.03 for Windows (GraphPad Software, San Diego, CA, USA). 
The correlation analysis between intraneuronal Aβ and the following parameters was 
performed by Thomas Schneider-Axmann. Diagnosis, gender, age, brain weight, post-mortem 
delay, number of ApoE4 alleles, and Braak stage data were supplied directly from the Brain 
bank. Atherosclerosis and plaque stage were extracted from a document describing the 
patients’ disease history and post-mortem examination.  
Kolmogorov-Smirnov test was applied to examine which variables showed significant 
deviations from normal distribution. Most of the parameters, especially intraneuronal Aβ, 
showed significant deviation from normal distribution and thus the following tests are non-
parametric. Non-linear Spearman correlations were used to analyze the correlation between 
intraneuronal Aβ and atherosclerosis, followed by Spearman rank correlations between 
intraneuronal Aβ and age, brain weight, and post-mortem delay. Non-parametric Mann 
Whitney U test was performed between intraneuronal Aβ and the factors gender, diagnosis 
and number of ApoE 4 alleles. Non-parametric Kruskal Wallis tests were performed between 
intraneuronal Aβ and Braak stage and plaque stage, where subgroup analysis between two 
groups was performed with Mann Whitney U tests. As the study is explorative, the p-values 
are given without Bonferroni adjustments. 
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xamine A-related effects 
3 Results 
The background of the individual experiments is described in chapter 1.6. The details of the 
methods applied are given in the previous section. The results are discussed separately in 
section 4, and a final unified conclusion is given in section 5. 
3.1 Neuron loss in the cholinergic system of APP/PS1KI mice 
Cholinergic pathology 
To initially characterize cholinergic fiber pathology in the APP/PS1KI mice, staining for 
ChAT was qualitatively analyzed in relation to A deposition throughout the brain in a double 
ABC staining in paraffin embedded sections. ChAT-positive dystrophic neurites, which are 
swollen neuronal processes, were found to decorate amyloid plaques in the cortex and 
thalamus (Fig. 20A, B) as well as in the hippocampal formation occasionally disrupting the 
granular cell layer of the DG (Fig. 20C). This pathology starts already at 2 months of age, but 
is most abundant in 6- to 10-month-old mice. At later time points, ChAT-positive axonal 
varicosities independent of plaques were detected in some brain regions e.g. in the lateral 
septum (Fig. 20D, E), probably indicating axonal transport disturbance. Strong plaque 
associated ChAT-positive 
dystrophic neurites were also 
detected in the striatum; whereas 
control animals were consistently 
negative (Fig. 20F, G).  
To e
on the number of cholinergic 
neurons in the present 
APP/PS1KI mouse model, we 
analyzed the expression pattern 
of the human mutant APP 
transgene and the associated A 
deposition in the brain 
Fig. 20 Cholinergic fiber pathology in APP/PS1KI mice. Six to 10 
months old APP/PS1KI mice showed ChAT-positive dystrophic 
neurites (reddish brown) decorating Aβ[N]-positive amyloid plaques 
(blue) in the cortex (A) and thalamus (B), as well as occasionally in 
the granular cell layer of the dentate gyrus (C). ChAT-positive axonal 
varicosities independent of plaques were detected e.g. in the lateral 
septum (D, E). Strong plaque-associated ChAT-positive neurites 
were also detected in the striatum (F); whereas control animals were 
consistently negative (G). Scale bars: (A, B) 20 µm, (C - E) 33 µm, 
(F, G) 50 µm. 
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cholinergic system by double-labeled fluorescent immunohistochemistry. In the brain 
cholinergic system, human APP was found to be expressed in motor nuclei of the brain stem 
that also accumulated intracellular Aβ peptides (Fig. 21M - P). In contrast, no APP expression 
and almost no deposition of Aβ plaques was observed in either of the two cholinergic 
projecting nuclei groups of the brain, the forebrain (Ch1-Ch4, Fig. 21K, L) and pons (Ch5-
Ch6, Fig. 21I, J) complexes. However, fibers from these nuclei were severely affected as 
many plaques surrounded by cholinergic dystrophic neurites could be found in their 
projecting areas: cortex, hippocampus, and thalamus (Fig. 21A - F). The APP transgene was 
also found not to be expressed in the cholinergic interneurons of the caudate putamen, a 
region containing numerous smaller plaques and dystrophic neurites (Fig. 21G, H). Thus in 
the brain cholinergic system, only motor nuclei of the brain stem were found to express the 
APP transgene and consequently accumulate intracellular Aβ peptides (Fig. 21N- P). Of the 
motor nuclei in the brain stem, Mo5 and 7N are fairly large and were chosen for stereological 
Fig. 21 Expression of APP transgene and Aβ1-x deposition in the cholinergic system of APP/PS1KI mice.
In 6-month old APP/PS1KI mice, ChAT is visualized in red, APP and Aβ1-x in green using the 23850 and 
Aβ[N] antibodies, respectively, and cell nuclei in blue by DAPI staining. Cholinergic dystrophic neurites were 
found surrounding plaques in the cortex (A, B), hippocampus (CA1; C, D), and thalamus (E, F). No expression 
of the APP transgene or accumulation of intracellular Aβ was observed in either the forebrain (K, L) or pons 
(I, J) complex. The same held true for the cholinergic interneurons of the caudate putamen (CPu: G, H). 
However, cholinergic neurons of the motor nuclei Mo5 and 7N were found to express the APP transgene (M, 
N) and accumulate intracellular Aβ (N, P). Scale bars: (A-F) 33 µm, (G-P) 50 µm. 
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Analysis of cholinergic neuron numbers 
 by stereology at 2, 6, and 12 months of age in 
quantification representing areas with accumulation of intracellular Aβ. In comparison, the 
forebrain cholinergic neurons projecting to the hippocampus (Ch1/2) and cortex (Ch4) were 
chosen representing areas with cholinergic fiber pathology, and the interneurons of the 
caudate putamen of the striatum were chosen representing an area with cholinergic fiber 
pathology as well as extracellular Aβ plaque deposition surrounding the neuron bodies, 
however, without any intracellular A accumulation.  
Cholinergic neuron numbers were quantified
APP/PS1KI and PS1KI control mice by counting ChAT-positive neurons in caudate putamen, 
the forebrain complex (Ch1/2 and Ch4), and in the two motor nuclei: Mo5 and 7N (Fig. 22A). 
Depending on age and genotype as cofactors, quantification revealed no changes in the 
number of cholinergic neurons in the caudate putamen or in any of the cholinergic projecting 
nuclei of the forebrain complex (Ch1/2, Ch4) (Fig. 23A - C). In contrast, Mo5 and 7N 
accumulating intracellular Aβ peptides showed a significant loss of cholinergic neurons in the 
APP/PS1KI mice. Thus the number of cholinergic neurons was decreased by 27% in the Mo5 
already at 6 months of age (P < 0.001) and by 33% at the age of 12 months (P < 0.001), 
whereas the cholinergic neuron number in the 7N was significantly decreased only at 12 
months of age (-19%; P < 0.01) (Fig. 23D, E). 
Fig. 22 Definition of counting areas. A) Schematic presentation of stereologically quantified cholinergic areas: 
Caudate putamen (CPu, Bregma 1.70 to -2.30 mm), Ch1/2 comprising the medial septal nucleus and vertical 
limb of the diagonal band of Broca (Bregma 1.34 to 0.26 mm), Ch4 comprising the horizontal limb of the 
diagonal band of Broca, ventral pallidum, nucleus basalis, and substantia innominata (Bregma 0.26 to -1.34 
mm), as well as motor nuclei Mo5 (Bregma -4.84 to -5.34) and 7N (Bregma -5.68 to -6.48). Figures were created 
from the mouse atlas by Paxinos and Franklin (2001) with orientation according to Bregma beneath each section. 
B) 12-month-old APP/PS1KI and PS1KI control mice showing examples of the free-floating ChAT staining in 
the quantified regions. Scale bar = 100µm. 
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Fig. 23 Stereological quantification of ChAT-positive neurons in APP/PS1KI mice. No change in 
cholinergic neuron numbers was found depending on either age or genotype neither in the hippocampal 
projecting Ch1/2 nuclei (A), in the cortical projecting Ch4 nuclei of the forebrain complex (B), nor in the 
cholinergic interneurons of the caudate putamen (C). However, in the motor nuclei of the brain stem, a 
cholinergic neuron loss in the APP/PS1KI mice compared to the PS1KI control mice was found. In the Mo5 
(D), the cell loss was 27% in 6-month-old mice and 33% in 12-month-old mice, whereas the cholinergic neuron 
number in the 7N was significantly decreased only in 12-month-old mice (E, -19%; P). Data were analyzed 
using two-way ANOVA followed by Newman-Keuls posthoc test. The number of animals per group is given 
directly in the bars. All error bars represent mean  s.e.m. ***P < 0.001; **P < 0.01. 
Intracellular Aβ accumulation and cell death 
Loss of cholinergic neurons occurred earlier and to a larger extent in the motor nucleus Mo5 
compared to the 7N (Fig. 23D, E). Therefore, a qualitative fluorescent immunohistochemical 
analysis was carried out in paraffin sections, comparing the accumulation pattern of different 
A species in the two motor nuclei. The accumulation of intracellular Aβ1-x began earlier and 
to a larger degree in the Mo5 than in the 7N. This difference in Aβ1-x accumulation was 
especially evident at 2 and 6 months of age where the Mo5 showed extensive accumulation of 
Aβ peptides that were virtually absent in the 7N at these time points (Fig. 24A – F, J – O). 
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This distinction was less evident at 12 months, where substantial intracellular Aβ1-x 
accumulation could be detected also in the 7N (Fig. 24P - R). The same held true for fibrillar 
oligomeric and fibrillar Aβ, visualized by use of OC antibodies (Kayed et al. 2007) (Fig. 25A 
- C, G - I), as well as for highly aggregated Aβ visualized by use of the amyloid binding dye 
Fig. 24 Intracellular Aβ accumulation in the cholinergic motor neurons of Mo5 and 7N in APP/PS1KI 
mice. In 2-, 6-, and 12-month-old APP/PS1KI mice, the Mo5 was found to accumulate intracellular Aβ1-x
labeled by Aβ[N] antibodies at an earlier age than the 7N. ChAT staining is shown in red and Aβ1-x in green. 
Merged images are shown in C, F, I, L, O, R. Scale bars: 50 µm. 
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Thioflavine S, which detects aggregated beta sheet structures and disclosed a punctuate 
somatodendritic staining pattern already in 2-month-old mice in the Mo5 being much more 
prominent than in the 7N (Fig. 25D - F, J - L).  
 
Fig. 25 Fibrillar oligomeric Aβ and Thioflavin S positive material in motor neurons of the 
Mo5 and 7N. In 2-, 6-, and 12-month-old APP/PS1KI mice, fibrillar oligomeric and fibrillar Aβ 
(OC antibody, green) as well as Thioflavin S positive material (green) were found to accumulate 
intracellular in a larger amount and at an earlier age in the Mo5 as compared to the 7N. DAPI 
staining in blue shows cell nuclei and only merged pictures are shown. Scale bars: A – C, G – I: 
100 µm; D – F, J – L: 50 µm. 
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3.2 Effect of intraneuronal Aβ versus plaques on 
neurodegeneration 
Aβ accumulation in the frontal cortex and thalamus 
Massive intra- and extracellular Aβ accumulations were observed in the frontal cortex by 
immunohistochemical staining using the 4G8 antibody recognizing the central epitope Aβ17-24 
(Fig. 26A - H). The intraneuronal pathology of the frontal cortex is already very prominent at 
the age of 1.5 months, where virtually no or very few plaques are visible (Fig. 26A, E). 
Already at 2 months, plaque pathology starts to develop at a greater degree; however, 
Fig. 26 Aβ peptides in frontal cortex and thalamus of APP/PS1KI mice. Micrographs shows immunostaining 
of Aβ peptides using 4G8 antibodies in frontal cortex (A - H) and thalamus (I - P) of 1.5-, 2-, 6-, and 12-month-
old APP/PS1KI mice in paraffin embedded sections. Prominent accumulation of intraneuronal Aβ is seen in the 
frontal cortex already at 1.5 months with only little plaque pathology (A, E). More plaques are evident in the 
frontal cortex of 2-month-old mice where intraneuronal Aβ is still highly abundant (B, F). Plaque pathology 
dramatically increases in the frontal cortex from 2 to 6 months, with a concomitant decrease in intraneuronal Aβ 
accumulation (C, G), whereas the pathology is mostly unchanged from 6 to 12 months (D, H). No Aβ pathology 
is observed in the thalamus of 1.5-month-old mice (I, M) which start to develop plaques at the age of 2 months
with no accumulation of intraneuronal Aβ (J, N). Plaque pathology increased dramatically in the thalamus from 
2- to 6-month-old mice (K, O) and even further to 12-month-old mice (L, P). Scale bars: A – D, I – L: 200 µm; E 
– H, M – P: 33 µm. 
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intraneuronal Aβ is still abundantly present (Fig. 26B, F). At the age of 6 months, plaque 
pathology has been dramatically developed, however, the staining of intracellular Aβ 
aggregates decreases and is no longer a dominating pathological feature (Fig. 26C, G). From 6 
to 12 months, the pathology of the frontal cortex does not seem to change much except that 
the plaques may become more densely packed (Fig. 26D, H). The thalamus is found to 
develop only plaques and no intraneuronal aggregates (Fig. 26I - P). The pathology of this 
region starts later than in the cortex at about the age of 2 months with no pathology at 1.5 
months (Fig. 26I, M). From 2 to 6 months, numerous plaques develop and the pathology even 
increases further till the age of 12 months (Fig. 26J - L, N - P). As the 4G8 antibody has been 
shown to weakly cross react with APP in western blots, the antibody was highly diluted 
(1:10,000) in order to recognize only A. Using a variety of different dilutions, this 
concentration was found to show no staining of APP. The presence of intracellular Aβ 
aggregates was confirmed by immunostaining with the N-terminal specific Aβ antibody, 
Aβ[N]. Again, prominent accumulation of intraneuronal Aβ staining was found in the frontal 
cortex already at the age of 1.5 and 2 months, but being absent at 6 and 12 months (Fig. 27A - 
D). Furthermore, confirming the 4G8-staining, no intraneuronal Aβ immunoreactivity was  
Fig. 27 Confirmation of intracellular Aβ accumulation in APP/PS1KI mice by Aβ[N] antibody. As 
observed with the 4G8 antibody, intracellular Aβ1-x staining was found to be prominent in AP/PS1KI 
mice already at 1.5 months of age (A) as well as at 2 months (B), but decreased at 6 and 12 months (C, 
D). No intraneuronal Aβ1-x staining was detected in the thalamus regardless of age (E - H). Scale bar: a –
h: 33 µm. 
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detected in the thalamus regardless of age (Fig. 27E - H). In addition, different end-specific 
A antibodies were used to demonstrate the specificity of intraneuronal A immunorectivity 
in the frontal cortex (Fig. 28E – G). The regional difference in the accumulation of 
intraneuronal Aβ seems to be a consequence of the APP transgene expression pattern, as the 
APP transgene is abundantly expressed in the pyramidal layers of the frontal cortex, whereas 
no expression is found in the thalamus (Fig. 28A - D). To further characterize the 
development of Aβ pathology over time in the two regions chosen for stereology, the Aβ 
accumulation was quantified using the 4G8 antibody and a software density measurement 
technique (Fig. 29). At 2 months of age, the area covered by Aβ deposits was already 4.7 % in 
the frontal cortex owing to the massive accumulation of intraneuronal Aβ, but only 1.5 % in 
the thalamus because of the absence of intracellular Aβ and the later onset of extracellular 
plaque pathology. At 6 months of age, the percentage of the area covered by Aβ deposits had 
increased to 12.1 % in the frontal cortex and 8.5 % in the thalamus. From the age of 6 to 12 
months, the A-covered area remained stable in the frontal cortex, but increased further to 
13.9 % in the thalamus (Fig. 29A, B). Looking at average Aβ grain size and grain numbers in  
Fig. 28 APP transgene expression and further confirmation of intracellular Aβ in APP/PS1KI mice.
Immunostaining of human APP using the 23850 antibody in paraffin embedded sections of 2-month-old 
APP/PS1KI mice showed that the APP transgene is expressed in the neurons of the frontal cortex (A, C) but 
not of those in the thalamus, where only dystrophic fibers mostly surrounding plaques were stained (B, D). The 
following endspecific Aβ antibodies were applied to further confirm the intraneuronal Aβ staining in the frontal 
cortex: N1D (E, N-terminal Aβ starting with aspartate at position 1), N3pE (F, N-terminal Aβ starting with 
pyroglutatmate at position 3), and G2-10 (G, C-terminal Aβ40 peptides). Scale bars: A, B: 200 µm; C, D: 50 
µm; E – G: 33 µm. 
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Fig. 29 Quantification of Aβ accumulation in frontal 
cortex and thalamus. About 5% of the frontal cortical 
area is covered by Aβ peptide in 2-month-old 
APP/PS1KI mice increasing to 12.1% in 6-month-old 
mice with no further increase in 12-month-old mice (A). 
Only 1.5% of the thalamic area was covered by Aβ
peptide in 2-month-old APP/PS1KI mice, which
increased to 8.5% in 6-month-old mice, and further 
progressed to 13.9% at the age of 12 months (B). The 
increase in Aβ load in the frontal cortex from the age of 2 
to 6 months was due to an increased number of deposits 
(C) as no change in average deposit size was detected 
(E). In the thalamus, the steady increase in Aβ load was 
solemnly due to increased number of deposits (D) as the 
average deposit size did not change with age (F). The 
number of animals analyzed was at 2 months: 3; 6 
months: 5; and 12 months: 4. Data were analysed using 
one-way ANOVA followed by Tukeys post-hoc test. All 
error bars represent mean  s.e.m. ***P < 0.001; **P < 
0.01; *P<0.05. 
each region, it is evident that the steady increase in the percentile Aβ-covered area observed 
in the thalamus over time is solemnly due to a dramatic increase in plaque number, as the 
grain number increases a total of 11 times from 2 to 12 months, without major changes in 
their size (Fig. 29D, F). In the frontal cortex, the increase observed in the percentage of the 
Aβ-covered area between 2 and 6 months of age is also exclusively dependent on a 2.7-fold 
increase in grain numbers as the average grain size is unchanged. However, in contrast to the 
thalamus, changes are seen in the composition of frontal cortical deposits as the average size 
decreases, confirming the observation that the plaques become more dense and the number of 
deposits tend to increase being close to significance. 
In order to separate the effect of intracellular Aβ and plaques on neuronal survival in the 
frontal cortex, we selected the thalamus as an appropriate region for comparison as the 
amount of extracellular accumulated plaques is in a comparable range to the A load 
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observed in the frontal cortex, however, without any accumulation of intraneuronal Aβ 
peptides. 
Stereology in the frontal cortex and thalamus 
The counting areas of the frontal cortex and thalamus were defined according to Fig. 30A. A 
loss of neurons of 28 % and 35 % was found in the frontal cortex of the APP/PS1KI mice 
compared to PS1KI control mice at the age of 6 and 12 months, respectively (Fig. 30B, 
P<0.001). However, the loss did not significant progress between these ages in APP/PS1KI 
mice correlating with the finding of no further changes in Aβ accumulation in the frontal 
cortex after 6 months of age. Corresponding reductions in frontal cortical volumes were found 
at the age of both 6 (25%, P<0.001) and 12 months (23%, P<0.01) (Fig. 30D). Due to normal 
growth, frontal cortical volumes increased 86% and 50% between the age of 2 to 6 months in 
PS1KI control and APP/PS1KI mice, respectively. Strikingly, no change was observed in the 
neuron numbers of the thalamus between 2-, 6-, and 12-month-old mice despite the 
development of massive plaque pathology (Fig. 30C). Correspondingly, no differences in 
thalamic volume were found between APP/PS1KI and PS1KI control mice at any age 
investigated (Fig. 30E). As for the frontal cortex, normal growth from 2 to 6 months was 
Fig. 30 Schematic presentation of counting areas and stereological quantification of neuron numbers. A) 
The frontal cortex was quantified from Bregma 3.08 to 0.26 and the thalamus from -0.94 to -2.54. Adapted from
(Paxinos and Franklin 2001) with orientation according to Bregma below each section. Significant neuron 
losses of 28% and 35% were found in the frontal cortex of APP/PS1KI mice 6 and 12 months, respectively (B). 
Corresponding decreases of 25% and 23% were observed in frontal cortical volumes (D). No differences in 
neuron numbers or volumes were observed of the thalamus between APP/PS1KI and PS1KI control mice at 2-, 
6-, and 12 months of age (C, E). The number of animals analyzed is given directly in the bars (B, C). Data were 
analyzed by two-way ANOVA followed by Tukeys post-hoc test. All error bars represent mean  s.e.m. ***P < 
0.001; **P < 0.01; *P<0.05. 
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evident by an increase in the thalamic volume of 75 % (P<0.05) in the PS1KI mice and 30 % 
in the APP/PS1KI mice, however, only being close to significance (P = 0.072).  
3.3 Intraneuronal Aβ staining in AD patients and transgenic AD 
mouse models 
Optimization for staining of intraneuronal Aβ in mouse models of AD 
Quantitative optimization for staining of intracellular Aβ as compared to plaques was 
performed in 6-month-old APP/PS1KI transgenic mice in the CA1 and thalamus 
Fig. 31 Quantitative optimization of intracellular Aβ1-x staining in APP/PS1KI mice. Parallel sections from 
6-month-old APP/PS1KI transgenic mice stained with Aβ[N] antibodies in paraffin embedded sections showing 
micrographs of intracellular Aβ1-x in CA1 and plaque labeling in thalamus using protocols with either no antigen 
retrieval (A, G), 3 min formic acid (FA) pretreatment (B, H), 10 min FA pretreatment (C, I), 10 min microwave 
heating in a citric acid buffer pH 6 (D, J), combined heating and 3 min FA pretreatment (E, K), or combined 
heating and 10 min FA pretreatment (F, L). Area percentile quantifications of the corresponding Aβ loads showed 
that FA pretreatment regardless of exposure time is essential for the intraneuronal staining of Aβ in the CA1 (M), 
whereas heat and FA treatment have equal antigenic retrieval effect on extracellular Aβ plaque pathology in the 
thalamus (N). Scale bars: (A-F) 50 µm, (G-L) 100 µm. Three sections from 5 mice were analyzed in each group. 




accumulating either intracellular Aβ or plaques, respectively. Parallel sections containing the 
two areas of interest were stained with the Aβ[N] antibody that recognizes Aβ1-x comparing  
protocols with either no antigen retrieval, 10 min microwave heating in a citric acid buffer pH 
6 (heat), 3 and 10 min FA pretreatments, or combined heat and FA pretreatments. Virtually no 
intracellular Aβ staining and only very little labeling of Aβ plaques were observed in the CA1 
and thalamus without any pretreatment (Fig. 31A, G). FA pretreatments revealed an obvious 
Fig. 32 Optimization of intraneuronal Aβ[N] staining in APP, APP/PS1KI, APP/PS1, and 5xFAD mice.
Qualitative optimization for intraneuronal Aβ staining in the medial cortex of APP, APP/PS1KI, APP/PS1, and 
5xFAD mice was performed with the N-terminal specific antibody Aβ[N]. No clear intraneuronal Aβ1-x
staining was observed in APP, APP/PS1KI, and APP/PS1 mice without heat or FA treatment (A, B, C), 
whereas 5xFAD mice showed some intraneuronal Aβ staining without any pretreatment (D). Ten min heat 
treatment in citric acid buffer pH 6 had a minor increasing effect on the intracellular staining in all 4 mouse 
models (E, F, G, H), however, 3 min FA pretreatment markedly increase the intracellular Aβ1-x disclosing a 
distinct granular pattern being most obvious in the APP/PS1KI, APP/PS1, and 5xFAD mice (I, J, K, L). The 
combination of heat and FA pretreatment further increase the intracellular staining in APP mice and had a 
minor intensifying effect in the APP/PS1KI, APP/PS1, and 5xFAD mice (M, N, O, P). Scale bar: 33 µm. 
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granular intracellular staining in CA1 as well as a much clearer labeling of plaques with both 
3 and 10 min exposure times (Fig. 31B, C and H, I). Applying the heat pretreatment alone did 
not reveal much staining of intracellular Aβ in the CA1, however, staining of plaques was 
dramatically increased in the thalamus (Fig. 31D, J). Combining the heat and FA treatments 
seemed to intensify the staining of intracellular Aβ as compared to FA treatment alone, 
whereas plaques were equally well disclosed (Fig. 31E, F and K, L). These observations were 
confirmed by quantification of the area covered by Aβ1-x staining where it became evident 
that heat pretreatment alone did not increase the staining of intraneuronal Aβ in the CA1. FA 
pretreatments for 3 and 10 min both significantly increased the intraneuronal staining 
independent of exposure time (Fig. 31M). The combined effect of heat and FA also 
significantly increased the area of intraneuronal Aβ staining compared to no pretreatment, but 
not compared to FA pretreatment alone (Fig. 31M). Concerning plaque pathology in the 
thalamus, all pretreatments significantly increased the plaque staining in an equal manner as 
compared to no pretreatment (Fig. 31N). 
The analysis of optimization for staining of intraneuronal Aβ was extended to a qualitative 
comparison in four different AD mouse models: APP, APP/PS1KI, APP/PS1 and 5xFAD 
mice of ages where intraneuronal accumulation of Aβ was evident in the medial cortex above 
the hippocampus. No pretreatment was compared to the antigen retrieving effect of heat, FA 3 
min, and the combined effect of heat and FA 3 min. Applying the Aβ[N] antibody, APP, 
APP/PS1KI, and APP/PS1 mice showed no detection of intraneuronal Aβ1-x without heat or 
FA pretreatment (Fig. 32A, B, C, respectively), in contrast to 5xFAD mice that showed some 
intraneuronal Aβ staining without any pretreatment (Fig. 32D). Heat pretreatment had a minor 
increasing effect on the intracellular Aβ1-x staining in all mouse models (Fig. 32E, F, G, H), 
however, 3 min FA pretreatment revealed an intense granular intracellular staining being most 
evident in the APP/PS1KI, APP/PS1, and 5xFAD mice (Fig. 32I, J, K, L). The combination of 
heat and FA treatment further increased the intracellular staining of Aβ1-x in single transgenic 
APP mice and had an intensifying effect in the bigenic APP/PS1KI, APP/PS1, and 5xFAD 
mouse models (Fig. 32M, N, O, P). 
The effect of heat and FA was additionally studied in the same four mouse models using the 
4G8 antibody recognizing Aβ17-24. Applied in the concentration of 1:10.000 this antibody 
previously showed no cross-reaction with APP in immunostainings in APP/PS1KI transgenic  
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mice (Christensen et al. 2008). As observed with the Aβ[N] antibody, weak intraneuronal Aβ 
staining without any pretreatment was only observed in the 5xFAD model (data not shown) 
and 3 min FA pretreatment was found to reveal a granular intracellular staining pattern in all 
four mouse models being most intense in the APP/PS1KI mice (Fig. 33A, B, C, D). However, 
in contrast to the Aβ[N] staining, heat pretreatment of 4G8 stained sections revealed a 
staining pattern of much smaller Aβ granules dispersed throughout the cytoplasm of cortical 
neurons in all four mouse models (Fig. 33E, F, G, H). This heat-induced Aβ staining was 
Fig. 33 The effect of formic acid (FA), heat, and combined heat and FA antigen retrieval on intracellular 
4G8 staining was qualitatively compared in the medial cortex of APP, APP/PS1KI, APP/PS1, and 5xFAD mice. 
Three min FA pretreatment was found to reveal a distinct granular intracellular staining pattern as observed with 
the Aβ[N] antibody  (A, B, C, D). In contrast, 10 min heating in citric acid buffer pH 6 revealed a more 
homogenous intracellular staining pattern in all four mouse models (E, F, G, H), however, this seemed to 
decrease with combined pretreatment of heat and 3 min FA showing mainly the granular intracellular staining 
observed with FA pretreatment alone (I, J, K, L). Thioflavin S staining in green disclosed the same granular 
intracellular staining pattern as observed with the 3 min FA treatment alone in all four mouse models (M, N, O, 
P). Scale bar: 33 µm. 
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decreased with combined pretreatment of 
heat and 3 min FA, disclosing mainly the 
granular intracellular staining similar to the 
effect of FA alone (Fig. 33I, J, K, L). To 
investigate the specificity of the heat-
induced 4G8 staining, 4G8 (red) and APP 
(green) were fluorescently labeled in 
APP/PS1KI mice (Fig. 34). With application 
of the heat pretreatment alone, most of the 
4G8 staining co-localized with the APP 
staining within the cytoplasm of cortical 
neurons (Fig. 34A, B, C). With the 
combination of heat and FA pretreatment, 
the 4G8 antibody mainly labeled the larger 
granules at the axon hillock, which did not 
co-localize with the APP staining (Fig. 34D, 
E, F). Fluorescent green Thioflavin S staining visualizing aggregated proteins was applied to 
analyze the aggregation state of the intraneuronal Aβ peptides and disclosed the same 
granular intraneuronal staining pattern as observed with 3 min FA pretreatment alone or 
together with heat in all four mouse models (Fig. 33M, N, O, P), indicating that the 
intraneuronal Aβ enhanced by FA is in an aggregated state. 
Fig. 34 Fluorescent double labeling of 4G8 and APP 
in APP/PS1KI mice. 4G8 (red) and APP (green) was 
fluorescently double labeled in heat and heat + FA 
pretreated sections from 1.5-month-old APP/PS1KI 
mice. With heat pretreatment alone, much of the 4G8 
staining co-localized with the APP staining within the 
cytoplasm of cortical neurons (A, B, C). With the 
combination of heat and FA, the 4G8 antibody mainly 
labeled larger granules at the axon hillock of cortical 
neurons and did not co-localize with APP staining (D, 
E, F). Blue counterstaining of nuclei in the merged 
pictures was performed with DAPI. Scale bar: 10 µm. 
Staining of intraneuronal Aβ in brain tissue from AD patients 
Optimization for intraneuronal Aβ staining was performed in hippocampal paraffin sections 
of sporadic, familial Swedish, and familial Arctic AD cases using the Aβ[N] antibody. Even 
without any antigen retrieval, a faint fairly homogenous intraneuronal Aβ1-x staining could be 
detected in all three types of AD cases (Fig. 35A, E, I). Yet, 10 min heat treatment in 0.01 M 
citric acid buffer pH 6 dramatically increased the intraneuronal Aβ1-x staining that in higher 
magnification showed a granular appearance and concentration around the nucleus (Fig. 35B, 
F, J). Compared to no pretreatment, 3 min FA pretreatment did not improve the staining of 
intracellular Aβ1-x (Fig. 35C, G, K), and actually very clearly counteracted the enhancing 
effect of the heat pretreatment on intraneuronal Aβ1-x staining (Fig. 35D, H, L). In addition to 
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the fairly homogenous cytoplasm staining, some nuclei were observed to be surrounded by a 
highly granular Aβ staining pattern, which were present in all three AD cases with all applied 
protocols (Fig. 35C, G, K; black arrows). Double labeling of Aβ1-x and astrocytes using the 
Aβ[N] antibody visualized by DAB and a GFAP antibody visualized by Histogreen proofed 
this highly granular staining pattern to be astrocytes accumulating Aβ, which could be found 
abundantly in CA4 and CA3 of the hippocampal formation of many sporadic AD cases (Fig. 
36A, B; black arrows). In a few cases, astrocytes with no granular Aβ accumulation could be 
found in close proximity to neurons (Fig. 36C, D).  
Fig. 35 Optimization for intraneuronal Aβ[N] staining in the CA4 region of AD brain tissue. The 
optimization was performed in hippocampal sections from sporadic, familial Swedish, and familial Arctic AD 
cases using the Aβ[N] antibody in paraffin embedded sections. A faint homogenous intraneuronal Aβ1-x staining 
could be detected even without any antigen retrieval in all three types of AD cases (A, E, I). However, 10 min 
heat pretreatment in citric acid buffer pH 6 dramatically increased the intraneuronal Aβ1-x staining that in higher 
magnification show granularity and concentration around the nucleus (B, F, J). Compared to no treatment, 3 min 
formic acid (FA) pretreatment did not improve the staining of intraneuronal Aβ1-x (C, G, K) and  in the 
combined treatment of heat and FA, FA actually counteracted the enhancing effect of the heat pretreatment (D, 
H, L). Besides the intraneuronal Aβ1-x staining, smaller nuclei surrounded by a highly granular Aβ staining 
pattern were observed in all three AD cases with all protocols (C, G, K, black arrowheads). Scale bar: 50 µm. 
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The presence of intraneuronal Aβ in the 
hippocampal region of sporadic AD cases was 
confirmed by staining with OC antibodies 
recognizing Aβ fibrils and fibrillar oligomers 
(Kayed et al. 2007). The OC antibody produced 
an intraneuronal staining much like that of 
Aβ[N] with heat pretreatment alone (Fig. 37A, 
B) as well as with combined heat and 3 min FA 
pretreatment, actually being slightly more 
intense than that enhanced by heat alone (Fig. 
37C, D). The 4G8 antibody was applied to 
further confirm the presence of intraneuronal 
Aβ using heat pretreatment, but was found to 
produce a highly abundant intense granular 
staining very different from that detected by OC 
or Aβ[N] antibodies (Fig. 37E, F) with the 
granules being much larger and surrounding the 
nucleus in a cap-like manner. Fluorescent 
labeling of 4G8 and Aβ[N] with and without Sudan Black B pretreatment proved this 4G8 
staining to be a cross-reaction with lipofuscin (Schnell et al. 1999). Thus, staining with 4G8 
antibodies using a green secondary antibody showed only the intense staining of large 
intracellular granules (Fig. 38B) which were also evident in the blue DAPI channel (Fig. 38A) 
and as red auto fluorescence (Fig. 38C). Merging of the pictures showed complete co-
localization of this intense labeling of large cap-like granules (Fig. 38D). Pretreatment with 
Sudan Black B abolished the fluorescent staining observed in all channels (Fig. 38E, F, G), 
and merging of the pictures showed no remaining specific staining from the green 4G8 
channel (Fig. 38H). In contrast, visualization of intraneuronal Aβ using the Aβ[N] antibody 
with a green fluorescent secondary antibody showed the same intense labeling of large 
intracellular granules, however, with an additional staining of smaller granules dispersed 
throughout the cytoplasm as well as at the axon hillock (Fig. 38J). DAPI and red auto 
fluorescence (Fig. 38I, K) showed only the very intense labeling of the larger granules, and 
merging of the pictures revealed co-localization of the very intense cap-like staining, but with 
Fig. 36 Double labeling of Aβ1-x and astrocytes.
Using a double ABC labeling in paraffin 
embedded sections is shown Aβ[N] staining in 
reddish brown (DAB) and GFAP  in blue 
(Histogreen, black arrowheads). The highly 
granular staining pattern surrounding smaller 
nuclei was found to be astrocytes accumulating 
Aβ and could be found in CA4 (A) as well as in 
CA3 (B) of many sporadic AD cases. However, 
in some AD cases, astrocytes without granular 
staining were found close to neurons in both CA4 
(C) and CA3 (D). Scale bar: 33 µm. 
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an additional green staining of the smaller granules (Fig. 38L). Pretreatment with Sudan 
Black B abolished the intense cap-like granular staining from all channels (Fig. 38M, N, O), 
and the merged picture showed only the green staining of the smaller granules specific for the 
Aβ[N] antibody (Fig. 38P).  
 
Fig. 38 Analysis of 4G8 and Aβ[N] cross reactivity 
with lipofuscin in CA4 of a sporadic AD case.
Fluorescent staining using 4G8 antibodies with a 
green secondary antibody showed an intense 
intracellular labeling of large granules (B). However, 
merging of the 4G8 staining in green (B) with 
autofluorescence from the DAPI (A) and red channel 
(C) showed complete co-localisation (D). 
Pretreatment with Sudan Black B abolished the 
fluorescence observed in all channels (E, F, G), and 
the merged picture showed no remaining specific 
staining in the green channel (H). In contrast, 
fluorescent staining using Aβ[N] antibodies with a 
green fluorescent secondary antibody produced the 
same intense staining of large intracellular granules, 
but with an additional staining of smaller intracellular 
granules throughout the cytoplasma and in the axon 
hillock (J). The DAPI (I) and red channels (K) 
showed only the very intense large granules and 
merging of the pictures showed co-localisation only 
of the intensely labeled large granules (L). 
Pretreatment with Sudan Black B abolished the 
intense granular staining from DAPI (M), Aβ[N] 
green labeling (N), and red autofluorescence (O), and 
the merged picture showed only the weaker green 
staining specific for the Aβ[N] antibody (P). Scale 
bar: 20 µm. 
Fig. 37 Intraneuronal staining detected by OC 
and 4G8 antibodies in a sporadic AD brain tissue.
The OC antibody disclosed intraneuronal Aβ 
staining much like that of Aβ[N] with both 10 min 
heat pretreatment alone (A: CA4, B: CA1) and 
combined heat and 3 min formic acid (FA) treatment 
(C: CA4, D: CA1). With 10 min heat pretreatment, 
the 4G8 antibody produced a much different highly 
abundant and granular intracellular staining (E: CA4, 
F: CA1). Bottom left corners of A, C, and E show 
intracellular staining in high magnification. Scale 
bar: 50 µm. 
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Intraneuronal Aβ staining intensity in sporadic AD patients 
Hippocampal sections from 10 controls and 20 
AD patients were stained with Aβ[N] 
antibodies and their intraneuronal Aβ1-x 
intensity was analyzed based on evaluation of 
the staining intensity in CA4, CA3, and CA1. 
Thus “+++” was assigned to cases with very 
strong intraneuronal Aβ staining in CA4, CA3, 
as well as in CA1 (Fig. 39A, B, C). “++” was 
assigned to cases with weaker but still obvious 
intracellular Aβ staining in CA4 and CA3, but 
low or no staining in CA1 (Fig. 39D, E, F). “+” 
was assigned to cases with a very faint 
intracellular staining in CA4 and CA3 and no 
staining in CA1 (Fig. 39G, H, I), and “0” was 
assigned to cases showing no intracellular Aβ1-x 
staining either in CA4, CA3, or CA1 (Fig. 39J, 
K, L). Four AD patients and 2 controls were 
found to accumulate the highest degree of 
intraneuronal Aβ1-x peptides, whereas 9 AD 
patients and 2 controls accumulated a moderate 
amount of these Aβ peptides. Six AD patients 
and 4 controls accumulated low amount of Aβ peptides, whereas only 1 AD patient and 2 
controls showed no accumulation of Aβ1-x peptides (Table 8). By non-parametric statistical 
analysis, the accumulation of intraneuronal Aβ1-x was found not to correlate with age, brain 
weight, post-mortem delay, gender, diagnosis, and Braak stage, whereas a weak but 
significant correlation was found with atherosclerosis and plaque pathology. Yet, ApoE 
genotype was found to very strongly correlate with the presence of intraneuronal Aβ where 
having one ApoE4 allele highly significantly correlated with increased intraneuronal Aβ1-x 
staining (Table 9, P=0.002), which was even significant after Bonferroni adjustment 
(P=0.023). 
Fig. 39 Rating of intraneuronal Aβ[N] staining 
intensity. +++ was assigned to cases with very 
strong intraneuronal Aβ staining in CA4, CA3, as 
well as in CA1 (A, B, C). ++ was assigned to cases 
with weaker but still obvious intracellular Aβ
staining in CA4 and CA3 and low staining in CA1 
(D, E, F). + was assigned to cases with a very faint 
intracellular Aβ staining in CA4 and CA3 and 
apparently no staining in CA1 (G, H, I). 0 was 
assigned to cases showing no intracellular Aβ
staining either in CA4, CA3, or CA1 (J, K, L). Scale 





Table 8 Patient data giving diagnosis, gender, age, post mortem delay (PMD, hrs:min), Brain weight (g), Braak 
stage, Plaque load, ApoE genotype (combination of alleles 2, 3,and 4), intraneuronal Aβ1-x staining intensity, 





Table 9 Statistical analysis of the correlation between intraneuronal Aβ accumulation and the following data 
from AD patients and control cases: atherosclerosis, age, brain weight (g), post mortem delay, gender, 
diagnosis, number of ApoE4 alleles, Braak stage, and plaque stage. 20 AD patients and 10 controls were 




3.4 Effect of Aβ on axonopathy in transgenic AD mouse models 
APP expression and Aβ load with increasing PS1KI gene dosage  
Staining with antibodies against human APP 
revealed approximately equal numbers of 
APP-positive cells in APP, APP/PS1KIhe 
and APP/PS1KIho mice at 10 months of age, 
but with dystrophic fibers accumulating 
APP in APP/PS1KIhe and APP/PS1KIho 
mice (Fig. 40A – C). A qualitative western-
blot analysis confirmed that the overall 
expression of human full-length APP in the 
three mouse lines was equal with no 
considerable variation between the different 
genotypes. In contrast, the levels of the -
secretase cleavage product C99 as well as 
A increased with increasing mutant PS1 
gene dosage (Fig. 40D). 
The accumulation of Aβ was quantified in 
the frontal cortex, pons and spinal cords of 
10-month-old APP, APP/PS1KIhe, and APP/PS1KIho mice using computer-based analysis of 
4G8 DAB stained sections (Fig. 41). Very little or no Aβ accumulation was observed in the 
pons and spinal cords of APP transgenic mice harboring no PS1KI mutations (Fig. 41E, H, I, 
L), whereas 3.9% of the frontal cortex was covered by Aβ staining (Fig. 41A and D). 
Introducing one PS1KI allele generating APP/PS1KIhe mice caused a significant increase in 
the Aβ load in the frontal cortex by 80% leading to an overall Aβ load of 7% (Fig. 41A). 
Also, considerable pathology was observed in the pons and spinal cord which had Aβ loads of 
3.6% and 3.3%, respectively (Fig. 41F, H, J, L). A further increase in the PS1KI gene dosage 
resulting in the APP/PS1KIho mice caused an approximate doubling of the Aβ load in all three 
Fig. 40 Analysis of APP transgene expression in 
APP, APP/PS1KIhe, and APP/PS1KIho mice.
Immunostaining of human APP in spinal cords of 
APP (A), APP/PS1KIhe (B), and APP/PS1KIho (C) 
mice showing comparable numbers of APP-
expressing cells in all three genotypes. Western-blot 
analyses revealed no differences in the amount of 
human full-length APP among the three genotypes, 
however, the levels of C99 and Aβ increased with 
increasing PS1KI gene dosage (D). Scale bar: 50 µm.
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regions measured (Fig. 41C-D, G-H, K-
L), whereas PS1KIho mice were 
consistently negative for 4G8 staining 
(data not shown). This directly 
proportional rise in Aβ load observed 
with increasing PS1KI gene dosage in 
mice hemizygous for the APP transgene 
also applied to intraneuronal Aβ as 
exemplified in motor neurons of the 
spinal cord (Fig. 42).  
Fig. 41 Immunostaining of Aβ in APP, APP/PS1KIhe, and APP/PS1KIho mice. Aβ accumulation was 
analysed using 4G8 immunostaining, which is shown in 10-month-old APP, APP/PS1KIhe, and APP/PS1KIho
mice in frontal cortex (A-C), pons (E-G), and spinal cord (I-K) together with their respective quantifications 
of the percentile area covered by DAB staining (D, H, L). Virtually no Aβ peptide accumulation was 
detected in the pons and spinal cord of APP mice, whereas about 4% of the frontal cortical area was covered 
by Aβ staining. Upon introduction of one PS1KI gene (APP/PS1KIhe mice), the accumulation of Aβ was 
found to rise significantly in all three regions investigated and further approximately doubled with the 
introduction of an additional PS1KI gene (APP/PS1KIho mice), reaching percentile Aβ covered areas of 14%, 
8%, and 6.5% in the frontal cortex, pons, and spinal cord, respectively. Data was analyzed from 6 mice of 
each genotype and analyzed using one-way ANOVA followed by t-tests. All error bars represent mean 
s.e.m. **P < 0.01; *P<0.05. Scale bar: 200µm. 
Fig. 42 Intraneuronal Aβ accumulation in APP, 
APP/PS1KIhe, and APP/PS1KIho mice. In spinal cords, 
intraneuronal Aβ accumulation was found to rise 
proportionally with increasing PS1KI gene dosage in 10-
month-old APP (A), APP/PS1KIhe (B), and APP/PS1KIho
mice (C) visualized by the 4G8 antibody. Scale bar: 50 µm.
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Quantification of dystrophic fibers with increasing PS1KI gene dosage 
The number of plaque-independent dystrophic neurites was quantified in the pons and spinal 
cord using antibodies toward phosphorylated APP (anti-pT668) and neurofilament (NF-200) 
as markers of axonopathy in double ABC-stainings with 4G8 visualizing Aβ plaques. 
Examples of the quantification of plaque-independent dystrophic fibers in 10-month-old APP, 
APP/PS1KIhe, and APP/PS1KIho mice are visualized in Fig. 43, showing NF-200 staining in 
the pons (Fig. 43A-C) and anti-pT668 staining in the spinal cord (Fig. 43E-G). The 
quantification showed practically no dystrophic neurites in the pons and spinal cord of APP 
mice with either NF-200 (Fig. 44A, C) or anti-pT668 (Fig. 44B, D). In contrast, a 
considerable amount of dystrophic fibers was found in the APP/PS1KIhe mice using both NF-
200 and anti-pT668 in pons as well as spinal cord, and increased even further in APP/PS1KIho 
mice (Fig. 44). No dystrophic fibers were found in PS1KIho (Fig. 43D and H) or wildtype 
control mice (not shown). Thus using the two markers NF-200 and anti-pT668, the amount of 
dystrophic fibers was found to rise proportionally to the dosage of the PS1KI gene and was 
absent in mice harboring either only the APP transgene or the PS1KIho gene alone. 
Fig. 43 Dystrophic fibers together with Aβ pathology in APP, APP/PS1KIhe, and APP/PS1KIho mice.
Double ABC-immunostaining showed Aβ in blue using 4G8 antibodies together with visualization of fibers in 
reddish brown using either NF-200 or anti-pT668. The number of plaque-independent dystrophic neurites (black 
arrowheads) was found to increase with PS1KI gene dosage; examples of stainings from APP, APP/PS1KIhe, 
APP/PS1KIho, as well as PS1KIho mice are shown using the NF-200 antibody in the pons (A-D) and anti-pT668 
antibody in the spinal cord (E-H). Scale bar: 100µm.
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Intraneuronal accumulation of ubiquitin and Aβ peptides 
Immunostaining of ubiquitin in the spinal 
cord of 10-month-old APP, APP/PS1KIhe 
and APP/PS1KIho mice revealed 
considerable intracellular accumulation 
of ubiquitin in all three genotypes. 
However, APP/PS1KIhe and 
APP/PS1KIho mice in addition 
accumulated large amounts of ubiquitin-
positive material in both plaque-
independent and plaque-dependent 
dystrophic fibers (Fig. 45A-C). Ubiquitin 
western-blot analysis confirmed the 
finding of dramatically increased levels 
of ubiquitinated proteins ranging from 
approximately 70-180 kDa in 
APP/PS1KIhe and APP/PS1KIho mice as 
compared to wildtype (WT) and PS1KIho 
Fig. 44 Quantification of plaque-independent dystrophic fibers in APP, APP/PS1KIhe, and 
APP/PS1KIho mice. Increasing numbers of NF-200 and anti-pT668-positive plaque-independent dystrophic 
fibers were found with increasing PS1 gene dosage in both pons (A, B) and spinal cord (C, D) with 
practically no dystrophic fibers in the APP mice. Data from 6 animals of each genotype was analyzed using 
one-way ANOVA followed by t-tests. All error bars represent mean  s.e.m. **P < 0.01; *P<0.05. 
Fig. 45 Ubiquitin in APP, APP/PS1KIhe, and 
APP/PS1KIho mice. Ubiquitin staining showed many 
ubiquitin-positive dystrophic fibers in spinal cords of 10-
month-old APP/PS1KIhe (B) and APP/PS1KIho mice (C) 
with only cell body staning in APP mice (A). Western-blot 
analysis (D) confirmed increased levels of ubiquitin in 
APP/PS1KIhe and APP/PS1KIho mice compared to 
wildtype (WT) and PS1KIho. Protein size bar in kDa and β-
actin blot below showing equal loading of samples. Scale 
bar: 50 µm. 
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mice, but with no obvious difference 
in the amount of ubiquitin monomers 
(7 kDa band) (Fig. 45D). 
In double ABC-immunostaining using 
a combination of NF-200 and 4G8 
(Fig. 46A) or anti-pT668 and 4G8 
(Fig. 46B), A could be detected in the 
close vicinity of plaque-independent 
axonal spheroids, suggesting that 
axonal swellings are able to release Aβ 
peptides locally. This was confirmed by confocal imaging showing accumulation of Aβ inside 
and in the vicinity of large plaque-independent axonal spheroids using the OC antibody 
recognizing fibrillar Aβ oligomers and Aβ fibrils (Fig. 47A-C). Generally, many plaque-
Fig. 46 Aβ deposits in the vicinity of large dystrophic 
neurites.  Double ABC immunostaining 4G8 antibodies (blue) 
together with either anti-pT668 (A) or NF-200 (B) (reddish 
brown) occasionally showed small Aβ deposits (black 
arrowheads) in the vicinity of large dystrophic neurites in both 
APP/PS1KIhe and APP/PS1KIho mice. Scale bar: 12.5 µm. 
Fig. 47 Confocal images of fibrillar Aβ oligomers and Aβ fibrils inside dystrophic fibers. Using confocal 
imaging in 6-month-old YFP/APP/PS1KIhe mice with DAPI counterstaining confirming the lack of nuclei 
(blue), fibrillar Aβ oligomers and Aβ fibrils (OC antibody, red) were found to accumulate inside large 
dystrophic fibers (green). Merged images are shown (A, D, G) together with the isolated OC (B, E, H), and 
DAPI staining (C, F, I). Extracellular accumulation of Aβ (White arrowhead) could be detected near large 
dystrophic fibers accumulating intracellular Aβ (A-C). The intracellular accumulation of intracellular granules 
of OC-stained Aβ peptides were observed in many large dystrophic neurites, both plaque-independent (D-F) as 
well as occasionally in the vicinity of plaques (G-I). A-C are generated as a sum of 20 confocal images within 
the dystrophic fibers, whereas D-I are images in a single confocal plane. Scale bars: 10µm. 
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independent swollen fibers were found to accumulate Aβ showing a weaker scattered staining 
of smaller granules throughout the lumen together with the accumulation of larger Aβ 
granules (Fig. 47D-F). The same pattern could also be found in some large dystrophic neurites 
in the vicinity of plaques (Fig. 47G-I). Abundant accumulation of intraneuronal Aβ inside cell 
bodies, especially in the cortex, was confirmed using the OC antibody, where Aβ granules 
were also observed in the axon (Fig. 48A) and large apical dendrite (Fig. 48B) projecting 
from the cells, indicating that Aβ can be transported into axons as well as dendrites. 
Furthermore, occasionally, axonal swellings accumulating Aβ could be found directly 
connected to cortical neurons accumulating abundant amounts of intraneuronal Aβ at the axon 
hillock (Fig. 48C, D). This might indicate that the intracellular Aβ accumulating in large 
plaque-independent dystrophic neurites originates from neurons accumulating intraneuronal 




Fig. 48 Confocal images of intraneuronal Aβ accumulation in cortical neurons. Using confocal imaging in 
the cortex of 6-month-old YFP/APP/PS1KIhe mice, Aβ was found to accumulate inside cell bodies as well as in 
axons (A) and large apical dendrites (B) projecting from the cell body (OC antibody, red). Also, axonal 
swellings accumulating intracellular Aβ were found directly connected to cortical neurons accumulating 
abundant amounts of intraneuronal Aβ at the axon hillock (Aβ[N] antibody, red) (C, D: enlargement of C). 
Scale bars: 10µm (A, B, D), 40µm (C). 
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3.5 Interaction between α7 nAChR and Aβ 
Effect of an α7 nAChR agonist on Aβ pathology 
The Aβ pathology of 9-month-old APP/PS1ΔE9 mice chronically treated with saline, 10 
mg/kg SSR180711, or 10 mg/kg nicotine twice daily for 10 days was assed by quantification 
of 4G8, LOC, and Aβ[N] immunostainings (Fig. 49), where LOC is an OC-like antibody also 
Fig. 49 Aβ staining in saline, SSR180711, and nicotine treated APP/PS1ΔE9 mice.  Immunostaining 
of Aβ was performed using 4G8, LOC, and Aβ[N] antibodies and micrographs show 4G8 staining in the 
parietal cortex (A-C) and LOC (D-F) and Aβ[N] (G-I) staining in the hippocampal region of 9-month-
old APP/PS1ΔE9 mice chronically treated with saline, 10 mg/kg SSR180711, or 10 mg/kg nicotine 
twice daily for 10 days. Quantification showed no significant differences in 4G8 (J) and LOC (K) 
pathology, whereas a significant increase in Aβ[N] pathology (L) of the hippocampal region was 
observed in chronically nicotine treated animals as compared to control saline treated mice. In each 
group of treatment, 4-6 APP/PS1ΔE9 mice were analyzed using one-way ANOVA followed by 
Dunnett’s post-hoc test. Error bars represent mean  s.e.m. ***P < 0.001.
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recognizing Aβ fibrils and fibrillar oligomers (Kayed et al. 2007). The percentile areas 
covered by Aβ immunoreactivity were measured in the hippocampal formation as well as in 
the parietal cortex just above the hippocampal formation and showed no significant 
differences in either 4G8 (Fig. 49J) and LOC (Fig. 49K) pathology, however, a significant 
increase in Aβ[N] pathology (Fig. 49L) was observed in the hippocampal region of 
chronically nicotine treated APP/PS1ΔE9 mice as compared to control saline treated animals.  
To asses the effect of Aβ accumulation in vivo on the level of α7 nAChRs, α-BTX 
autoradiographic binding studies were carried out in the 9-month-old saline treated 
APP/PS1ΔE9 and wild-type mice. Measurements were performed in the medial prefrontal 
cortex, the parietal cortex (S1) as well as in the hippocampal region (Fig. 50A-H). No 
significant differences were observed in α-BTX binding level between the two genotypes in 
any of the quantified regions (Fig. 50 I, J).  
Fig. 50 α-BTX radioactive ligand binding in wild-type and APP/PS1ΔE9 mice. Autoradiograms show 
total α-BTX binding in coronal sections at the level of the frontal cortex and hippocampal region of 9-month-
old wild-type (A, C) and APP/PS1ΔE9 mice (B, D) together with their corresponding non-specific binding 
(NSB, E-H). Quantification in 5 wild-type and 6 APP/PS1ΔE9 mice showed no significant differences in 
specific α-BTX binding either in the medial prefrontal cortex (mPFC), the parietal cortex (S1), or the 
hippocampal formation (I), which were delineated as illustrated (J). Data was analyzed by unpaired Student’s 
t-tests in each region. 
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3.6 Functional integrity of immediate early gene responses 
following novelty stimulation 
The regulation of Arc and c-fos gene expression was measured 
by in situ hybridization in the mPFC, the parietal cortex (S1), 
CA1, CA3, and the upper DG (Fig. 51) following a single 
episode of novelty in APP/PS1ΔE9 as compared to wild-type 
mice. Examples of the quantified autoradiograms are given for 
the Arc gene expression analysis (Fig. 52). A single episode of 
novelty increased Arc gene expression about 60% in the mPFC 
(Fig. 53A) and 30% in the parietal cortex (Fig. 53D) of wild-type 
mice, where the corresponding percentile increases in the 
APP/PS1ΔE9 mice were 90% in the mPFC and 65% in the 
parietal cortex. The cortical inductions of Arc gene expression 
was thus higher in the transgenic mice than in the wild-type, 
however, basal Arc gene expression levels in home-cage control 
mice were found to be about 40% lower in APP/PS1ΔE9 mice as 
compared to wild-type mice in both the mPFC (Fig. 53A) and the 
Fig. 51 Quantified areas of 
the in situ hybridization 
analysis. Quantification was 
performed in the medial 
prefrontal cortex (mPFC), 
cortex (S1), CA1, CA3, and 
upper DG. 
Fig. 52 Arc in situ hybridization in wild-type and APP/PS1ΔE9 novelty stimulated and control mice.
Autoradiograms show the pattern of Arc mRNA hybridization using pseudo colors at the level of the prefrontal 
cortex (A-D) and the hippocampal region (E-H) in wild-type and APP/PS1ΔE9 mice in home-cage control (A, E 
and C, G, respectively) and novelty stimulated animals (B, F and D, H, respectively). To the right is found the 
14C-calibration scale used for quantification of the autoradiograms. 
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parietal cortex (Fig. 53D). The induced levels of Arc gene expression after novelty thus 
remained significant lower in the APP/PS1ΔE9 mice as compared to wild-type. In the 
hippocampal formation, percentile inductions of Arc gene expression following novelty were 
about 50%, 40%, and 35% in the CA1, CA3, and upper DG of wild-type mice as compared to 
70%, 20%, and 30% in APP/PS1ΔE9 mice (Fig. 53G, J, M), although the increase in the CA3 
of APP/PS1ΔE9 mice was only significant with a t-test (p=0.0043) and not with the one-way 
ANOVA Newman-Keuls post-hoc test. Only in the CA1 was the basal level of Arc gene 
expression found to be lower in APP/PS1ΔE9 than in wild-type mice (Fig. 53G, 26%), but 
induced levels of Arc gene expression were found to be lower in the APP/PS1ΔE9 mice as 
compared to the wild-type in all three measured regions of the hippocampal formation.  
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Fig. 53  Quantification of Arc, c-fos and synaptophysin expression. Mean (± SEM) levels of Arc, c-fos and 
synaptophysin expression is shown in the medial prefrontal cortex (mPFC, A, B, C) and parietal cortex (D, E, 
F) as well as in the CA1 (G, H, I), CA3 (J, K, L), and upper dentate gyrus (DG) (M, N, O) of the hippocampal 
formation. Data was analyzed by one-way ANOVA followed by Newman Keuls post-hoc test (n = 6). Error 




novelty exposure and showed an
mRNA levels of 
ly stimulated the 
In comparison, only cortical deficits in the induction of c-fos gene expression following a 
single episode of novelty were detected in the APP/PS1ΔE9 mice compared to wild-type 
mice, whereas no differences in basal or induced c-fos expression levels were detected in 
either the CA1, CA3, or upper DG of the hippocampal formation (Fig. 53H, K, N). In the 
mPFC, APP/PS1ΔE9 mice completely failed to up-regulate c-fos expression following 
 80% higher basal expression level of c-fos as compared to 
wild-type mice (Fig. 53B). In the parietal cortex, the pattern 
of c-fos expression was similar to that of Arc with about 
70% induction of c-fos expression in wild-type mice and 
105% induction in APP/PS1ΔE9 mice following novelty 
exposure, but with a basal difference of 40% resulting in a 
25% lower induced c-fos expression level after novelty in 
APP/PS1ΔE9 as compared to wild-type mice (Fig. 53E). 
In contrast, no changes were observed in 
the house keeping gene synaptophysin, in any of the 
quantified regions (Fig. 53C, F, I, L, O).  
The five-min exposure to novelty strong
HPA axis in mice of both genotypes as a significant increase 
in plasma levels of corticosterone was found in novelty 
exposed wild-type (2.4 fold) as well as APP/PS1ΔE9 (3.8 
fold) mice as compared to home-cage controls (Fig. 54). 
 
Fig. 54 Plasma corticosterone in 
wild-type and APP/PS1ΔE9 
novelty stimulated and control 
mice. The level of corticosterone 
was measured in plasma of home-
cage control and novelty stimulated 
wild-type and APP/PS1ΔE9 mice, 
and showed an increased 
corticosterone level after novelty 
exposure in both genotypes. Data 
was analyzed by unpaired Student’s 





4.1 Neuron loss in the cholinergic system of APP/PS1KI mice 
Numerous transgenic mouse models have been generated and investigated over the past years 
in order to amongst others model the cholinergic neuron loss of the basal forebrain found in 
AD patients. So far, most AD mouse models have shown either no change or even an increase 
in the number of forebrain cholinergic neurons (Boncristiano et al. 2002; Bronfman et al. 
2000; German et al. 2003; Hartmann et al. 2004; Jaffar et al. 2001; Perez et al. 2007). 
Exceptions are the TgCRND8 mouse model of AD showing a loss of Ch4 neurons (Bellucci 
et al. 2006), and the Ts65Dn mouse model of Down’s syndrome showing loss of Ch1/2 
neurons (Salehi et al. 2006; Seo and Isacson 2005). Regarding other cholinergic regions, a 
neuron loss in the pons complex was described using a semi-quantitative assessment (Zhang 
et al. 2005), and another recent study reported a minor loss of cholinergic interneurons in the 
motor cortex (Perez et al. 2007). However, cholinergic cortical interneurons are bipolar 
GABAergic interneurons co-expressing ChAT and cannot be found in all rodent species, thus 
they may not be regarded as part of the cholinergic system (Bhagwandin et al. 2006). None of 
the studies showing loss of cholinergic neurons mentioned whether or not the degenerating 
neurons accumulated intraneuronal Aβ, though the degenerating cholinergic forebrain neurons 
in the Ts65Dn mouse model of Down’s syndrome were shown to accumulate APP in early 
endosomes, leading to a blockage of neuronal growth factor transport (Salehi et al. 2006). 
The objectives of the present study were a quantitative assessment of cholinergic neuron 
numbers in the APP/PS1KI mouse model of AD as well as the potential impact of 
intraneuronal Aβ deposition and accumulation on neuronal survival. Therefore, areas showing 
different degrees of Aβ pathology were included in the quantitative analysis. The cholinergic 
forebrain complex consisting of Ch1-4 showed virtually no Aβ pathology with neither 
extracellular Aβ plaque deposition, nor intracellular accumulation of Aβ peptides. However, 
fibers from this region displayed swollen ChAT-positive dystrophic neurites surrounding Aβ 
plaques in the cortex and hippocampal formation as previously reported in other mouse 
models of AD (Aucoin et al. 2005; Bellucci et al. 2006; Bronfman et al. 2000; Hu et al. 2003; 
Luth et al. 2003; Wong et al. 1999). The Ch1/2 and Ch4 regions of the cholinergic forebrain 
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complex were quantified separately as they project to separate areas: the hippocampal 
formation and the cortex, respectively. No cholinergic neuron loss was found in either the 
Ch1/2 or Ch4 cholinergic nuclei. The Ch1/2 region of the forebrain complex projects to the 
hippocampal formation which in the present mouse model is known to develop a significant 
neuron loss of more than 50% in the CA1 at 10 months of age (Casas et al. 2004). This could 
have had additional influence on the survival of the Ch1/2 cholinergic neurons, as they have 
been shown to be highly dependent on external growth factor stimuli retrogradely transported 
from the hippocampus (Burke et al. 1994). However, growth factor stimuli could be provided 
by hippocampal cell types other than the degenerating CA1 neurons. In conclusion, the 
APP/PS1KI mouse model does not model the well-established loss of cholinergic forebrain 
neurons of the nucleus basalis of Meynert in AD patients (Arendt et al. 1988; Mufson et al. 
1989; Whitehouse et al. 1981). However, pathological alterations in transgenic mouse models 
must be considered to be determined by the expression pattern of the respective transgene. 
Thus as the APP transgene is not expressed in the forebrain complex of the APP/PS1KI 
mouse model, the lack of neuron loss in this region does not subtract from the valid use of this 
model to study the impact of Aβ in the regions of APP transgene expression. Accordingly, the 
motor nuclei Mo5 and 7N accumulating intracellular Aβ were found to exhibit significant loss 
of cholinergic neurons. This loss was most prominent in the Mo5 and was found to coincide 
with a more robust accumulation of various A species including Aβ1-x, fibrillar oligomers 
and fibrillar Aβ, aggregated Aβ, as well as AN3pE compared to the 7N. This finding is 
particularly interesting and corroborates our earlier reports of spinal cord axonal degeneration 
(Wirths et al. 2007) and severe motor pathology in aged APP/PS1KI mice that show severe 
deficits in motor performance, as analyzed by a series of motor tasks including the balance 
beam, string suspension test, vertical grip hanging task, and rotarod (Wirths et al. 2008b). 
These deficits occurred as early as at the age of 6 months and were preceded by a strong 
accumulation of various A peptides in motor neurons in the ventral horn of the spinal cord in 
APP/PS1KI mice (Wirths et al. 2007). In the light of the present results this accumulation of 
Apeptides could very well contribute to degeneration of the motor neurons in the spinal 
cord causing the detected motoric deficits.  
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The ChAT-positive cholinergic interneurons of 
the caudate putamen that did not accumulate 
intraneuronal Aβ, but were surrounded by 
numerous smaller Aβ plaques, also showed no 
loss of neurons. This adds further evidence to 
the assumption that extracellular plaques are not 
a substantial factor in mediating cell death 
(Wirths et al. 2004).  
In summary, Aβ plaque pathology leading to 
plaque associated dystrophic neurites was not 
sufficient to cause neuron loss in the cholinergic 
system of APP/PS1KI mice. However, 
accumulation of intracellular Aβ aggregates 
represented an early pathological alteration that 
strongly correlated with neuron death in brain 
stem motor nuclei (Fig. 55). 
Fig. 55 Summary of Aβ-mediated cell death in 
the cholinergic system. Extracellular plaque 
deposition leading to plaque associated dystrophic 
neurites was not sufficient to cause significant 
neuron loss in Ch1/2, Ch4, or caudate putamen 
(CPu). However, accumulation of intraneuronal
Aβ is considered an early pathological alteration 
that correlated with neuron loss in the Mo5 and 
7N.
4.2 Effect of intraneuronal Aβ versus plaques on 
neurodegeneration 
The previous study of Aβ pathology and neurodegeneration in the cholinergic system of the 
APP/PS1KI mouse model strongly supported the hypothesis of intracellular Aβ being a major 
trigger of neuron death in AD, and the present study was designed to more specifically 
investigate the toxic effect of intracellular Aβ versus extracellular Aβ plaques on neuronal 
survival. For this reason, the present study focused on two regions with distinct pathological 
differences regarding plaque development and intraneuronal Aβ accumulation. The frontal 
cortex was chosen for stereological quantification representing a region with massive and 
early accumulation of intraneuronal Aβ, with concomitant strong extracellular plaque 
pathology covering 12.1 % of the frontal cortex at the age of 12 months. To dissect the impact 
of intraneuronal A accumulation, the thalamus was chosen as a control region for 
stereological quantification representing a region with no accumulation of intraneuronal Aβ 
but harboring a comparable amount of extracellular plaques that covered 13.1% of the region 
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at the age of 12 months. Despite the massive amount of plaques, the thalamus was strikingly 
found to suffer no neuron loss in either 6- or 12-month-old APP/PS1KI mice as compared to 
PS1KI control mice. This is in line with the many negative results reporting no loss of 
neurons in many mouse models of AD accumulating various amounts of Aβ plaques 
(Duyckaerts et al. 2008; Games et al. 2006), and altogether suggests that plaques have no 
significant effect on neuronal survival. In contrast, a neuron loss of about 30 % was found in 
the frontal cortex already at 6 months of age, which did not significantly worsen from 6 to 12 
months. Importantly, the only evident pathological difference between the two regions in 
question was the massive transient accumulation of intraneuronal Aβ in the frontal cortex, 
which thus must be considered as a major trigger of the neuron loss observed in this region. 
Nevertheless, we can not completely rule out that thalamic neurons differ from cortical 
neurons in their cellular properties and may somehow be less vulnerable in general. Also, the 
recent finding of soluble oligomeric Aβ species being highly toxic could argue that the neuron 
loss in the frontal cortex could be caused by the presence of extracellular soluble Aβ that is, 
perhaps, not detected by our immunohistochemical protocol. However, in our opinion, it is 
unlikely that soluble extracellular Aβ oligomers are causing the observed neurotoxic effects as 
they should be present in all plaque-rich areas including the frontal cortex as well as the 
thalamus. In addition, mutant PS1 may induce toxic effects due to alterations in biological 
functions of PS1; however, as we have used PS1KI littermates as control mice, which showed 
unchanged neuron numbers during aging in the thalamus as well as frontal cortex, we 
conclude that the applied PS1-FAD mutations have no effect on neuronal survival. Only in 
the combination of the PS1-FAD mutations with transgenic APP, A-related 
neurodegeneration was observed.  
The transient nature of the intraneuronal accumulation of Aβ observed in the frontal cortex 
adds further support to the hypothesis of its toxicity. Thus significant neuron loss became 
evident at the age of 6 months; exactly the time point when a decreased intraneuronal A 
accumulation was evident. This corresponds to the possibility that the neurons accumulating 
intracellular Aβ at earlier time points are those lost at a time between the age of 2 and 6 
months and correlates with an earlier report claiming that neurons which accumulate A 
peptides undergo lysis to give rise to extracellular deposits (D'Andrea et al. 2001). However, 
the strong accumulation of plaques in the thalamus of the present mouse model which 
contains no neurons expressing the APP transgene suggests that plaques can be formed by Aβ 
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deposition from fibers. Thus other hypotheses exist for plaque formation, and compact 
plaques with high A40 load are suggested to have a different etiology than diffuse plaques 
with predominant A42 deposition, as in the current model. The transient nature of 
intraneuronal A accumulation preceding massive extracellular plaque pathology has been 
previously reported in a different APP/PS1 transgenic mouse model (Langui et al. 2004; 
Wirths et al. 2002). The relevance of this finding of an early transient accumulation of Aβ is 
supported from studies in Down’s syndrome (DS) patients who develop Aβ plaques and NFTs 
as found in AD patients. Intraneuronal Aβ42 was found to accumulate only in younger DS 
patients declining with the development and maturation of plaques (Gyure et al. 2001; Mori et 
al. 2002). In addition, another study claims that intraneuronal Aβ42 in human AD is only 
detectable in patients with low Braak stages and short disease duration and that the 
intraneuronal Aβ immunoreactivity is lost in patients with more progressive AD (Gouras et al. 
2000). This would correlate with the fact that neurons are not yet lost in pre-clinical AD 
(West et al. 2004) where intraneuronal accumulation of Aβ42 would still be detectable; 
however, with the transition to AD, the intraneuronal immunoreactivity will be strongly 
decreased or undetectable, due to the loss of the respective neurons. The possibility of a 
transient intraneuronal Aβ accumulation is of great importance for the difficulties of 
providing proof of the intracellular Aβ hypothesis in human AD tissue. As this most often 
represents end stage pathology where adverse neuron loss has already occurred, intraneuronal 
Aβ may no longer be present.  
Altogether, the present study strongly suggests that plaques have no effect on neuronal 
survival, but that a transient intraneuronal accumulation of Aβ coincides with neuron loss. 
These findings are in line with the modified β-amyloid cascade hypothesis, in which early 
intraneuronal Aβ accumulation represents the central pathological alteration upstream of 
extracellular plaque deposition and neuronal dysfunction (Wirths et al. 2004). 
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4.3 Intraneuronal Aβ staining in AD patients and transgenic AD 
mouse models 
Optimization for staining of intraneuronal Aβ in mouse models of AD 
FA is widely used to enhance immunostaining of plaques and has been shown to covalently 
modify Aβ by formate esterification of serine residues, leading to solubilization of the peptide 
(Alafuzoff et al. 2008; Klunk et al. 1994). The effect of FA on the immunohistochemical 
staining of intraneuronal Aβ is currently debated with reports of low or similar effects to heat, 
as well as FA having a counteracting effect on the heat-induced enhanced intraneuronal Aβ 
staining in human AD tissue (D'Andrea et al. 2003; Ohyagi et al. 2007). In addition, the  
exposure time for FA pretreatment varies greatly between studies; however, one study showed 
no significant difference in the intensity of the amyloid plaque detection between 10 min and 
12 hours of FA pretreatment in AD tissue (D'Andrea et al. 2003). Corroborating this result, 
we did not find any significant difference between 3 and 10 min FA treatment in the 
percentile area of intraneuronal Aβ or plaque staining in the CA1 and thalamus of APP/PS1KI 
mice, respectively. The effect of a short FA exposure is also in line with other studies in mice 
where intraneuronal Aβ could be detected in paraffin embedded sections using only 5 min FA 
incubation (Knobloch et al. 2007; Van Broeck et al. 2008).  
Regarding the effects of heat versus FA on intraneuronal Aβ detection, FA pretreatment was 
found to be essential for the staining of Aβ1-x peptides in the CA1 of APP/PS1KI mice, 
whereas no or heat antigen retrieval alone disclosed no or very little detection of intraneuronal 
Aβ1-x. Yet, the combination of FA and heat seemed to even further intensify the staining of 
intraneuronal Aβ1-x, although no significant increase in the stained area was observed 
compared to FA pretreatment alone. Regarding the detection of plaques, heat and FA were 
found to have an equal enhancing effect on the extracellular staining of Aβ plaques in the 
thalamus of APP/PS1KI mice. This finding of FA to enhance staining of plaques is in general 
agreement with the literature (Alafuzoff et al. 2008; Kitamoto et al. 1987), however, the 
equally enhancing effect of heat pretreatment does not seem to have been systematically 
investigated in AD tissue. The enhancing effect of FA on intraneuronal Aβ staining in mouse 
tissue is in contrast to the observations in human AD tissue reporting FA to have no effect or 
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even to counteract the heat-inducing effect on staining of intracellular Aβ (D'Andrea et al. 
2003; Ohyagi et al. 2007).  
To further compare the effect of heat and FA pretreatment on the detection of intraneuronal 
Aβ, the three protocols using heat, 3 min FA exposure, or their combination were compared to 
no pretreatment in three additional mouse models. Corroborating the observations in 
APP/PS1KI mice, 3 min FA was confirmed to have a markedly increasing effect on the 
staining of intraneuronal Aβ1-x peptides revealing an intense staining of large granules at the 
axon hillock of cortical neurons in APP, APP/PS1, and 5xFAD mice, whereas heat 
pretreatment was found to have a minor increasing effect on intracellular Aβ staining. Yet, the 
combination of heat and FA pretreatment showed the highest staining intensity. The same 
protocols were applied for immunostaining with the 4G8 antibody, recognizing the central 
epitope Aβ17-24. The 4G8 is a highly sensitive antibody used in routine staining of Aβ in AD 
tissue (Alafuzoff et al. 2008), and was found not to cross-react with full length APP at high 
dilutions (1:10.000) using a combined heat and FA protocol in the APP/PS1KI mouse model 
(Christensen et al. 2008). With the application of FA, the 4G8 antibody revealed the same 
intense granular staining pattern as the Aβ[N] antibody, however, surprisingly, heat 
pretreatment alone disclosed an obvious homogenous staining pattern of smaller granules 
dispersed throughout the cytoplasm in all four mouse models investigated that decreased upon 
the combination with FA. When the two protocols of heat and heat + FA were compared in a 
fluorescent double labeling of APP and 4G8, the fainter heat-induced intraneuronal Aβ 
staining turned out to largely co-localize with APP, in contrast to the FA-induced staining of 
larger granules, suggesting that heat pretreatment alone increases the cross-reaction of the 
4G8 antibody to APP. Alternatively, heat and FA could induce the staining of Aβ peptides of 
different aggregation states corresponding to a suggestion that two unique forms of Aβ exist 
as a function of their sensitivity to FA (D'Andrea et al. 2003). These heat-induced 4G8 stained 
Aβ peptides would then be co-localized with APP in intracellular compartments and their 
decreased reactivity by FA corroborates a previous result of a counteracting effect of FA on 
heat enhanced Aβ staining in human AD tissue (Ohyagi et al. 2007). 
To investigate the aggregation state of the intraneuronal Aβ revealed by FA pretreatment, the 
immunohistochemical stainings were compared to a Thioflavin S staining labeling aggregated 
Aβ peptides (LeVine 1993). In all four mouse models, the Thioflavin S pattern was found to 
correspond to the intense granular intraneuronal Aβ staining disclosed by FA or FA together 
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with heat using 4G8 as well as Aβ[N] antibodies, suggesting that the intraneuronal Aβ 
peptides induced by FA are highly aggregated in mouse models of AD. That FA reveals 
aggregated Aβ is further supported by the observation that the FA worked best in the three 
mouse models with PS1 mutations, and to a lesser extend in the APP single transgenic mice 
not harboring the PS1 mutations that are known to increase the production of the more 
aggregation prone Aβ42 peptides (Guo et al. 1999; Jankowsky et al. 2004).  
Our optimization of the staining protocol with regard to FA and heat shows that the two 
antigen retrieval methods may disclose separate species of Aβ peptides with FA, especially 
detecting aggregated Aβ, leading to the assumption that in mouse models of AD, FA is an 
essential pretreatment for immunohistochemical detection of intraneuronal aggregated Aβ 
peptides. 
Staining of intraneuronal Aβ in brain tissue of AD patients 
The four protocols qualitatively investigated in the mouse models were applied to human AD 
tissue using Aβ[N] antibodies specific to Aβ1-x. The optimization was performed in paraffin 
embedded hippocampal sections from sporadic as well as Swedish and Arctic FAD brain 
tissue since the familial cases were considered more likely to show similarities to the mouse 
models and thus accumulate intraneuronal Aβ. Also, the Arctic mutation has been shown to 
favor intracellular Aβ production in cultured cells and mouse models (Sahlin et al. 2007). 
Some intraneuronal Aβ1-x staining was evident even without any pretreatment, but heat 
dramatically increased the intraneuronal staining of smaller granules throughout the 
cytoplasm concentrating around the nucleus in all three types of AD hippocampal tissues, 
especially in the CA4 region. In contrast, FA pretreatment did not increase the staining of 
intraneuronal Aβ1-x as compared to no antigen retrieval and even counteracted the enhancing 
effect of heat as the combination of heat and FA only slightly increased the staining of Aβ1-x 
as compared to no pretreatment with much less inducing effect than heat alone. The 
counteracting effect of FA on the heat-induced staining of intraneuronal Aβ1-x peptides 
corroborates one other study using an Aβ42(43) specific antibody (BC-05) and an autoclave 
heating protocol reporting a counteracting effect of FA on heat-induced Aβ42 staining 
(Ohyagi et al. 2007). These findings are in contrast to the observations in the mouse models 
where FA clearly enhanced the staining of intraneuronal Aβ peptides and heat had no or only 
a minor increasing effect. The difference in the effect of heat and FA between mouse and 
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human tissue could be explained by differences in Aβ species accumulating within the cells. 
In the AD mouse models, much of the intraneuronal Aβ induced by FA pretreatment seemed 
to be aggregated peptides. Possibly, the intraneuronal Aβ1-x in AD tissue could be mostly 
soluble oligomeric species that may be enhanced by heat but counteracted by FA. In 
agreement, low-n oligomeric Aβ have been detected inside primary human neurons (Walsh et 
al. 2000). The presence of soluble oligomeric Aβ inside neurons would add further 
importance to the impact of intraneuronal Aβ since two studies have so far indicated that 
soluble Aβ may be the best correlate of cognitive decline in AD (McLean et al. 1999; Naslund 
et al. 2000). 
 The presence of intraneuronal Aβ in sporadic AD tissue was confirmed by staining with the 
polyclonal OC antibody recognizing fibrillar Aβ oligomers and Aβ fibrils (Kayed et al. 2007). 
The OC antibody disclosed an intense intraneuronal Aβ staining with heat as well as with 
additional FA pretreatment that had an intensifying effect on the intraneuronal OC staining. 
This is in contrast to the counteracting effect of FA on the detection of Aβ1-x, but is in line 
with the suggestion that FA enhances the staining of aggregated Aβ fibrils that are recognized 
by the OC antibody. The staining disclosed by heat could be owing to detection of oligomeric 
Aβ fibrils that are also recognized by the OC antibody and would thus agree with two 
previous studies stating that Aβ oligomerization starts within neurons (Takahashi et al. 2004; 
Walsh et al. 2000). 
It was attempted to further confirm the presence of intraneuronal Aβ using the 4G8 antibody 
recognizing the central epitope Aβ17-24, as this is a commercially available widely used Aβ 
antibody. However, the 4G8 antibody produced an intracellular staining pattern with a large 
granular cap-like staining adjacent to the nucleus that was completely different from the 
staining patterns of the Aβ[N] and OC antibodies. This 4G8 staining proved to be caused by a 
cross-reaction with lipofuscin as Sudan Black B pretreatment abolished all intraneuronal 
fluorescence detected with the 4G8 antibody as well as autofluorescence from the UV and red 
channel. This observation corroborates another study suggesting cross-reaction between 
lipofuscin and several monoclonal antibodies toward the Aβ17-24 sequence, including the 4G8 
antibody (Bancher et al. 1989). Despite this report of cross-reactivity to lipofuscin, the 4G8 
antibody has been repeatedly applied to show intraneuronal Aβ in AD disclosing this large 
granular cap-like staining adjacent to the nucleus characteristic of lipofuscin (LaFerla et al. 
1997; Ohyagi et al. 2007; Wegiel et al. 2007). In contrast, the Aβ[N] antibody disclosed a 
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highly specific staining pattern of small granules throughout the cytoplasm that remained 
following Sudan Black B pretreatment, which thereby is in good agreement with a previous 
study showing that lipofuscin and Aβ peptides do not co-localize inside neurons (D'Andrea et 
al. 2002a).  
The mechanism whereby intraneuronal Aβ could mediate toxicity is yet unclear. Most 
evidence points to the accumulation of Aβ in the endocytic pathway where it has been 
reported to accumulate in multi-vesicular bodies (MVB) (Takahashi et al. 2002) and impair 
their sorting (Almeida et al. 2006). In agreement, we observed a staining pattern of smaller 
granules dispersed throughout the cytoplasm, but often concentrated around the nucleus with 
both the Aβ[N] and OC antibodies. This corresponds to earlier observations using an Aβ42 
specific antibody (D'Andrea et al. 2002a) and cell biology studies locating the intracellular 
generation of Aβ from the endoplasmic reticulum to the trans-Golgi network and the 
endosomal-lysosomal system (Cook et al. 1997; Perez et al. 1999; Rajendran et al. 2007; 
Selkoe 1998; Xu et al. 1997). Accordingly, abnormalities in the endocytic pathway have been 
reported to precede Aβ plaque deposition in sporadic AD as well as Down´s syndrome 
patients (Cataldo et al. 2000), indicating that intraneuronal Aβ may be a mediator of early 
pathological changes. 
Whether intraneuronal Aβ origins exclusively from intraneuronal sources or if it can in 
addition be internalized from external sources is not yet clarified. Yet, much evidence support 
the possibility of reuptake of Aβ peptides into cells by endocytosis. Thus members of the 
lipoprotein receptor (LDLR) family (Bu et al. 2006), α7 nicotinic receptors (Nagele et al. 
2002), as well as scavenger receptor for advanced glycation end products (RAGE) (Deane et 
al. 2003; Sasaki et al. 2001; Yan et al. 1996) have all been reported to interact with Aβ and 
lead to internalization of extracellular Aβ peptides. In particular, RAGE-Aβ complexes have 
been shown to be internalized and co-localize with the lysosomal pathway in astrocytes in AD 
brains (Sasaki et al. 2001), which is supported by our observation of astrocytes accumulating 
high amounts of intraneuronal Aβ granules. The LDLR-related protein (LRP) is a member of 
the LDLR family and functions as an ApoE receptor. LRP has been shown to facilitate rapid 
endocytosis of APP thereby promoting APP processing and thus Aβ generation. In addition to 
the effect on APP trafficking, LRP-induced rapid endocytosis also facilitates cellular uptake 
of Aβ peptides from the extracellular space, either directly through binding to Aβ or indirectly 
through interaction with ligands such as ApoE (Bu et al. 2006). Accordingly, knock out of 
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APOE in PDAPP transgenic mice reduced the accumulation of intracellular Aβ (Zerbinatti et 
al. 2006). With these implications for a role of ApoE in the accumulation of intraneuronal Aβ, 
we correlated the intensity of the intraneuronal Aβ1-x staining in the hippocampal regions of 
20 AD patients and 10 controls to ApoE genotype and found a highly significant correlation 
between the intensity of intraneuronal Aβ1-x staining and the presence of at least one ApoE4 
allele (P=0.002). This correlation nicely concurs with the observation of ApoE4 being a major 
risk factor of sporadic AD (Ashford 2004; Raber et al. 2004) and further supports an 
important role of intraneuronal Aβ in the pathogenesis of AD. 
 A possible criticism of the importance of intraneuronal Aβ is its presence in AD patients as 
well as in non-demented controls, which could be observed in the present study and is also 
reported by others (D'Andrea et al. 2002a; D'Andrea et al. 2002b; D'Andrea et al. 2001; 
Gouras et al. 2000; Wegiel et al. 2007). However, this is to be expected since plaques are 
likewise found in non-demented controls (Aizenstein et al. 2008) and the pools of intracellular 
and extracellular Aβ most likely have a common origin. What needs to be investigated is 
whether there are differences in the Aβ species accumulating within neurons of AD patients 
versus non-demented controls. Furthermore, an obstacle in immunopathological studies is that 
we are most often dealing with end-stage pathology where many neurons are already lost and 
early pathological mechanisms are not easily identified. Thus a transient nature of 
intraneuronal Aβ accumulation preceding massive extracellular plaque pathology has 
previously been reported in transgenic mouse models (Christensen et al. 2008; Langui et al. 
2004; Wirths et al. 2002), as well as in Down’s syndrome (DS) patients (Gyure et al. 2001; 
Mori et al. 2002), and intraneuronal Aβ42 in human AD has been claimed to be most 
detectable in patients with low Braak stages and short disease duration (Gouras et al. 2000). It 
is therefore very likely that the accumulation of intraneuronal Aβ may be much more 
prominent in MCI patients in which AD symptoms only begin to emerge and neurons have 
not yet been lost (West et al. 2004). 
The present study is a thorough report of intraneuronal N-terminal Aβ species in human AD 
which have so far believed not to accumulate inside neurons (Chui et al. 2001; Mori et al. 
2002) and confirmed the presence of intraneuronal Aβ in human AD by staining with the OC 
antibody recognizing fibrillar oligomers and fibrillar Aβ. Our optimization of the staining 
protocol regarding FA and heat shows that heat is essential for the detection of intraneuronal 
Aβ1-x peptides in human AD tissue and is counteracted by FA. However, the effects of heat 
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and FA seem to depend on the specificity of the antibody applied since intraneuronal staining 
with the OC antibody was increased and not counteracted by FA, probably owing to the 
observation from AD mouse models that FA enhances the staining of aggregated Aβ peptides. 
In addition, a highly significant correlation was identified between the accumulation of 
intraneuronal Aβ1-x peptides and ApoE4 genotype, supporting the view that the ApoE4 
isoform is a major risk factor of AD. 
4.4 Effect of Aβ on axonopathy in transgenic AD mouse models 
Axonal deficits and impairment of motor performance are common pathological alterations in 
mouse models expressing different isoforms of human mutant tau protein (reviewed in 
(Wirths and Bayer 2008)). However, in recent years, similar phenotypes have been reported 
for AD mouse models based on APP overexpression (Stokin et al. 2005; Wirths et al. 2007; 
Wirths et al. 2006), and disturbances of axonal transport rates have been reported in APP-
based transgenic mouse models of Down syndrome (Salehi et al. 2003) and AD (Smith et al. 
2007). Accordingly, APP has been demonstrated to undergo fast axonal transport (Koo et al. 
1990), presumably by a kinesin-I-mediated mechanism (Kamal et al. 2000). In addition, the β-
site cleaving enzyme (BACE) and PS1 have been shown to be associated with APP-resident 
membranous cargos, implying that Aβ can be produced directly in the axons (Kamal et al. 
2001), although this finding has recently been questioned (Lazarov et al. 2005). Accordingly, 
APP, BACE and PS1 were found to co-accumulate in swollen axons following traumatic 
brain injury (Chen et al. 2004). 
A recent report claiming that axonopathies in APP-transgenic mouse models entirely depend 
on APP overexpression and that co-expression of FAD-linked PS1 mutants and related 
increased Aβ levels suppress axonal defects (Stokin et al. 2008), prompted us to analyze 
axonal degeneration in our APP/PS1KIho mouse model, as well as in APP single transgenic 
and APP/PS1KIhe mice, all harboring equal APP transgene expression. Previous work in the 
APP/PS1KIho mouse model has demonstrated a severe age-dependent axonal degeneration 
phenotype, which is characterized by the accumulation of large axonal swellings. These 
swellings were most abundant in fiber-rich regions of the central nervous system such as 
corpus callosum, pons, medulla, and spinal cord. We demonstrated a significant increase in 
these swellings between 6 and 10 months of age, which only marginally worsened at the age 
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of 14 months (Wirths et al. 2007). The mice used in the present study are based on Thy1-
driven overexpression of APP751 with the Swedish and London mutations and carry either no 
(APP), one (APP/PS1KIhe) or two (APP/PS1KIho) mutant murine PS1 alleles under the 
control of the endogenous PS1 promoter. Using this strategy, we ensured that the APP 
expression level did not differ between the different mouse lines, which was confirmed by 
immunostaining using APP antibodies and western-blotting. However, the amount of Aβ 
peptides differs significantly between the analyzed mouse lines, leading to dramatic increases 
in the Aβ load comprising plaques as well as intraneuronal Aβ depending on the mutant 
PS1KI gene dosage. It has been previously shown that expression of mutant PS1 allele 
together with an APP transgene does not only lead to a higher overall Aβ load, but in addition 
causes a significant rise in the Aβ42/Aβ40-total ratio and an earlier plaque onset (6m in APP 
versus 2 m in APP/PS1KIho mice) (Casas et al. 2004).  
To quantify axonal defects we applied antibodies toward phosphorylated APP as well as NF-
200 as markers of axonal degeneration. Upon quantification of pAPP as well as NF-200-
positive plaque-independent axonal swellings in the pons and spinal cord, significant 
increases in the numbers of dystrophic spheroids were detected in APP/PS1KIhe mice 
compared to APP single transgenic mice, which were almost devoid of any axonal swellings 
in the analyzed regions. When comparing APP/PS1KIhe with APP/PS1KIho, a further 2 – 4 
times increase of spheroids was detected in both pons and spinal cord. This result is in 
apparent contradiction to the recently published finding that axonal defects were unchanged 
or even suppressed in mice expressing FAD mutant PS1 in combination with FAD mutant 
APP (Stokin et al. 2008). One major difference between the APP/PS1 double-transgenic mice 
used in this report and our mouse model is the fact that the endogenous murine PS1 gene was 
still present in the APP/PS1 transgenic mice, whereas it has been sequentially replaced by the 
FAD mutant form in our APP/PS1KI model. It has been hypothesized that kinesin-based 
axonal transport is compromised by mutations in PS1 via interaction with glycogen synthase 
kinase 3β (GSK3β) and it has been recently reported that the relative levels of GSK3β activity 
were increased in the presence of mutant PS1, as well as in the absence of wildtype PS1. This 
results in increased phosphorylation of kinesin-light chain and reduced anterograde transport 
(Pigino et al. 2003). In addition, anterograde fast axonal transport of APP and Trk receptors is 
impaired in the sciatic nerve of mice expressing FAD-linked PS1 mutations, resulting in an 
increased phosphorylation of tau and neurofilaments in the spinal cord (Lazarov et al. 2007). 
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No fiber pathology was detected in PS1KI mice, however, it is possible that disturbances in 
axonal transport may become evident upon additional mutant APP overexpression thereby 
contributing to the observed fiber disturbances in the APP/PS1KI mice. 
Ubiquitinated proteins were found to accumulate in the fibers of APP/PS1KIhe and 
APP/PS1KIho mice in higher levels than in APP single transgenic mice, indicating an overload 
of the protein degrading system in the transgenic mice carrying the PS1KI allele. This could 
be explained by the dramatically increased accumulation of Aβ peptides in these two models 
resulting in general accumulation of ubiquitinated proteins in the fibers that could contribute 
to the observed dystrophic axons. Furthermore, Aβ peptides were found to accumulate in the 
axonal swellings being plaque-independent as well as in the vicinity of plaques, raising the 
possibility that these swellings precede and contribute to the formation of extracellular 
plaques. Whether Aβ peptides are generated and released at the site of axonal swellings is 
currently unclear, however, Aβ-positive granules were also detected in the axons and apical 
dendrites of cortical neurons, indicating that Aβ can be transported within fibers. It has been 
hypothesized that if Aβ generation occurs at the sites of axonal blockage, amyloid deposition 
might be due to focally increased Aβ secretion or lysis of axonal spheroids that were enriched 
in Aβ peptides (Stokin et al. 2005). Our finding of Aβ transport and accumulation in fibers 
together with diffuse extracellular Aβ deposits in the close vicinity of axonal spheroids adds 
further evidence to the hypothesis that Aβ can be released from fiber swellings.  
4.5 Interaction between α7 nAChR and Aβ 
Much evidence supports a role of the α7 nAChR in the pathological mechanism of AD. Thus 
a direct interaction between the α7 nAChR and Aβ42 has been reported stating that Aβ42 
displaces α-BTX binding specific for α7nAChRs (Wang et al. 2000), although this has 
recently been questioned by a study reporting that Aβ does not bind to α7nAChRs, but to 
lipids within the plasma membrane (Small et al. 2007). However, Aβ42 has been shown to 
specifically block the response evoked by ACh or nicotine of α7 nAChRs in cell culture and 
hippocampal neurons (Liu et al. 2001; Pettit et al. 2001; Spencer et al. 2006), and α7 nAChR 
activation protected against Aβ-induced neurotoxicity (Kihara et al. 1997). In AD post-
mortem studies, reduction of the α7 subunit have been reported in the cortex and hippocampal 
formation (Guan et al. 2000; Teaktong et al. 2004), and α7 nAChRs have shown co-localise as 
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well as co-immunoprecipitate with Aβ42 in AD hippocampal neurons (Wang et al. 2000). In 
vivo, smoking was found to have a lowering effect on Aβ in the human brain (Hellstrom-
Lindahl et al. 2004b), which was supported by a study in APPswe mice where 10 days of 
treatment with nicotine reduced insoluble Aβ40 and Aβ42 levels by 80% in the mouse brain 
tissue (Hellstrom-Lindahl et al. 2004a). This prompted us to study whether this lowering 
effect of nicotine on Aβ levels could be mediated through the α7 nAChR and we thus 
chronically treated 9-month-old APP/PS1ΔE9 mice with nicotine as a positive control, saline 
as a negative control, and the α7 nAChR agonist SSR180711 twice daily for 10 days. 
Surprisingly, no changes in 4G8 and LOC immunohistochemical pathology were found in the 
hippocampal formation or parietal cortex of the nicotine treated animals that even showed an 
increase in Aβ[N] pathology of the hippocampal formation. The mice treated with α7 nAChR 
agonist showed no difference in Aβ pathology with any of the three applied antibodies, and 
we were thus not able to replicate the findings of nicotine to lower Aβ levels using the same 
dosing scheme as in the study of APPswe mice (Hellstrom-Lindahl et al. 2004a). Two main 
differences could potentially explain the lack of effect from the administration of nicotine in 
our studies versus its beneficial effect in the previous study in APPswe mice. First, our mouse 
model contains a familial PS1 mutation in addition to the Swedish mutations in APP and thus 
if any effect of nicotine should be mediate through interaction with PS1 they could be 
prevented by PS1 mutations as is observed for some γ-secretase inhibitors that only show 
effects on wild-type PS1 activity (Czirr et al. 2007). However, to the best of our knowledge, 
no studies have suggested such an interaction. In AD, it has been mainly been suggested that 
the effects of nicotine are mediated through a direct interaction of the α7 nAChR with Aβ. 
Secondly, we evaluated the drug effects by quantification of immunostainings applying Aβ 
specific antibodies, whereas the study in the APPswe mice measured Aβ levels in brain 
homogenates by ELISAs. Although our method may only be semi-quantitative, the study in 
the APPswe mice reported an 80% lowering effect of nicotine on insoluble Aβ40 as well as 
Aβ42 levels, and such a dramatic effect should also have been evident by our method of 
quantification, especially with the application of the LOC antibody recognizing fibrillar Aβ 
oligomers and Aβ fibrils that should be part of the insoluble Aβ species (Kayed et al. 2007).  
If Aβ interacts with the α7 nAChR it could mediate part of its toxic effect by inducing 
desensitization of the α7 nAChR, and we therefore measured the binding level of α7 nAChRs 
in APP/PS1ΔE9 mice as compared to wild-type C57Bl6 mice. No significant differences 
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could be detected in the mPFC, the parietal cortex, or the hippocampal formation; although a 
weak tendency towards lower α7 nAChR levels seemed to be present, especially in the 
hippocampal formation, which might become significant with the inclusion of more animals.  
In summary, our studies of a potential interaction between the α7 nAChR and Aβ in 
APP/PS1ΔE9 mice were not sufficient to support a role of the α7 nAChR in AD. However, a 
recent study showed that deletion of the α7 nAChR gene in an AD mouse model actually 
improved cognitive deficits and synaptic pathology without any evident effect on 4G8-
reactive Aβ immunoreactivity (Dziewczapolski et al. 2009). Interestingly, this is consistent 
with the intraneuronal Aβ hypothesis of AD since the α7 nAChR has been reported to mediate 
endocytosis of Aβ42 facilitating intraneuronal accumulation of Aβ and deletion of the α7 
nAChR may thus decrease the level of intraneuronal Aβ peptides (Nagele et al. 2002). It is 
therefore possible that α7 nAChR antagonists rather than agonists may be beneficial in AD 
patients.  
4.6 Functional integrity of immediate early gene responses 
following novelty stimulation 
It is well known that the expression levels of Arc together with other IEGs are significantly 
up-regulated in response to various stimuli. Seizure activity upregulates Arc mRNA levels in 
the hippocampal region and parietal cortex (Guzowski et al. 1999). Arousal stimuli such as 
acute restraint stress up-regulate Arc mRNA levels in the mPFC but not in the hippocampal 
formation or parietal cortex (Guzowski et al. 1999; Mikkelsen and Larsen 2006). Novel 
environment, a further emotional stressor, induces Arc and c-fos gene expression in the 
parietal cortex and the hippocampus as well as in forebrain regions including the mPFC and 
orbitofrontal cortex, and one study even saw an up-regulation in the caudate nucleus (Klebaur 
et al. 2002; Ons et al. 2004; Pinaud et al. 2001). However, there seem to be some anatomical 
specificity to the regulation of IEG mRNA where seizure activity upregulates Arc expression 
in neurons of the hippocampal formation or parietal cortex, whereas the pure stress stimuli up-
regulate Arc mRNA in the forebrain region, but not in the hippocampal region. This regional 
specificity could be explained by the effect of corticosterone on cognitive function. Thus two 
systems within memory generation have received a lot of attention: The hippocampal system 
and the caudate nucleus system each depending on the surrounding cortices (Packard and 
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Knowlton 2002). The hippocampal memory system is thought to be predominately 
cognitively driven depending on spatial cues, whereas the caudate nucleus memory system is 
thought to be driven more by instinct depending on single cues and is termed “stimulus-
response” or “habit” memory. Corticosterone is known to influence memory through 
corticosteroid receptors located in the hippocampal region as well as in the amygdala, and it 
has been shown in humans as well as mice that increased stress levels leading to increased 
blood corticosterone levels do not decrease the learning ability in total. However, they 
facilitate stimuli-response learning strategies at the expense of hippocampal-dependent 
cognitive learning strategies (Kim et al. 2001; Schwabe et al. 2007). Thus an increased 
corticosterone level seems to work as a switch between the hippocampal and the caudate 
nucleus based memory systems, which may explain why Arc mRNA is up-regulated only in 
mPFC and not in hippocampus or surrounding cortices after pure stress stimuli. The induction 
of Arc gene expression in the mPFC by acute stressors emphasizes that the mPFC is a central 
component of stress perception and the region is accordingly considered a key component of 
the neuronal circuitry mediating responses to stressful situations and contributes to the 
interplay between emotions and memory (Roozendaal 2002). The novelty paradigm is only a 
light stressor and has in addition the element of exploration; however, we found considerable 
increased plasma corticosterone levels in both genotypes and accordingly found the highest 
induction of Arc and c-fos gene expression following novelty in the mPFC providing input to 
the caudate nucleus. Relating to the genotypes, we found a difference in basal levels of Arc 
gene expression being most pronounced in the cortices (40%). The APP/PS1ΔE9 mice were 
generally capable of increasing the Arc gene expression in response to a novel environment, 
in some regions even with higher percentages; however, the absolute Arc mRNA level never 
reached the same level as in the wild-type mice. This could mean that a lesser number of 
neurons is activated in the APP/PS1ΔE9 mice or that their neurons are not activated as much 
as in the wild-type mice. Basal differences and deficits in c-fos expression and induction 
following novelty were only identified in the cortical regions with the parietal cortex showing 
the same pattern as for Arc mRNA, but with dramatically increased basal c-fos mRNA levels 
in the mPFC of APP/PS1ΔE9 mice and an inability to up-regulate c-fos expression in this 
region upon a novel environment. As no effect of novelty or genotype was observed in the 
house keeping gene synaptophysin, the effects on Arc and c-fos gene expression are not 
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artifacts of the plaque deposition and no neuron loss has been observed in any of the 
investigated regions of this AD mouse model (Oh et al. 2008).  
Three other studies have previously investigated the effect of novelty on the expression of 
immediate early genes in AD mouse models. One was conducted in another APP + PS1 
trangenic model and reported reduced basal expression levels of Arc, Nur 77, and Zif 268 in 
6-month-old APP + PS1 transgenic mice by qRT-PCR in hippocampus, posterior cortex, and 
caudate nucleus. Following 5 min environmental novelty in 18-month-old mice, they 
observed a decreased percentile induction of Arc and Nur77 expression in the hippocampal 
region by qRT-PCR in transgenic mice compared to littermate controls (Dickey et al. 2004). 
The finding of decreased basal cortical EIG expression levels is in agreement with our 
observations; however, we only found a minor decrease in basal expression of Arc in the CA1 
of the hippocampal formation in contrast to no difference in the CA3 or upper DG. No basal 
hippocampal differences were found in c-fos expression of the hippocampal formation. 
Likewise, the blunted induction of Arc gene expression following novelty observed by qRT-
PCR agrees partly with our findings as we observe a reduced percentile reduction of Arc gene 
expression in the CA3, however, in the CA1 and upper DG, the percentile inductions are 
equal or even higher in the transgenic animals, but reach a lower absolute level of Arc gene 
expression due to reduced basal expressions. However, in relation to c-fos, we did not observe 
any deficits in the functional response to novel environment in the hippocampal formation. 
Another study investigated EIG gene expression following novelty in hAPPFAD mice carrying 
the Swedish and Indiana FAD mutations using in situ hybridization and 
immunohistochemistry in the neocortex, CA1, and granular layer of the DG. They found 
decreased basal Arc and c-fos expression as well as protein accumulation only in the DG , 
which was also the only investigated region to show a complete abolishment of induced Arc 
and c-fos gene expression after novelty in the transgenic mice (Palop et al. 2005). We did not 
observe the same reduced basal expression levels of Arc and c-fos in the DG, and only found 
a minor decrease in the induction of Arc expression following novelty in this region, whereas 
no deficits were found in c-fos induction. Generally, we observe much greater deficits in the 
functional response of Arc and c-fos expression following novelty in cortical regions as 
compared to the hippocampal formation, which seems to have been the greater focus of earlier 
studies. A very recent study investigated the impact of different amyloid pathologies in three 
AD mouse models including an APP/PS1 model overexpressing APP carrying the Swedish 
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mutations together with hPS1 carrying the L166P mutation, the APP23 model harboring the 
Swedish double mutation, and APPDutch mice (Wegenast-Braun et al. 2009). By in situ 
hybridization as well as stereological quantification of Arc mRNA positive cells, this study 
reports decreased percentile inductions of Arc mRNA in the neocortex and granular cell layer 
of the DG following novelty in all three mouse models at old age compared to age-matched 
non-transgenic mice, which is in general agreement with our results. Interestingly, this study 
also found decreased induction of Arc mRNA before plaque deposition in young APP23 and 
APPDutch mice, but not in young APP/PS1 mice, correlating with only APP23 and 
APPDutch mice accumulating intraneuronal Aβ at young age. However, as the accumulation 
of intraneuronal Aβ was transient and APP/PS1 mice also develop deficits in Arc mRNA 
induction with advanced age, intraneuronal Aβ, plaques, as well as vascular CAA pathology 
were suggested to cause separate deficits in the induction of Arc mRNA expression 
(Wegenast-Braun et al. 2009). Not much intraneuronal Aβ could be detected in our 9-month-
old APP/PS1ΔE9 mice; however, they accumulated a vast amount of Aβ plaques as well as 
vascular CAA depositions, which, according to the previous results, are then both likely to 
contribute to the observed deficits.  
The present data reveal a suppressing effect of Aβ on basal and novelty induced neuronal 
activity in APP/PS1ΔE9 mice being most pronounced in cortical regions, where the mPFC 
seems to be especially affected showing an increased basal level of c-fos expression that did 
not increase upon novelty stimulation. This finding is in line with data from AD patients 
where increased protein levels of c-fos, c-jun, and Arc have been reported (Engidawork et al. 
2001; Marcus et al. 1998). It is thus possible that a decreased functional response in IEG 
systems could in part mediate cognitive deficits relating to environmental encoding as well as 
the interplay between emotions and memory in AD patients. 
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5 Summary and Conclusions 
The present thesis investigated the role of intraneuronal Aβ in pathological alterations in AD 
on a neuroanatomical level by the application of methods such as immunohistochemistry, 
image analysis, stereological quantification, as well as in situ hybridization and radioactive 
ligand binding. In two independent studies, the accumulation of intraneuronal Aβ was found 
to correlate with neuron loss in the APP/PS1KI mouse model of AD. Thus in the brain 
cholinergic system of APP/PS1KI mice, accumulation of intracellular Aβ aggregates 
represented an early pathological alteration that strongly correlated with neuron death in brain 
stem motor nuclei. In contrast, Aβ plaque pathology leading to plaque associated dystrophic 
neurites was not sufficient to cause neuron loss. A second study comparing neuron numbers 
in two regions accumulating either intraneuronal Aβ together with plaque pathology or 
plaques only, found that neurons were lost only in the region with accumulation of 
intraneuronal Aβ, whereas no neuron loss was observed in the region accumulating only 
extracellular plaques. Furthermore, the presence of intraneuronal Aβ was found to be transient 
and was virtually absent at the age where neuron loss was first detected, indicating that the 
neurons accumulating intraneuronal Aβ were the ones to be lost. 
The current ongoing debate concerning the presence of intraneuronal Aβ in human AD brains 
prompted an optimization of the immunohistochemical staining method for the detection of 
intraneuronal Aβ peptides. The optimization provided a strong and robust staining of 
intraneuronal N-terminal Aβ peptides as well as fibrillar oligomers and Aβ fibrils in the 
hippocampal formation of AD tissue, adding a valuable contribution to the evidence of 
intraneuronal Aβ in human AD brains. In the same experiment, a highly significant 
correlation between the accumulation of intraneuronal N-terminal Aβ peptides and the ApoE4 
genotype was identified, further emphasizing the impact of intraneuronal Aβ in AD pathology 
as the ApoE4 isoform is recognized to be the major risk factor for sporadic AD. 
Axonopathy recognized by dystrophic swellings of fibers is a well-known pathological 
alteration found in the human AD brain as well as in mouse models of AD; however, the 
origin of the dystrophic fibers is presently unclear. Using YFP transgenic mice crossed with 
APP/PS1KIhe mice and confocal imaging, Aβ-positive granules were detected in the axons 
and apical dendrites of cortical neurons, indicating that Aβ can be transported within fibers. 
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Accumulation of intracellular Aβ was also identified within large dystrophic fibers 
independent of plaques as well as in the vicinity of plaques and with diffuse Aβ deposits 
nearby the axonal swelling, suggesting that Aβ accumulation inside fibers may contribute to 
the generation of axonal spheriods and adding further evidence to the hypothesis that Aβ can 
be released from fiber swellings. 
Concerning functional deficits, the studies of an interaction between Aβ and the α7 nAChR in 
APP/PS1ΔE9 mice were not sufficient to support a role of the α7 nAChR in AD. 
Furthermore, the reported lowering effect of nicotine on Aβ pathology could not be 
confirmed; on the contrary, an increase in full-length Aβ plaques was observed in the 
hippocampal formation of nicotine treated APP/PS1ΔE9 mice. However, in the studies of the 
functional integrity of the IEG response systems, a suppressing effect of Aβ on basal and 
novelty induced expression of Arc and c-fos was identified in the APP/PS1ΔE9 mice being 
most pronounced in cortical regions, where the mPFC seemed to be especially affected 
showing an increased basal level of c-fos expression that did not increase upon novelty 
stimulation. Such a decreased functional response in IEG systems could in part mediate 
cognitive deficits relating to environmental encoding as well as the interplay between 
emotions and memory in AD patients. 
In conclusion, the present thesis corroborates the modified intraneuronal Aβ cascade 
hypothesis. It provides additional evidence for the presence of intraneuronal Aβ in human AD 
tissue and supports the view of intraneuronal Aβ as an early pathological initiator contributing 
strongly to pathological alterations in AD including large plaque-independent dystrophic fiber 
pathology and neuronal loss. In contrast, plaques are found likely to cause functional 
disturbances such as deficits in the induction of IEG systems upon neuronal activity, but seem 
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